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Cardiac vulnerability to injury following ischemia/reperfusion (I/R) during postnatal development 
displays a biphasic pattern in rats, with 14-day olds being least vulnerable. The underlying cause for 
this change is not currently known. We hypothesise that developmental differences in survival 
signalling pathways (e.g. Reperfusion Injury Salvage Kinase (RISK) & Survivor Activating Factor 
Enhancement (SAFE)) contribute to these biphasic changes. The work presented therefore looked to 
identify any changes in the expression of relevant proteins over the course of postnatal 
development, as well as to examine the effects of targeted inhibition of these proteins on cardiac 
injury, and to assess the morphology and abundance of cardiac ultrastructures related to survival 
signalling and the response to I/R. 
Hearts from 7-day old, 14-day old, 28-day old and adult male Wistar rats were extracted and 
processed for measurements of protein expression, cardiomyocyte viability, cardiac injury, and 
cardiac structural/ultrastructural differences. This was done using a range of techniques, including 
proteomics, Langendorff perfusion, cardiomyocyte isolation, western blotting, histology and 
electron microscopy. 
Several key survival signalling proteins, including AKT, PKCε, and AMPK, showed a biphasic profile of 
expression that parallels the biphasic profile of cardiac vulnerability to I/R. Inhibition of these 
proteins reduced cardiomyocyte viability and increased cardiac infarct size in 14-day olds, but not in 
adults. Mitochondria, which are important endpoints for survival signalling, displayed changes in 
morphology indicative of less injury and disruption in 14-day old than adult hearts following I/R. 
Ultrastructures associated with cardioprotection (e.g. caveolae and exosome containing MVBs) were 
also more abundant in 14-day old hearts in comparison with adults. In conclusion, these data show 
that the least vulnerable age group (14-day olds) has an abundance of pro-survival proteins and that 
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Chapter 1: Introduction 
1.1 Cardiac changes during postnatal development  
The cardiac pump changes during postnatal development to cope with a growing organism 
(Ostadal, Ostadalova et al. 1999, Janowski, Cleemann et al. 2006). These changes include 
those at the molecular, cellular, structural, and functional levels, which provide the basis 
upon which a transition from foetal and neonatal physiology to that seen in the mature heart 
can be achieved. In the foetal environment, hearts exist in a state of constant physiological 
hypoxia, with an oxygen saturation of 18% and oxygen tensions of 47 mm Hg in comparison 
to the usual 97% and 160 mm Hg levels seen postnatally (Ostadal, Ostadalova et al. 2009). 
Foetal hearts are well adapted to this hypoxic environment, with foetal haemoglobin 
displaying a correlating oxygen dissociation curve with a leftward shift, and are consequently 
less susceptible to hypoxic injury (Ostadal, Ostadalova et al. 2014). Transition from this 
hypoxic environment at birth therefore requires postnatal adaptation to atmospheric 
oxygen levels, such as the need for pulmonary circulation and a rapid increase in metabolic 
rate (Ostadal, Ostadalova et al. 2009). Due to this recent transition from a hypoxic state, 
early neonates still remain less vulnerable to ischemia and oxygen deprivation, as they are 
able to revert temporarily to their foetal metabolism (Ostadal, Ostadalova et al. 2009). Over 
the course of postnatal development, further changes in processes such as metabolism 
occur in order for the heart to adapt to its new oxygen-rich environment, for example, with 
a switch from anaerobic in foetal and neonatal hearts to aerobic respiration in adults 
(Ostadal, Ostadalova et al. 2014). Several of these changes are also implicated in the injury 
seen following ischemia and reperfusion (I/R) (Ostadal, Ostadalova et al. 2014), and their 
implications in the changing vulnerability to I/R injury (I/RI) during postnatal development 
(Ostadal, Ostadalova et al. 2009). Key cardiac developmental changes and their potential 
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involvement in reperfusion injury and in the design of cardioprotective strategies will 
subsequently be discussed.  
1.1.1 Metabolic changes & the role of mitochondria  
The switch from the hypoxic foetal environment to an oxygen-rich one, and subsequent 
postnatal developmental changes, are accompanied by significant changes in metabolism, 
transitioning from predominantly anaerobic respiration to aerobic respiration (Ostadal, 
Ostadalova et al. 2009). Changes in metabolic activity are critical over the course of postnatal 
development in providing the needed energy for a growing heart and for increasing cardiac 
pump function. As neonates begin to consume milk, the altered availability of substrates 
allow for a switch from a largely glycolysis-based to fatty acid β-oxidation-based metabolism, 
with glycolysis contributing < 10% of total ATP production by postnatal day 7 from the < 50% 
contribution seen immediately after birth (Lopaschuk and Jaswal 2010). This greater 
dependence on fatty acid β-oxidation supports the increased demands and transition of 
hearts from low to higher energy utilisation, as it is able to produce a significantly greater 
number of ATP molecules per unit substrate  (Neary, Ng et al. 2014). Whilst glycolysis is able 
to generate two ATP molecules per molecule of glucose (Liu 2006), a single C18 fatty acid 
molecule is able to yield 90 molecules of ATP via the citric acid (TCA) cycle and electron 
transport chain (ETC), with a further 30 molecules of ATP due to the capture of electrons by 
the β-oxidation cycle (Goetzman 2011). Fatty acid β-oxidation is known to be a key source 
for the oxidative metabolism of mitochondria (Lopaschuk and Jaswal 2010), and as such, 
these increases in fatty acid β-oxidation as the heart develops postnatally are accompanied 
by increases in mitochondrial number, size and functionality (Neary, Ng et al. 2014). 
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The mitochondria are known as the powerhouse of the cardiomyocyte, and have been found 
to transition from a single population with relatively high membrane potential in neonates, 
to two separate mitochondrial populations – the second arising during the weaning period 
with a lower membrane potential – in parallel with the gradual ordering of initially 
chaotically organised mitochondria and muscle fibres (Skarka et al. 2003, Milerova, 
Charvatova et al. 2010). There are also increasing cytochrome c oxidase (COX) levels and 
activity alongside increasing adenine nucleotide flux across the inner mitochondrial 
membrane during postnatal development (Johnson et al. 2006). Moreover, the number and 
volume of mitochondria themselves have been shown to rise during postnatal development 
(Olivetti, Anversa et al. 1980), with a doubling within the first 5 postnatal days of 
mitochondrial density, size, volume and number in rat hearts. These changes are critical to 
cope with increasing energy demands in rat hearts. 
Unlike fragmented foetal mitochondria, postnatal mitochondria possess a more elongated 
morphology associated with exit from the hypoxic prenatal environment and subsequent 
driving of mitochondrial fusion, and correlating with the postnatal switch from glycolysis to 
fatty-acid β-oxidation (Neary, Ng et al. 2014). Such changes have been suggested to result 
from decreases in Hypoxia Inducible Factor (HIF) signalling upon entering the oxygen-rich 
postnatal environment, resulting in alterations to the expression of lipid metabolism related 
genes (Neary, Ng et al. 2014). Indeed, previous work (Narravula and Colgan 2001, Zhang, 
Bosch-Marce et al. 2008) demonstrated that the overexpression of HIF resulted in a reduced 
respiratory capacity, in addition to decreased biogenesis of mitochondria. In keeping with 
relatively lower levels of aerobic metabolism in the neonatal heart in comparison with 
adults, the underdeveloped mitochondria have large separation between cristae, but 
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greater intake of Ca2+ into the mitochondria via the Ca2+-uniporter in neonates that shows a 
gradual decrease after 14 postnatal days in rats (Bassani, Fagian et al. 1998). 
1.1.2 Changes in Ca2+ cycling during E-C coupling 
Key processes that require a great deal of energy consumption in the heart are Ca2+ cycling 
and excitation-contraction (E-C) coupling, which change during postnatal development with 
the growing heart and increasing cardiac pump function, and are supported by the 
previously discussed changes in metabolic activity with age (Section 1.1.1). In the adult 
heart, E-C coupling involves the opening of voltage-gated Ca2+ channels (dihydropyridine 
receptors, DHPR) during an action potential (AP), allowing an influx of Ca2+ into the cell (Bers 
2002). This in turn triggers the release of Ca2+ from the sarcoplasmic reticulum (SR) via the 
ryanodine receptors (RyR) in a process known as calcium-induced calcium release (CICR), 
this local release from the SR creating Ca2+ sparks which are eventually summed, alongside 
the entry of extracellular Ca2+, to a sufficient cytosolic Ca2+ concentration for binding to 
troponin C present within the myofilaments and subsequent contraction (Bers 2002). During 
relaxation, cytoplasmic Ca2+ concentrations are lowered via closing of the RyRs, via the 
action of SR Ca2+-ATPases (SERCA) which transport Ca2+ from the cytosol back into the SR, 
and via the Na+-Ca2+ exchanger (NCX) which exports Ca2+ from the cardiomyocyte in 
exchange for Na+ to restore resting cytosolic Ca2+ concentrations (Eisner et al. 2017). In adult 
hearts, triggering of this signal from an AP is propagated throughout the cell via transverse 
tubules (t-tubules), which are invaginations of the plasma membrane extending from the 
cell surface and to the interior of the cardiomyocyte, allowing the rapid transmission of the 
signal throughout the entire cell and to the SR via the DHPR (Calderon et al. 2014). 
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Whilst both Ca2+-influx across the sarcolemma and Ca2+ release from the SR play important 
roles in the contraction of the adult myocardium, neonatal hearts are more reliant upon the 
influx of extracellular Ca2+, due to the underdevelopment of t-tubules and the SR (Ostadal, 
Ostadalova et al. 1999). As the SR develops postnatally, sufficient Ca2+ is accumulated  within 
them which is subsequently available for release during E-C coupling, resulting in a switch 
from more extracellular to more SR-based Ca2+ transients (Ostadal, Ostadalova et al. 1999). 
This is coupled to the formation of t-tubules over the course of postnatal development. As 
seen in Figure 1, neonatal cardiomyocytes do not display the characteristic striations 
indicative of t-tubules that are seen in the adult cardiomyocyte, meaning there is a lack of 
DHPR and RyR co-localisation at this stage of development, with Ca2+ sparks detectable 
predominantly around the subsarcolemmal region (Seki, Nagashima et al. 2003). As the 
heart develops postnatally, there is a gradual appearance of these striations (t-tubules) with 
age and as the cardiomyocytes increase in size, indicating that the usual coupling seen 
between the DHPR and SR via RyR at the dyadic junction – not present in neonates – begins 
to arise at 14-days of age, and fully into adulthood (Schroder, Wei et al. 2006). 
 
Figure 1. Figure showing the development of t-tubules during postnatal development in rat 
hearts. Striations within the cells do not appear until 14-days postnatally, with some 
striations appearing by day 18. Scale bars: P7, 10 μm; P14, 5 μm; P18, 10 μm; adult, 20 
μm. (Seki, Nagashima et al. 2003) 
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As previously mentioned, this underdevelopment of t-tubules and lack of coupling with RyR 
and the SR in neonates means that cardiomyocytes at this stage of development have a 
much greater reliance on the entry of extracellular Ca2+ for contraction. It has been 
demonstrated that, in early postnatal cardiomyocytes, the NCX is instead key in controlling 
Ca2+ cycling, allowing entry of Ca2+ to the cell for direct binding and activation of myofilament 
components (Qu, Ghatpande et al. 2000).  Correlating with this dependence on the action 
of the NCX for Ca2+ influx, higher levels of both NCX protein expression and NCX mRNA have 
been found in neonates in comparison with adults, followed by a gradual decrease over the 
course of postnatal development (Boerth, Zimmer et al. 1994).  
Due to the underdevelopment of the SR and t-tubules, and reliance on the NCX, E-C coupling 
in immature rat hearts is slower in terms of Ca2+-cycling (Balaguru, Haddock et al. 1997, Seki, 
Nagashima et al. 2003), with a CICR threshold 10 times lower in 2 day old hearts compared 
with 30 day old hearts (Fabiato and Fabiato 1978).  
1.2 Cardiac structural changes during postnatal development 
Another important change during postnatal development is the transition from hyperplasic 
to hypertrophic growth. Increases in heart mass is supported by hyperplasia of the 
cardiomyocytes up until 4 days postnatally in rats (Olivetti, Anversa et al. 1980), following 
which growth continues as a result of hypertrophy of existing cardiomyocytes (Bicknell, 
Coxon et al. 2004, Chen, Yu et al. 2004), resulting in an increase in heart weight over the first 
11 postnatal days of 5-fold in rats (Johnson and Brown-Borg 2006). An increasing left 
ventricular radius accompanies this (Wu and Wu 2009). This initial period of hyperplasia 
correlates with a greater packing density of cardiomyocytes at this stage of postnatal 
development in comparison with 7-day old hearts, and with larger extracellular spaces in 7-
47 
 
day old hearts that may be present in order to allow for hypertrophic growth of existing cells 
to occur (Wu and Wu 2009). Similarly, myocardial fibre width was shown to be greater in 7-
day old hearts than 2-4 day olds, increasing further until day 21, after which point no 
significant changes are seen due to the cessation of hypertrophy, reflecting structural 
maturity at this stage of development (Wu and Wu 2009). Cardiac growth during 
development requires an associated and compensatory increase in blood flow to the heart 
to support the metabolic needs of the heart, and whilst capillaries within the heart have 
been shown to display corresponding growth, the same is not necessarily seen in the larger 
blood vessels, resulting in the increase in coronary vascular resistance over the course of 
postnatal development (Hudlicka and Brown 1996). Additionally, differences in Ca2+-
handling during postnatal development mean that myofibrils in neonates are initially 
disorganised and localised within the cell so as to optimise extracellular Ca2+ entry and 
binding to the contractile units (Vornanen 1996).  
1.3 Cardiac functional changes during postnatal development 
Due to the increasing haemodynamic load that occurs during postnatal development, 
developing hearts display a gradual increase in stroke volume and cardiac output, in addition 
to ejection fractions that have been shown in rat hearts to increase until 4 postnatal days, 
before decreasing at day 7, and then gradually increasing once more until day 21 (Wu and 
Wu 2009). At this stage, the ejection fraction stabilises, corresponding with the reaching of 
functional maturity. A similar change in ejection fraction with development was also 
described in human infants from 2 to 14 postnatal months (Oberhansli, Brandon et al. 1981). 
Furthermore, developing rat hearts display a change in contractile performance – as 
determined by measurements of developed force – that includes a decrease from day 1 to 
48 
 
day 4, before increasing over the course of postnatal development, mitochondrial mass, and 
myofibrillar ATPase activity that follows postnatal development (Oštá̀dalová, Kolář et al. 
1993, Wu and Wu 2009).  
These functional changes are accompanied by developmental changes in heart rate, 
increasing from approximately 300 beats/min at birth to a maximum of 500 beats/min in 
adult rats (Wekstein 1965, Adolph 1967). It is suggested that the altered Ca2+-handling seen 
during postnatal development (discussed in Section 1.1.1), with a switch from heavier 
dependence on extracellular Ca2+ influx for the activation of muscle contraction in the immature 
heart, to intracellular and SR-based Ca2+ in adult hearts, correlate with and may account for such 
changes in heart rate (Vornanen 1992). 
1.4 Cardiac Development and ischemia/reperfusion injury 
1.4.1 Ischemia/reperfusion injury: an overview 
Cessation or reduced blood flow to the heart, known as ischemia, predisposes the 
myocardium to reperfusion injury following reintroduction of blood flow (Hausenloy and 
Yellon 2013). The underlying cause of I/RI is multi-factorial, the key mechanisms being 
oxidative stress, Ca2+-overload, and opening of the mPTP. Lactate production and decreased 
intracellular pH resulting from the switch to anaerobic respiration during ischemia leads to 
activation of Na+-H+ exchanger, and subsequent Na+-overload (Hausenloy and Yellon 2013). 
This in turn causes an efflux of Na+ in exchange for Ca2+ via activation of the Na+-Ca2+ 




While mPTP opening does not occur during ischemia due to the high acidity, reperfusion 
results in restoration of pH and opening of the mPTP. Reperfusion also leads to the 
hyperactivity of the Electron Transport Chain (ETC), causing excessive ROS production, which 
in turn acts to sensitise the mPTP to Ca2+, as a neutrophil chemoattractant, and as a 
contributing factor to SR dysfunction. This oxidative stress not only further exacerbates Ca2+-
overload through dysfunction of the SR, but also through damage of the plasma membrane 
itself (Halestrap, Clarke et al. 2007, Hausenloy and Yellon 2013). mPTP opening is an 
important trigger for cell death that occurs with I/RI, as it results in either necrosis via ATP-
depletion, due to the permeation of the IMM resulting in collapse of the mitochondrial 
membrane potential needed to drive oxidative phosphorylation (Hausenloy, Ong et al. 
Figure 2. The cellular, metabolic and ionic changes that occur during a relatively short period 






2009), or activation of the apoptotic pathway via the release of factors such as Cytochrome 
c and Apoptosis Inducing Factor (AIF) (Shintani-Ishida, Inui et al. 2012). 
1.4.2 Ischemia/reperfusion injury during postnatal development 
The vulnerability of hearts to I/RI changes over the course of postnatal development, with a 
bell-shaped profile that can be seen in Figure 3. Ostadalova et al. (1998) demonstrated that 
recovery of the developed force falls from day 1 to day 7, before increasing once again from 
day 7 to day 10 in rats, an improvement in recovery that was shown by Riva & Hearse (1991) 
to further increase until a peak at 17 postnatal days that subsequently falls when going into 
adulthood (Riva and Hearse 1991, Ostadalova, Ostadal et al. 1998). This pattern of change 
in vulnerability correlates with the previously described switch from proliferative, 
hyperplasiac growth 4 days postnatally in rat (Bicknell, Coxon et al. 2004, Chen, Yu et al. 
2004), with the highest percentage recovery levels seen at 17 and 25 postnatal days 
potentially reflecting the reported achievement of functional and structural maturity at 21 
days of age (Wu and Wu 2009). Similarly to this, findings from Modi & Suleiman (2004) 
highlight a peak in functional recovery following I/RI at 14-days of age in rats, a pattern that 
was shown to be mimicked in rabbit hearts (Suleiman et al, unpublished data) as shown in 
Figure 3A. Notably, this apparent “triphasic” pattern of change in tolerance was found to 
exist only in male rats (Ostadal, Ostadalova et al. 2014), whereas female rats deviated from 
males in terms of cardiac vulnerability following the end of the weaning period at 28-days 
postnatally (Ostadal, Netuka et al. 2009, Ostadal and Ostadal 2014). Cardiac vulnerability to 
injury therefore shows a more “biphasic” pattern of change during postnatal development, 
as the decrease in tolerance seen in male rats from day 30 to day 60 is not seen in females, 
indicating a greater resistance in the adult female rat heart to I/RI related damage (Ostadal, 
51 
 
Ostadalova et al. 2014). These changes in vulnerability to cardiac injury have also been linked 
to changes in caloric intake and body mass during development, which has been shown to 
be lower both during the first days post-partum and at the start of the weaning period at 
around day 16, suggesting a link between tolerance to hypoxia and decreases in body mass 
(Ostadalova and Babicky 2012, Ostadal, Ostadalova et al. 2014).  
 
Figure 3. The cardiac vulnerability profile of developing hearts in rats (left) and rabbits 
(right) following 60 minutes and 35 minutes of ischemia, respectively (A). The profile for 
earlier postnatal development in rat hearts following 40 or 60 minutes of ischemia (B). 
RRP = Rate Pressure Product. DF = Developed Force. (Modi and Suleiman 2004, Ostadal, 




Rat (60 min) Rat (40 or 60 min) 
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The exact underlying mechanism behind this difference in vulnerability between age groups 
is currently uncertain. Possible causes include some of the previously discussed changes that 
occur during the course of postnatal development, including the switch from glycolytic 
metabolism to fatty acid β-oxidation, changes in Ca2+-cycling and EC-coupling, and structural 





Table 1. The key changes proposed to be involved in the differences in vulnerability to 
Ischemia/Reperfusion Injury during postnatal development in rat hearts. Adapted from 




1.4.3 Changes in antioxidant status 
As mentioned in Section 1.4.1, the production of ROS during I/RI is an important step leading 
to cardiomyocyte damage, apoptosis and necrosis (Figure 4). Antioxidants are important 
components that scavenge ROS in order to maintain normal levels in the cell, preventing 
such damage (Zhou, Prather et al. 2018). As a result of this, potential differences in 
antioxidant protein expression and activity at different stages of postnatal development has 
been investigated as a possible contributor to the cardiac vulnerability profile (Figure 3). 
 
Figure 4. Summary of the production of ROS following I/RI, and the action of antioxidants in 
scavenging excess ROS. NADPH = nicotinamide adenine dinucleotide phosphate (reduced), 
NOS = nitric oxide synthase, ROS = reactive oxygen species, mPTP = mitochondrial 
permeability transition pore, SOD = superoxide dismutase, GPx = glutathione peroxidase, 
Prx = peroxiredoxin. (Modified from (Murphy and Steenbergen 2008) (Granger and 




Whilst current knowledge of the postnatal changes in cardiac antioxidant status is limited in 
mammals, studies have demonstrated that postnatal differences in antioxidant expression 
can be found in rat hearts, with lower xanthine oxidase – a producer of reactive oxygen 
species (ROS) – activity with an associated reduced release of ATP-catabolites following 
reperfusion in neonatal hearts in comparison with adults (Achterberg, Nieukoop et al. 1988). 
More recent work undertaken by Sarah Martin (unpublished PhD thesis, 2010) examining 
the changes in antioxidant expression over the course of postnatal development found that 
while the activity of total superoxide dismutase (SOD) remained unchanged, SOD1 showed 
a gradual increase in protein expression from 4 days of age to a maximal level in adult hearts. 
However, this change did not follow the characteristic biphasic profile of cardiac 
vulnerability seen across these age groups, and therefore likely represent general 
developmental changes as opposed to a causal mechanism underlying these developmental 
differences in the response to I/RI. Furthermore, analysis of SOD1 gene expression did not 
mimic these age-dependent changes in protein expression. 
In addition to work on SOD, Sarah Martin found that glutathione peroxidase (GPx) activity, 
protein expression and gene expression showed gradual changes during postnatal 
development that did not follow the biphasic changes seen in cardiac vulnerability. GPx 
activity and protein expression both displayed decreasing levels with increasing age, a trend 
mimicked by gene expression albeit without statistical significance, again suggesting it is 
involved in general developmental changes as opposed to linking directly with the 
differential responses to I/RI seen across these age groups. 
In contrast to SOD and GPx, catalase was found to mimic the biphasic changes seen in cardiac 
vulnerability both in terms of activity, protein expression and gene expression. In all three, 
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levels peaked at 14-days of age – although protein expression did show the greatest levels 
at 21 days of age before dropping again at 28-days of age – in a manner similar to the peak 
in cardiac resistance to I/RI seen at 14-days of age. As a result, the antioxidant activity of 
catalase remains a potential component of the underlying mechanism below postnatal 
developmental changes in cardiac vulnerability.  
1.4.4 Mitochondrial permeability transition in postnatal heart 
Sensitivity of the mitochondrial permeability transition pore (mPTP) has also been shown to 
be lower in neonates than adults, with relative reductions in both rate and degree of Ca2+-
induced swelling associated with greater resistance to high Ca2+ concentrations, which is 
suggested to at least in part be linked to aforementioned differences in Ca2+-cycling, as well 
as mitochondrial structure, in neonates in comparison with adults (Milerova, Charvatova et 
al. 2010). While this does appear to correlate with the greater vulnerability of adult hearts 
to I/RI, this study looked at rats that were 7-days of age, which in fact showed poorer 
resistance to I/RI injury than those of 14-days of age. Due to these uncertainties as to the 
exact mechanism by which neonatal I/RI tolerance is conferred, an alternative potential 
explanation for the vulnerability profile seen during postnatal development could involve 
the survival signalling pathways.  
1.5 Role of survival signalling in ischemia/reperfusion injury 
Survival signalling pathways have been shown to provide cardioprotection against I/R. Two 
of the key pathways that have thus far been identified are the Reperfusion Injury Salvage 
Kinase (RISK) and Survivor Activating Factor Enhancement (SAFE) pathways (Tamareille, 
Mateus et al. 2011), the summaries of which are shown in Figure 5. Cardioprotective 
strategies termed ischemic pre- (IPreC) or post-conditioning (IPostC) have been shown to 
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increase the expression and activity of survival signalling proteins through the application of 
brief episodes of coronary occlusion and reperfusion either before or after the ischemic 
event (Heusch 2015). This increase in survival signalling has been found to correlate with a 
reduction in infarct size (Tsang, Hausenloy et al. 2004), and these cardioprotective strategies 
have subsequently been employed during cardiac surgery or following myocardial infarction 
in an attempt to reduce the degree of cardiac injury that follows (Hausenloy, Lecour et al. 




1.5.1 The RISK Pathway  
The RISK pathway consists of a network of pro-survival signalling kinases, the key effectors 
of which are phosphatidylinositol-3 kinase (PI3K), protein kinase B (Akt), and extracellular 
Figure 5. An overview of the RISK-SAFE survival signalling pathways, which involve activation 
of key survival kinases and subsequent activation of pro-survival proteins and inhibition 




regulated kinase 1/2 (ERK1/2), which act to trigger a cascade of cellular signalling events that 
promote cell growth and survival, as well as to counteract or inhibit pro-apoptotic signalling 
(Hausenloy and Yellon 2007, Lecour 2009). Activation of the pathway through administration 
of factors such as insulin, urocortin, atorvastatin, bradykinin, opioid receptor agonists, and 
Glucagon-Like-Peptide 1 (GLP1) upon reperfusion of the myocardium has been 
demonstrated to reduce infarct size following I/R (Hausenloy, Whittington et al. 2013, 
Heusch 2015). Further members of the signalling pathway include kinases such as protein 
kinase C (PKC), protein kinase G (PKG) and p70 ribosomal S6 kinase (p70S6K), and 
downstream targets of phosphorylation including, but not limited to, pro-survival proteins 
B-cell lymphoma 2 (BCL-2), BCL-XL and heat shock proteins (HSPs), as well as pro-apoptotic 
proteins such as Glycogen Synthase Kinase 3 beta (GSK3β), B-cell lymphoma 2-associated 
agonist of cell death (BAD), B-cell lymphoma 2-associated X protein (BAX), BCL-2-like protein 
11 (Bim) and members of the caspase family (Boengler, Schulz et al. 2009, Calvert, Jha et al. 
2009, Lacerda, Somers et al. 2009, Lecour 2009). The overall effect of these activating or 
inactivating phosphorylation events is to confer cardioprotection to the heart through 
inhibition of the apoptotic process. 
Whilst many of the other downstream effectors of the RISK pathway currently remain 
unidentified, ERK1/2 signalling has been shown to result in signalling via Signal Transducer 
and Activator of Transcription 3 (STAT3). STAT3 is a key component of the second survival 
signalling pathway, SAFE (Boengler, Schulz et al. 2009, Calvert, Jha et al. 2009), that has been 
shown, among other actions, to lead to decreases of the pro-apoptotic Bax gene and 
increase of the anti-apoptotic BCL-2 gene (Lecour 2009). The key proposed action of the RISK 
pathway in cardioprotection is via inhibition of mPTP opening (Lacerda, Somers et al. 2009, 
Lecour 2009). Whilst the underlying mechanism behind this effect on mPTP opening remains 
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uncertain, several potential pathways have been proposed, including GSK3β signalling 
(Juhaszova, Zorov et al. 2004), activation of eNOS, inhibition of Bax translocation to the 
mitochondria, and activation of mitochondrial hexokinase II (Murphy and Steenbergen 
2008). 
1.5.2 The SAFE Pathway 
Although a degree of overlap has been proposed between the two survival signalling 
pathways (Lecour 2009), the key mediators of the SAFE pathway are Janus Kinase (JAK) and 
STAT3. Activation of this pathway has been demonstrated to occur via the actions of opioids, 
insulin, sphingosine-1 (Heusch 2015), in addition to Tumor Necrosis Factor α (TNFα) through 
binding and activation of TNF Receptor 2 and subsequent phosphorylation of JAK (Lacerda, 
Somers et al. 2009). Following activation of JAK, they are able to in turn phosphorylate 
STATs, which hetero- or homo-dimerise and translocate to the nucleus in order to promote 
the transcription of pro-survival proteins (Cohen and Downey 2015). Similarly to the RISK 
pathway, activation of STAT3 is able to reduce mPTP opening and the associated apoptotic 
cell death through inactivation of pro-apoptotic Bad and promotion of anti-apoptotic BCL-2 
and BCL-XL (Lecour 2009). 
1.5.3 The role of AMPK & GSK3β during ischemia/reperfusion 
GSK3β is known to be a key target of the RISK-SAFE survival signalling pathways, with 
inhibition of reportedly pro-apoptotic GSK3β by pro-survival Akt resulting in 
cardioprotection, as previously discussed. However, studies have also shown that GSK3β 
activation, as well as that of energy-sensing protein AMP-activated Protein Kinase (AMPK), 
during ischemia specifically is actually protective to the heart. AMPK works to monitor 
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cellular energy levels, and is able to detect low energy environments that arise, for example, 
during ischemia in order to switch to energy-conserving, ATP-synthesising processes 
(Moussa and Li 2012). Both GSK3β and AMPK have been shown to provide cardioprotection 
when active during ischemia through several processes, as outlined in Figure 6, one of the 
key being the inhibition of the mTORC1 complex, which in its active state works to promote 
protein synthesis and inhibit autophagy in response to growth factor and stress signalling 
(Sciarretta, Volpe et al. 2014). The triggering of autophagy following ischemic insult is 
important in reducing cardiac injury, as it results in the degradation of cellular organelles 
and macromolecules for recycling to support ATP-synthesis, as well as the removal of 
damaged organelles and proteins which may otherwise remain as cytotoxic and injurious 
components within cells (Moussa and Li 2012). Thus, GSK3β and AMPK-mediated inhibition 
of mTORC1 and promotion of autophagy during ischemia serves as a cardioprotective 
mechanism. 
As mentioned previously, GSK3β activity during reperfusion is known to be harmful as it 
promotes opening of the mPTP, and it is subsequently inhibited by Akt and other members 
of the RISK-SAFE signalling pathway. While autophagy is protective during ischemia via 
maintenance of energy stores and production, autophagy is also known to be harmful during 
reperfusion, potentially through excessive degradation of organelles and proteins resulting 
in autophagic cardiomyocyte death, or through suggested cross-talk between autophagic 
and apoptotic mechanisms (Ma, Wang et al. 2015). During reperfusion, Akt activation 
opposes AMPK action through the alleviation of mTORC1 inhibition, thus allowing for the 
attenuation of autophagy and subsequent reduction in cell injury (Chaube and Bhat 2016). 
While AMPK and Akt appear to have conflicting roles in terms of the activation of mTORC1 
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and autophagy during reperfusion, both AMPK and the RISK-SAFE pathways have been 
shown to be activated by the same signalling molecules and cardioprotective agents 
(Moussa and Li 2012)(Hausenloy and Yellon 2007), with AMPK also demonstrating the ability 
to inhibit mPTP opening and reduce myocardial infarct size (Paiva, Rutter-Locher et al. 2011). 
Other studies have indicated that autophagy during the reperfusion period is independent 
of AMPK, instead being mainly mediated by beclin-1, suggesting it is possible that increased 
AMPK activity as a response to depleted energy supplies and subsequent increased 
autophagy during ischemia is cardioprotective, whereas beclin-1 activity during reperfusion, 
which occurs regardless of the replenishment of energy supply, results in excessive 
autophagy, and is in fact harmful to the cell (Matsui, Takagi et al. 2007).  
Figure 6. An overview of the roles of GSK3β, AMPK, and autophagy during ischemia and 
reperfusion respectively (based on figures from (Sciarretta, Volpe et al. 2014) & (Chaube 




1.5.4 Conditioning signalling in the neonatal heart 
Researchers investigating the cardioprotective efficacy of pre- and post-conditioning in 
neonates have shown that both were ineffective at reducing infarct size or improving 
functional recovery following I/RI (Jones, Pepe et al. 2013, Schmidt, Stottrup et al. 2014, 
Doul, Charvatova et al. 2015). It is possible that this is due to a higher baseline level of the 
proteins involved in survival signalling in neonatal hearts, meaning cardioprotective 
therapies aiming to increase activation of these pathways may have little to no effect. 
Indeed, work by Naqvi et al. (2014) discovered a sudden spike in IGF-1/IGF-1R/AKT pathway 
activation at postnatal day 15 in mice, accompanied by a spike in the proliferative capacity 
of cardiomyocytes at this point. Whilst this spike in activity does correlate with the improved 
resistance to I/RI in 14-day old rats, it does not account for the lack of cardioprotective 
efficacy of pre- and post-conditioning in rat hearts in the first 10 days of postnatal life (Doul, 
Charvatova et al. 2015). The potential role of survival signalling in the vulnerability profile to 
I/RI has also been supported by previous findings from Liaw et al. (2013), in which the 
authors found that, in neonates, a greater expression of unphosphorylated AKT, acting as a 
“reserve” for activation upon injury, in addition to other pro-survival proteins such as HIF1-
α, Caveolin-3, BCL-2 and Bax. Moreover, Glycogen Synthase Kinase 3β (GSK3β) was found to 
be highly phospho-inhibited in neonatal hearts in comparison with adults (Liaw, Hoe et al. 
2013, Ostadal, Ostadalova et al. 2014).  
1.6 Cardiac mitochondrial morphology & subpopulations  
As discussed above (see Figure 2) the predominant end effect of the RISK-SAFE pathways is 
prevention of mPTP opening. This highlights an important role of mitochondria in the 
response to I/RI and survival signalling pathways, which has been supported by previous 
63 
 
reports of significant morphological changes in mitochondria following I/R. However, recent 
work has uncovered a strong link between the location and the function of the mitochondria 
in heart cells, which may have implications for injury following cardiac insults. Three distinct 
mitochondrial subpopulations exist (Figure 7); Interfibrillar (IF) mitochondria situated 
between the myofibrils & predominantly responsible for providing energy for contraction, 
perinuclear (PN) mitochondria that cluster around the poles of the nucleus and provide 
energy for gene transcription, and subsarcolemmal (SSL) mitochondria that sit just below 
the cell membrane and generate energy for sarcolemmal activities ion channel function 
(Hwang and Kim 2013). These subpopulations have been shown to exhibit distinct functional 
characteristics, such as differences in oxidative phosphorylation and utilisation of substrates, 
resistance to Ca2+-overload, and sensitivity to opening of the mPTP (Hollander, Thapa et al. 
2014). Moreover, IF mitochondria display a greater capacity for Ca2+-accumulation and 
slower mPTP opening times than SSL, indicating potential differences in the apoptotic 
response to I/RI between these subpopulations (Hollander, Thapa et al. 2014). 
Figure 7. Mitochondrial subpopulations. Electron micrograph showing the three 





The morphology of mitochondria is known to be altered by I/R. Recently, work by Kalkhoran 
et al. (2017) looked to identify differences in the morphology of these distinct mitochondrial 
subpopulations from control hearts, following ischemia, and with ischemic preconditioning 
(IPreC). Cardiac sections were analysed from electron microscopy images, and it was found 
that IF showed the most elongated morphology, with PN having the smallest areas and 
greatest measures of sphericity similar to SSL. Following ischemia, all three subpopulations 
had increased sphericity, with reduced elongation in IF and increased area in PN. However, 
the morphology of mitochondria was not shown to display any differences following IPreC 
(Kalkhoran et al. 2017). It is clear from this that ischemia does have a significant effect on 
mitochondrial morphology in adult heart, however, little has been reported about this effect 
over the course of postnatal development, and how differences in post-ischemic 
morphology may be linked to cardiomyocyte survival and vulnerability to I/RI.  
1.7 Summary & Conclusions 
It is clear that, during postnatal development, there are important changes in the 
vulnerability of the heart to I/RI, the causes of which are currently not fully understood. With 
the exception of the antioxidant catalase (Section 1.1.3), identified postnatal differences 
such as those outlined in Table 1 above demonstrate only gradual, unidirectional changes 
which occur during development as opposed to the biphasic profile of cardiac vulnerability, 
indicating they are not contributory to these differences in the response to I/RI seen at 
different stages of postnatal development. Survival signalling pathways have been shown to 
play critical roles in the response and subsequent recovery of the heart following I/RI, with 
some initial reports indicating potential differences in the expressions of the proteins 
involved with development (Section 1.5.4). It is therefore crucial to further explore and 
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elucidate the underlying mechanisms of these differences, as this will provide potential 
targets for future therapies, and a foundation upon which the progression of 
cardioprotective strategies can occur.  
1.8 Hypothesis & Aims 
Current knowledge as to the contribution of survival signalling proteins to the cardiac 
vulnerability profile seen during postnatal development is limited. Although previous work 
has been undertaken to examine any changes in the expression of these proteins, this 
previous study excluded a critical age group required for full elucidation of the biphasic 
profile – 7-day olds – and instead looked only at 0-day, 14-day, 28-day and adult hearts (Liaw 
et al. 2013). Furthermore, this previous study did not further examine whether targeted 
inhibition or activation of these identified proteins had an effect on cardiac injury following 
I/RI. Our work therefore looked to further build upon this knowledge, examining the full 
biphasic profile of survival signalling protein expression and investigating potential age-
dependent differences in the vulnerability of hearts to inhibition of identified proteins.  
The proposed work in this thesis aims to address the following hypothesis: “Changes in 
cardiac vulnerability during postnatal development are due to developmental alterations in 
survival signalling, and that identification and targeting of significant proteins within these 
pathways could provide an avenue through which novel therapies could be devised to 
combat cardiac injury following I/R.”  
As a result, the overall aims of this work are: 
1. To identify any changes that occur in survival signalling through changes in the 
expression of pro-survival and apoptosis-related proteins during development. 
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2. To see if specific inhibition of the identified proteins affects the vulnerability to I/RI 
during postnatal development in isolated cardiomyocytes. 
3. To see if specific inhibition of the identified proteins affects the vulnerability to I/RI 
during postnatal development in whole hearts. 
4. To identify any changes that may subsequently occur in terms of survival signalling 
protein expression or activity following I/RI. 
5. To identify differences in cardiomyocyte structure and ultrastructure that may 
influence the response to I/RI at different stages of development, including: 
i.  blood vessel dimensions, cardiomyocyte hypertrophy and sarcomere lengths   
ii. caveolae, multivesicular body (MVB) and exosome abundance 
iii.  mitochondrial subpopulation morphology and distribution 
6. To observe any changes that may occur in the cardiomyocyte structure and 
ultrastructure following ischemic insult and reperfusion.  
67 
 
Chapter 2: Materials & Methods 
2.1 Materials 
2.1.1 Reagents 
Experimental reagents used and their companies of origin are listed below: 
Agar Scientific (Essex, UK) 
Glutaraldehyde solution (25 %) 
Bio-Rad (Hertfordshire, UK) 
Laemmli sample buffer 
Precision Plus Protein™ All Blue Standards 
Quick Start™ Bradford 1 x Dye Reagent 
BOC Healthcare (Surrey, UK) 
95 % oxygen/5 % carbon dioxide medical gas mixture 
Medical oxygen (99.5 % minimum) 
BOC Industrial Gases (Surrey, UK) 
Liquid nitrogen 
Fisher Scientific UK Ltd (Leicestershire, UK) 
D-glucose anhydrous 
Magnesium sulphate (MgSO4·7H2O) 
Sodium chloride (NaCl) 
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Sodium dodecyl sulphate (SDS) 
GE Healthcare Life Sciences (Buckinghamshire, UK) 
Amersham hyperfilm 
Enhanced chemiluminescence (ECL) western blotting detection reagents 
Marvel (Lincolnshire, UK) 
Original dried skimmed milk 
Merck (New Jersey, USA) 
Magnesium chloride (MgCl2) 
Randox (County Antrim, UK) 
CK-NAC assay (CK113) 
CK-NAC assay (CK522) 
Roche (Sussex, UK) 
cOmplete, EDTA-free protease inhibitor cocktail tablets 
PhosSTOP phosphatase inhibitor cocktail tablets 
Sigma-Aldrich™ (Dorset, UK) 
2, 3, 5-triphenyl-tetrazolium chloride (TTC) 
2-mercaptoethanol 
Albumin from bovine serum (BSA) 




Dimethyl sulphoxide (DMSO) 
Ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA) 
Folin and Ciocalteu’s phenol reagent 




Nonidet™ P 40 substitute solution 
Phosphate buffered saline (PBS) tablets 
Ponceau S solution 
Protease from Streptomyces griseus, Type XIV 
Sodium deoxycholate 
Sodium hydroxide (NaOH) 
Trizma® base 
Trypan blue solution (0.4 %) 
TWEEN® 20 
Thermo Scientific (Leicestershire, UK) 
Polyvinylidene difluoride (PVDF) transfer membrane (0.45µm) 
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Tocris Bioscience (Bristol, UK) 
TWS 119 
Dorsomorphin Dihydrochloride 
VWR International Ltd (Leicestershire, UK) 
4-(2-Hydroxyethyl)piperazin-1-ylethanesulphonic acid (HEPES) 
Di-sodium hydrogen phosphate (Na2HPO4) 
Hydrochloric acid fuming (37 %) (HCl) 
Potassium chloride (KCl) 
Potassium dihydrogen phosphate (KH2PO4) 
Sodium hydrogen carbonate (NaHCO3) 
Worthington Biochemical Corportation (New Jersey, USA) 
Collagenase, Type 2 
2.1.2 Antibodies 
Antibody Source Dilution Company & code 
HSP90 Rabbit, monoclonal 1:1000 Cell Signaling Technology, #4877 
Caveolin-1 Rabbit, polyclonal 1:1000 Cell Signaling Technology, #3238 
Caveolin-3 Rabbit, polyclonal 1:1000 abcam, ab2912 
14-3-3η Rabbit, polyclonal 1:1000 Cell Signaling Technology, #9640 
AKT Rabbit, polyclonal 1:1000 Cell Signaling Technology, #9272S 
pAKT (S473) Rabbit, polyclonal 1:1000 Cell Signaling Technology, #9271S 
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pAKT (S129) Rabbit, monoclonal 1:1000 abcam, ab133458 
β-Catenin Rabbit, monoclonal 1:1000 BD Transduction Laboratories™, 
610153 
pβ-Catenin (S552) Rabbit, polyclonal 1:1000 Cell Signaling Technology, #9566 
PKCε Rabbit, monoclonal 1:1000 abcam, ab124806 
pPKCε (S729) Rabbit, polyclonal 1:1000 abcam, ab63387 
GSK3β Rabbit, monoclonal 1:1000 Cell Signaling Technology, #12456 
pGSK3β (S9) Rabbit, monoclonal 1:1000 Cell Signaling Technology, #9327 
AMPKα Rabbit, polyclonal 1:1000 Cell Signaling Technology, #2532 
pAMPKα (T172) Rabbit, monoclonal 1:1000 Cell Signaling Technology, #2535 
mTOR Rabbit, polyclonal 1:1000 Cell Signaling Technology, #2972 
pmTOR (S2481) Rabbit, polyclonal 1:1000 Cell Signaling Technology, #2974 
BAX Rabbit, polyclonal 1:1000 Cell Signaling Technology, #2772 
BCL-2 Rabbit, polyclonal 1:1000 abcam, ab59348 
Mfn1 Rabbit, polyclonal 1:1000 abcam, ab104585 
β-actin Rabbit, polyclonal 1:1000 Abcam, ab8227 






Donkey 1:10000 GE Healthcare Life Sciences, 
NA934 
 





Adult Wistar Han rats were purchased by weight (Table 3) from Charles River (Margate, UK). 
Upon delivery the animals were housed at the University of Bristol animal unit, allowed to 
recover from transit and then used when required. Early postnatal rats, i.e. 7-day olds, 14-
day olds and 28-day olds, were ordered directly from ASU Service (University of Bristol), and 
delivered to the DHB animal housing facility on the day of intended use. Treatment of 
animals and all procedures were in accordance with Home Office guidance, Animal (Scientific 
Procedures) Act of 1986. Prior to culling, each rat was weighed, and data for the average 
weights of each age group are shown in Table 3. Rats were then culled using Schedule 1 
methods, before excision of the heart.  
 
2.3 Cardiomyocyte Isolation 
The cardiomyocyte isolation protocol used was based on previous work undertaken within 
the research group of Professor Suleiman (Williams et al. 2001), as described below. 
2.3.1 Animals, weights and perfusion flow rates 
Rats from 3 age groups were used for cardiomyocyte isolation; 14-day (n = 6), 28-day (n = 
4), and adult (n = 3). 7-day olds were excluded due to the changes to the protocol required 
Table 3. Descriptive data for the average weights of rats in each age group. Mean adult 





in order to keep cells alive following isolation, making direct comparison between the age 
groups difficult. Following Schedule 1 culling, hearts were extracted from rats and placed 
directly into cold Solution B. Weights for each rat were taken and are shown in Table 4. The 
flow rates required for hearts from different age groups varied due to physiological and 
developmental differences in cardiac size and function. The flow rates used were based on 
previous work undertaken by Sarah Martin, who determined optimal flow rates for each age 




All solutions used for heart perfusion and isolation of myocytes were made from a primary 
solution with no added CaCl2, Solution A, containing 137 mM NaCl, 5 mM KCl, 1.2 mM 
MgSO4, 1.2 mM NaH2PO4, 20 mM Hepes, 16 mM Glucose, 5 mM C3H3NaO3, 1.8 mM MgCl2, 
made up to 2 L with distilled water and adjusted with NaOH to pH 7.25. A series of solutions 
were then made up containing different levels of CaCl2 from Solution A.  Solution B was made 
with the addition of CaCl2 to Solution A for a Ca2+ concentration of 750 µM. Solution C was 
made up by adding 90 µM of Ca2+ chelator EGTA to Solution A.  Solutions E, F & G were made 
from Solution A with final concentrations of 150 µM Ca2+, 0.5 mM Ca2+, and 1 mM Ca2+, 
Table 4. Average weights of animals used and the perfusion flow rates required, as 
outlined by previous work from Sarah Martin. Mean adult weight corresponds to 





respectively. Enzyme containing solution (Solution D), was made freshly on the day of 
isolation with 50 mg of collagenase and 5 mg protease to 50 ml of Solution A.  
2.3.3 Isolation of cardiomyocytes 
Extracted hearts were trimmed in a tray of cold Solution B (750 µM Ca2+) to remove excess 
tissue, before cannulation via the aorta onto the isolation apparatus shown in Figure 8. Once 
cannulated, additional trimmings were made to allow the removal of blood clots and to 
ensure the heart was beating well. The heart was perfused at a constant flow rate dependent 
on the age of the rat (see Section 2.3.1) for 2 minutes with warm, oxygenated Solution B in 
order to wash out any remaining blood. Hearts were then perfused for 4 minutes with EGTA 
containing Solution C, a chelator of Ca2+, thus removing resisdual calcium from buffers and 
from the myocardium in order to loosen connection between myocytes. Enzymatic digestion 
was then undertaken by perfusing hearts with enzyme-containing Solution D until soft to the 
touch, indicating sufficient digestion has occurred. The times required to fully digest the 
hearts varied with age, and are outlined in Table 5. However, it should be noted that these 
times were significantly longer than those previously reported for all ages of rat. This may in 
part have been due to the EGTA used at the start as, upon switching to a new source of 
EGTA, the time required for digestion of an adult rat heart was reduced from approximately 





Figure 8. Cardiomyocyte isolation equipment. A. Experimental setup for cardiomyocyte 
isolation. B. Example of a cannulated adult rat heart. C. Example of a cannulated 14-
day old heart. 
 
Table 5. Average times required for complete digestion and average starting 




Finally, hearts were perfused with Solution E, in order to both wash out the remaining 
enzyme to prevent further digestion and killing of the cells, as well as to begin the gradual 
reintroduction of Ca2+. Following perfusion with Solution E, the heart was cut down from the 
apparatus and placed into a fresh tray of warmed and perfused Solution E, at which point 
the heart tissue was gently pulled apart to release the cardiomyocytes, and transferred to a 
beaker for shaking at 37°C for 4 minutes. The heart was shaken a subsequent 2 times in fresh 
Solution E each time to release a sufficient number of cells from the tissue for use in the next 
step of the experimental procedure, before each sample was combined and poured through 
a cheesecloth to filter the cell solution from the tissue. This solution was left to sediment for 
8 minutes, before removal of the top layer of solution – containing debris and dead cells 
which are lighter – and addition of warmed and perfused Solution F. This process was 
repeated after a further 5 minutes of sedimentation, but with the addition of Solution G. 
These solutions containing progressively larger concentrations of Ca2+, therefore allowing 
for the gradual reintroduction of Ca2+ to the cells without killing them with a sudden increase 
in calcium concentration. Due to the lower yield of cells from 14-day old hearts, CaCl2 was 
added directly to the isolated cells at 0.5 mM followed by 1mM, to avoid dilution of the cell 
solution or loss of cells when pipetting away the top layer. A sample of cell solution was 
collected in a pre-weighed Eppendorf, centrifuged for 1 minute, and frozen in liquid nitrogen 




2.3.4 Simulation of ischemia/reperfusion injury and cell viability 
Cells were kept incubated in a water bath at 37°C with gentle shaking throughout the 
experiment, and were only removed in order to obtain samples for examination under the 
microscope by pipette. Cell solutions were gently mixed by pipette prior to each separation 
of groups or removal of samples for cell counts, in order to ensure cells that had settled 
between time points were well mixed into the rest of the solution.  Two groups of cells (5ml 
of the final cell solution each) were taken, one as a control and the other as an experimental 
sample. Nothing further was added to the control group, whereas I/RI was simulated within 
the experimental group with the addition of 3 mM CaCl2 (for a final Ca2+ concentration of 4 
mM), 20 mM KCl, and 0.5 mM H2O2. Cell viability was measured from the total cell solution 
Adult. 
P14. 
Figure 9. Isolated cardiomyocytes 
from a 14-day old heart (P14), a 28-
day old heart (P28), and an adult 
heart, with non-viable cells stained 
with Trypan Blue only for the 14-





as a start viability, at 5 minutes post-addition of the I/RI simulation solutions, and then at 1 
hour and 2 hours following the start of the experiment.  
Cell viability was measured using Trypan Blue solution (0.4% in 0.81% NaCl and 0.06% 
KH2PO4), which identifies cells that are no longer viable with a blue stain, but leaves those 
that are unstained, as live cells maintain an intact cell membrane that does not allow entry 
of Trypan Blue into the cell. Cell viability was defined as the percentage of cells without 
Trypan Blue staining, including those that were rounded but unstained, and was taken as an 
average of 3 field per cell group at each time point. Examples of these stained cells at each 
time point are given in Figure 10 below.  
 
2.3.5 Cell morphometry measurements  
The size of cardiomyocytes isolated from different age groups was measured using a light 
microscope with a grid-lined slide. Each cell length and width was measured by the number 
of squares spanned on the grid, and converted from this number into an actual size in 
micrometres using the scale 1 square = 0.01 mm. 
Figure 10. Examples fields of cells at each time point for the two experimental groups, taken 




2.4 Proteomics Studies 
2.4.1 Tissue collection & protein extraction 
2.4.1.1 Whole tissue samples 
Samples for proteomics were collected by Dr Martin Lewis. Male Wistar rats of three age 
groups in the first run, 14-day old (n = 3), 28-day old (n = 3) and adult (n = 4), and four age 
groups in the second run, 7-day old (n = 4), 14-day old (n = 8), 28-day old (n = 8), and adult 
(n = 7), were used in all experiments. All animals were kept at the Animal Services Unit, 
University of Bristol until used. Animals were culled using Schedule 1 methods. All animals 
were weighed prior to killing. Treatment of animals and all procedures were in accordance 
with Home Office guidance under the Animals (Scientific Procedures) Act of 1986. Hearts 
were excised and dissected into atria, ventricles, and apex, and frozen in liquid nitrogen. 
The cardiac tissue was weighed and RIPA buffer (1x PBS tablet, 1% (v/v) Nonidet P-40, 0.5% 
(w/v) sodium deoxycholate, 0.1% (w/v) SDS), adjusted to pH 7.4 and with the addition of one 
tablet of protease (Complete, mini, EDTA-free protease inhibitor cocktail tablets, Roche, UK) 
and phosphatase (PhosSTOP, phosphatase inhibitor cocktail tablets, Roche, UK) inhibitor, 
was added at 10 µl/mg of tissue. 1.4mm Zirconium oxide beads were added to 2ml tubes 
with the cardiac samples and RIPA buffer, before homogenisation at maximum speed twice 
for 10 seconds each time using the minilys tissue homogenizer (Bertin Technologies, France). 
Samples were then left on ice for 30 minutes, before centrifugation at 10,000 x g for 10 
minutes at 4°C. The resulting supernatant was then stored at -80°C.  
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2.4.1.2 Protein extraction from isolated cardiomyocyte pellets  
Cell pellets from cardiomyocyte isolation were weighed, subtracting the initial weight of the 
Eppendorf tube alone, and RIPA buffer (see Section 2.4.1.1) added at 1 µl/mg. These tubes 
were then vortexed until the pellet had fully mixed into solution, before centrifugation at 
10,000 x g for 10 minutes at 4°C. The resulting supernatant was stored at -80°C. 
2.4.2 Protein quantification 
2.4.2.1 Lowry method 
A protein standard was made using a BSA stock solution (5 mg/ml) diluted to 400 µg/ml, and 
was then used to create a standard curve at 10, 20, 40, 60, 80 and 100 µg/ml BSA. 400 µl of 
Lowry reagent (40 ml of distilled water, one bottle of Sigma Protein Assay Kit Lowry reagent 
powder) was added to each tube, and left to incubate for 30 minutes at room temperature. 
200 µl of Folin-Ciocalteu reagent was then added to the standards, vortexed, and then left 
to incubate for a further 30 minutes. At this time, distilled water was used to blank the 
spectrophotometer at 750 nm, before measurement of absorbance at each concentration 
of BSA, producing a standard curve of concentration versus absorbance.  
Samples were diluted at a 1:2 ratio (5µl protein sample to 10 µl of distilled water) to ensure 
the measured absorbance would remain within the range of the standard curve. The 
protocol above was then repeated with 4µl of each protein sample, and duplicated for each 
sample. Protein concentrations of each sample were calculated using the straight-line graph 
equation from the standard curve, and adjusted for the dilution factors used.    
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2.4.2.2 Bradford assay 
Concerns over variations in the expression of supposed housekeeping protein, GAPDH, and 
thus the accuracy of protein quantification performed on samples prepared for western 
blotting originally done using the Lowry method were encountered, as discussed in Section 
9.3.1. As a result, this was repeated using the Bradford method in order to rule out errors in 
sample protein quantification. From 5 mg/ml BSA stock solution, 1 µl, 2 µl, 3 µl, 4 µl and 5 µl 
was added to LP4 tubes in duplicate. 3 ml of Bradford reagent was then added, vortexed, 
and left to incubate for 15 minutes. Using 3 ml of Bradford reagent as a blank, absorbance 
for each concentration was measured at 595 nm, and a standard curve plotted from these 
measurements.  
Protein samples were diluted at a 1:2 ratio (5 µl protein sample to 10 µl of distilled water) 
to ensure the measured absorbance would remain within the range of the standard curve. 
3 ml of Bradford reagent was added to 5 µl of each sample, in addition to 5 µl of RIPA buffer 
as a blank, and left for 15 minutes before measurement of absorbance. Protein 
concentrations of each sample were calculated using the straight-line graph equation from 
the standard curve, and adjusted for the dilution factors used.   
2.4.3 Proteomic analysis – Tandem Mass Tagging 
2.4.3.1 Total proteins 
Extracted protein samples were diluted with double distilled water to adjust the protein 
concentration of each sample to 2 mg/ml, according to previous protein quantification 
(Section 2.2.2.2). Samples were then sent for Tandem Mass Tag (TMT) analysis 
(ThermoFisher Scientific, UK) by the University of Bristol Proteomics Facility. Protein samples 
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were processed and digested, and the resulting peptides in each sample were labelled with 
a unique reporter group (126, 127, 128, 129, 130), in addition to a total pooled sample of 
peptides from each individual sample (131) (Littlejohns, Heesom et al. 2014), as shown in 
Figure 11a. Each TMT label consists of a NH2 reactive group, which allows amine-specific 
binding to peptides, a Mass Normaliser, which ensures the overall mass of each tag is 
constant in spite of the differing reporter groups, in addition to a Mass Reporter group, 
which is specific to each sample in a single run (Abdul-Ghani, Heesom et al. 2014) (Figure 
11b). This group is released during fragmentation by Collision Induced Dissociation (CID) 
following cleavage of the linker region during LC-MS/MS, allowing detection of the different 
reporter ions ranging 126-131 Da, which cluster at the low mass end of each MS/MS spectra 
to indicate the relative abundance of each peptide by sample, as outlined in Figure 11a 












2.4.3.2 Phosphorylated proteins 
Phosphorylated proteins follow a similar process of proteomic analysis as non-
phosphorylated protein, with the addition of a phosphopeptide enrichment step. Following 
labelling with TMT reagents, the pooled samples were passed through a titanium dioxide 
(TiO2) column, during which phosphorylated and non-phosphorylated peptides were 
separated as phosphopeptides bind to the column, whereas non-phosphopeptides pass 
straight through and elute first (Abdul-Ghani, Heesom et al. 2014). The phosphopeptides 
were subsequently eluted and underwent LC-MS/MS analysis.  
2.4.4 Analysis of proteomic output 
Proteomic output was presented as a Proteome Discoverer file. The relative levels of protein 
in each sample were displayed as a ratio of protein expression in the individual sample to 
the level of protein expressed within the total pooled sample. Proteins previously found to 
be involved in the apoptotic or survival signalling process were identified from the literature, 
relevant cell signalling pathways using the Kegg Pathway database, as well as the PANTHER 
protein database. Those that were present within the proteomic output were then selected, 
Figure 11. Summary of the protocol 
for proteomics. A. The process of 
proteomic analysis. B. General 
structure and function of each 
region of a TMT reagent molecule. 





extracted, and analysed using One-way ANOVA in SPSS for statistically significant differences 
in the mean protein levels between the age groups (Section 2.8).  
This process was replicated for the phospho-proteomic output, before further analysis of 
their individual phosphosites was performed. Phosphosites with a ‘low’ confidence rating – 
as indicated within the Proteome Discoverer file – were excluded, in addition to those not 
present within each of the age groups. The remaining phosphosites were analysed using 
One-way ANOVA (Section 2.8), in order to compare the pattern of change of each individual 
phosphosite over age with that of the total phosphoprotein.  
2.5 Western Blotting 
2.5.1 Sample preparation 
For western blotting, samples containing 0.15 mg were needed, therefore the amount of 
sample needed for 0.15 mg in a final volume of 100 µl was calculated based on protein 
quantification previously undertaken (see Section 2.4.2), and the remaining volume made 
up with distilled water. Loading buffer was made using 1425 µl of 2x Laemmli buffer and 75 
µl β-mercaptoethanol (βME), and added to the samples at a 1:1 ratio. After vortexing, 
samples were then heated at 95°C for 5 minutes, releasing the pressure by opening the 
Eppendorf caps at the start, and then transferred to an ice box.  
2.5.2 Gel electrophoresis 
Running buffer was made from 10x stock solution (30.3 g TRIS base, 114 g glycine, and 10 g 
SDS in 1 L, pH 8.1-8.6), using 50 ml of stock solution with 450 ml of distilled water. The gel 
electrophoresis tank was assembled with two Mini-PROTEAN® TGXTM precast gels (4-20% 
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acrylamide, 15-well comb), and tested for leaks by pouring transfer buffer into the centre 
and checking for a decrease in the level of solution.  
Following centrifugation of the samples, 10 µl of loading buffer was pipetted into the first 
well, with 6 µl of a known molecular weight marker to the second well and 3 µl of the marker 
to the end well, before 12 µl of each sample was added to the remaining wells. Samples 
were loaded by alternating age groups to avoid the possibility of uneven development of 
one end of the membrane at a later stage accounting for any differences between the age 
groups. The gels were then run at 100 V for approximately 10 minutes in order to allow the 
samples to run to the edge of the stacking gel, before increasing the voltage to 150 V until 
bands reached the end of the gel.  
2.5.3 Membrane Transfer 
Transfer buffer was made from 100 ml stock solution (250 mM Trizma base, 192 mM glycine, 
10% (v/v) methanol), 100 ml methanol, and 800 ml distilled water, before placing into the 
fridge to cool. Two PVDF membranes were cut to size and the orientation marked with a cut 
to one corner, before wetting with 100% methanol, 3 washes with distilled water, and finally 
being left to soak in transfer buffer for approximately 15 minutes.  
Following electrophoresis, the gels were removed from their plastic casing, removing the 
top section of the gel with the well remnants, and placed down onto 4 pieces of wet blotting 
paper, with one PVDF membrane placed on top of the gel. These layers were then placed 
into a transfer buffer filled tub containing a transfer cassette and one mesh layer. 4 
additional pieces of wet blotting paper were placed onto the PVDF membrane, with a final 
layer of mesh, before rolling to remove any air bubbles and closing the cassette. This process 
was repeated for the second gel, and both cassettes were placed into a tank for transfer, 
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with the black side facing the black wall of the tank. An ice block and stirrer were added to 
the tank to ensure an even temperature was maintained throughout the tank during the 
transfer process, before filling the tank with transfer buffer and running at 300mA for 90 
minutes in the cold room.  
2.5.4 Ponceau S Staining 
Following transfer, membranes were washed with TBST (100 ml stock solution – 250mM 
Trizma base, 136 mM NaCl, 2.7 mM KCl, and 2 % (v/v) Tween 20 – with 900ml distilled water), 
before incubation with Ponceau S solution (Sigma-Aldrich) for 5 minutes. Membranes were 
then rinsed with double distilled water to remove background staining and images were 
taken for analysis. Staining was removed by washing membranes in 0.1M NaOH for 1 minute, 
before rinsing with running double distilled water for 3 minutes. Membranes were then 
ready for blocking. 
2.5.5 Incubating the membrane 
First, the membrane was blocked using 10% milk in TBST, incubating the membranes with 
this solution for 1.5 hours. This was to prevent non-specific binding of the primary or 
secondary antibody to the membrane, which would otherwise create a high level of 
background binding and thus result in unclear bands for the protein of interest.  
The marker band ladder was then marked with biro on each membrane, and the membranes 
were washed in TBST twice for 5 minutes each time. Following this, each membrane was cut 
in two to separate the region of the membrane with the expected molecular weight for each 
protein of interest from that of the housekeeping protein, GAPDH (37 kDa). Each section of 
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the membranes was placed into a separate container, and the relevant primary antibody 
was added. These were then left to rock in the cold room overnight. 
The following morning, 3% milk was made using 0.9 g of milk powder in 30 ml TBST. Primary 
antibodies were poured back into their original containers for re-use, and the membranes 
were washed in TBST 3 times for 5 minutes each time. 10 ml of milk was added to the large 
containers containing the membranes for the proteins of interest (5 ml for the smaller 
GAPDH membranes), and secondary antibody corresponding to the source species of the 
primary antibody was added (1.25 µl in 10 ml of milk, 0.65 µl in 5 ml milk). The membranes 
were rocked in secondary antibody at room temperature for 1 hour.  
2.5.6 Development and analysis of bands 
Following this period, membranes were washed in TBST 4 times for 5 minutes each wash, 
before a final rinse of each membrane with water. Membranes were covered with Enhanced 
ChemiLuminescence (ECL) solution for 4 minutes (target protein membranes) or 2 minutes 
(GAPDH membranes), before being placed into cassettes for development in the dark room. 
High performance chemiluminescence hyperfilm was placed into and left within the 
cassettes for varying times depending on the strength of the bands produced, adjusted to 
produce bands with optimum density and definition, and developed via exposure to x-ray 
using the OptiMax® (UK) machine. Bands were then analysed using ImageJ, producing values 
of density for each band, and calculating the level of the target protein in each sample as a 
ratio of the target protein band density to the band density of GAPDH for that sample. 
Statistical analysis for the significance of any differences in protein levels between age 
groups was performed using SPSS. 
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2.5.7 Membrane stripping 
In instances where a membrane needed to be re-probed, for example, to measure the level 
of the phosphorylated and non-phosphorylated forms of the same protein on a blot, a mild 
stripping method was used to remove previously bound antibodies. Stripping buffer was 
made using 15 g of glycine, 1 g of SDS, 10 ml of Tween-20, HCl as required to adjust the pH 
to 2.2, and made up to 1 L with distilled water. The membrane was covered with this 
stripping buffer and set to rock for 5-10 minutes, before discarding the buffer and repeating 
this step with fresh buffer. The membrane was then rocked in PBS twice for 10 minutes each 
time, followed by TBST twice for 5 minutes each, at which point the membrane was ready 
to be re-used beginning from the blocking stage of the western blotting protocol (as outlined 
in Section 2.5.5). 
2.6 Ischemia/reperfusion experiments in perfused heart 
2.6.1 Ischemia protocol 
Adult (n = 3) and 14-day old (n = 3) rats were culled using Schedule 1, as described in Section 
2.2. Hearts were removed, cannulated onto Langendorff apparatus (Section 2.3) and 
perfused with Krebs-Henseleit solution (120 mM of NaCl, 25 mM of NaHCO3, 11 mM of 
Glucose, 1.2 mM of KH2PO4, 1.2 mM of MgSO4, 4.8 mM of KCl, 2 mM of CaCl2 – made up to 
2 L with double distilled H2O). After 20 minutes of stabilisation, hearts were exposed to 30 
minutes of global ischemia, before removal from the cannula. Small cardiac cubes were 
taken from the left ventricular wall and placed into fixative solution and left overnight, 
before being transferred into phosphate buffer and sent for processing. The remaining 
sections of heart were collected and immediately frozen in liquid nitrogen and stored in -
80°C for later protein extraction.  
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2.6.2 Ischemia & reperfusion protocol 
Hearts were extracted from 14-day old (n = 6) and adult (n = 6) rats and cannulated onto 
Langendorff apparatus for perfusion, as described in Section 2.6.1. However, in this case, 
following the ischemic period, flow was restarted and hearts were reperfused for 60 
minutes. The effluent was collected before ischemia and at 1, 5, 10, 20, 30 and 60 minutes 
of reperfusion for use in creatine kinase measurements. Additionally, at the end of 
reperfusion, hearts were collected and tissue taken from the left ventricular wall for electron 
microscopy. The remaining tissue was frozen in liquid nitrogen and stored at -80°C for future 
protein extraction. 
2.6.3 Creatine kinase measurements 
The release of creatine kinase from cells is used as a marker of the degree of tissue damage 
resulting from I/R (Zuurbier et al. 2004). As a result, effluent samples collected during 
reperfusion (Section 2.6.4) were analysed for creatine kinase concentration using a ‘Randox 
CK-NAC’ kit. 40 μl of effluent was added to 1 ml of the kit buffer, which contained the 
substrates necessary for a series of reactions culminating in the production of NADPH. As 
these substrates were provided in excess within the buffer, the rate of NADPH production 
was dependent on the concentration of creatine kinase within each effluent sample. This 
rate of NADPH production was measured at 37°C via absorbance readings taken at 340 nm 
using a ‘Jenway Multi-cell Changer Spectrophotometer’, over a period of 4 minutes. The 
subsequent readings were multiplied by 4047.5 for conversion to international units of 
creatine kinase per litre (U/L) (Randox Laboratories Ltd. information sheet, Ben Littlejohns 
PhD thesis, 2013). 
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2.6.4 TTC staining for infarction 
To measure the size of infarction, hearts were perfused with Triphenyl Tetrazolium Chloride 
(TTC) solution, comprised of 0.3g of TTC powder in 30ml of PBS solution, for 10 minutes at a 
flow rate of 2ml/min for adult hearts and 1ml/min for 14-day old hearts. Hearts were then 
incubated in PBS for 5 minutes at 37°C, weighed to obtain the wet weight of the heart, and 
then frozen for 20 minutes. Hearts were then cut into slices and stored in 4% (v/v) formalin 
in PBS for storage overnight at 4°C, before transfer into PBS for storage until scanning. Both 
sides of each heart were imaged using an Epson scanner, and slices were then left to dry in 
order to obtain the dry weight of each slice. Images were analysed using Image J in order to 
determine the percentage of each slice that was made up of infarcted tissue, identified as 
any regions not stained brick red (viable tissue) and are instead pale areas of tissue. 
Alongside the dry weights of each slice, these areas were used to calculate the volume of 
infarcted tissue as a percentage of the total volume of the heart. 
2.7 Histology 
2.7.1 Light Microscopy 
2.7.1.1 Tissue Fixation 
Hearts were extracted from 14-day old (n = 4), 28-day old (n = 5), and adult (n = 5) rats, 
flushed with Krebs-Henseleit buffer (120mM NaCl, 25mM NaHCO3, 11mM D-glucose 
anhydrous, 1.2mM KH2PO4, 1.2mM MgSO4.7H2O, 4.8mM KCl and 1.2mM CaCl2), and cut to 
remove the apex and any excess tissue. The remaining heart sections were placed into 5ml 
tubes containing fixative solution (10% paraformaldehyde in 0.01M phosphate buffer) and 
left to fix for 24 hours. Following this fixation period, the fixative solution was pipetted out 
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of the tube, replacing it with phosphate buffer to wash, and again with fresh buffer to be 
left in the fridge until processing. 
2.7.1.2 Tissue processing and embedding 
Each heart section was placed into a white cassette, which were then stored in 0.01 M 
phosphate buffer ready for tissue processing. This was performed using the ThermoFisher 
Scientific ExcelsiorTM AS Tissue Processor, which automatically undertakes the process of 
dehydrating the tissue with a graded ethanol series, gradually displacing water from the 
tissue to allow the infiltration of paraffin wax. Processed tissue was embedded in paraffin 
wax using the Thermo Scientific™ HistoStar™ Embedding Workstation, by first pouring a 
layer of molten wax into the metal moulds, before placing the tissue in the desired 
orientation, covering this with a final layer of wax, and then placing the mould onto an ice 
block to allow the wax to solidify. The back section of the cassette was then placed on top 
and additional wax poured in order to fix the sample block to the labelled cassette.  
2.7.1.3 Production of slides – Microtome and staining 
Tissue was sectioned using the Thermo Scientific™ Shandon™ Finesse™ 325 Manual 
Microtome to a thickness of 5µm, and each section was placed into a water bath to flatten 
the sections, before being lifted from the water with a microscope slide. These slides were 
then left overnight to dry out in a 37°C oven. Slides were then ready for staining, and this 
was carried out using the Thermo Scientific™ Varistain™ 24-4 Automatic Slide Stainer in 
order to stain for blood vessels with Elastic Van Gieson. Stained slides were mounted using 
Thermo Scientific™ DPX Mounting Media, before placing a coverslip over the tissue, and left 
to dry.  
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2.7.1.4 Measurement of cardiac blood vessels 
Images were taken with the Olympus BX40 Microscope and QImaging QICAM Fast 1394 
digital camera, and analysed using the Image-Pro 6.2 software. The largest vein and artery 
present as a complete cross-section were selected in each region of the heart (left ventricle, 
right ventricle and interventricular septum), for comparison of the size of the largest vessels 
by age group and localisation. Vessel cross-sections were measured using the “Count/Size” 
option, in order to obtain the area in micrometers2 of the selected area in addition to the 
width and height measurements for each vessel.  
2.7.2 Electron Microscopy 
Rats were culled using Schedule 1 and hearts were removed from 14-day old (n = 3) and 
adult (n = 3) animals (Table 4), before being placed directly into ice cold cardioplegic solution 
(147 mM NaCl, 20 mM KCl, 16 mM MgCl2, 2 mM CaCl2, adjusted to pH 7.4), used to halt 
contractility of the heart. Hearts were cannulated via the aorta, and perfused with 
cardioplegia at a rate of 1 ml/min, in order to wash out any remaining blood. This was then 
repeated with EM fixative solution (0.1 M phosphate buffer, 0.5 mM CaCl2, 1.7 mM D-
glucose anhydrous, 1% (w/v) glutaraldehyde, 1% (w/v) paraformaldehyde) at a rate of 1 
ml/min for 4-6 minutes. Following perfusion, hearts were cut into small cubes taken from 
the left ventricular wall, and left in the fridge overnight in fixative, before being transferred 
into phosphate buffer and sent for processing and mounting by the Wolfson Bioimaging 
Facility, University of Bristol. The resulting grids were then imaged, with electron 
micrographs taken using the FEI TecnaiTM 12 Transmission Electron Microscope (TEM) and 
analysed using Image J. 
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2.8 Statistical analysis of data 
Statistical analysis was predominantly performed using IBM SPSS Statistics 24, and data 
presented as mean values ± SE. Outliers were detected using Boxplots and Q-Q Plots. On a 
few occasions, results were presented with or without outliers with emphasis on those 
deemed to result from experimental errors removed. Data was checked for normal 
distribution using a Shapiro-Wilks test and for homogeneity of variance using a Levene’s test. 
Those that did not violate these assumptions underwent either independent t-test (for 
experiments with two experimental groups) or one-way ANOVA (for experimental groups of 
3 or more) with Bonferroni post-hoc testing. Those that violated these assumptions 
underwent non-parametric Kruskal-Wallis testing. For data that included two independent 
variables, for example in experiments that factor in data collected across a succession of 
time points, Mauchly’s test for sphericity was performed in addition to Shapiro-Wilks testing 
for normal distribution. These data were then tested for statistical significance using a two-
way repeated measures ANOVA with a Bonferroni adjustment. P-values below 0.05 were 




Chapter 3: Quantification and validation of survival signalling 
proteins during postnatal development using proteomic and 
molecular biological techniques.  
3.1 Introduction 
In order to address our first aim and establish whether differences in the expression and 
phosphorylation state of RISK-SAFE proteins in control hearts – known to play crucial roles 
in the reduction of cardiac injury following I/RI (Section 1.4 and 1.5) – as well as those known 
to cross-talk with these signalling pathways, may exist at different developmental stages, 
proteomic and phosphoproteomic analysis was utilised. An existing proteomic output from 
Dr Martin Lewis with samples from 14-day old, 28-day old and adult rat hearts was used as 
an initial proof of concept that age-dependent changes in such proteins existed, and these 
samples were subsequently used for western blot validation of these trends in protein 
expression. Proteins of interest were identified through literature searches and signalling 
pathway maps, before statistical analysis to highlight those of which that showed a 
significantly greater expression in samples from 14-day old hearts in comparison with adult 
thus indicating potentially better resistance to cardiac insults for us to test our hypothesis. 
Of these, key proteins were selected for further validation using western blotting.  
3.2 Materials & Methods 
3.2.1 Animal groups & sample extraction 
Proteomic and phosphoproteomic analysis was conducted with samples taken from 14-day 
old (n = 3), 28-day old (n = 3) and adult (n = 4) rats. Rats were culled as outlined in Section 
2.2, hearts excised, and the apex removed for flash freezing in liquid nitrogen. Tissue then 
underwent protein extraction and quantification as described in Sections 2.4.1 and 2.4.2.  
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3.2.2 Proteomic and Phosphoproteomic Analysis 
The full process of proteomic and phosphoproteomic analysis has been described in Section 
2.4.3, but can be summarised as the dilution of the quantified samples mentioned in Section 
3.2.1 with double distilled water to adjust the protein concentration of each sample to 
2mg/ml for sending to the University of Bristol Proteomics Facility, in order for samples to 
undergo Tandem Mass Tag (TMT) analysis (ThermoFisher Scientific, UK). For 
phosphoproteomic analysis, samples underwent an additional phosphopeptide enrichment 
step using a TiO2 column (Section 2.4.3). 
The resulting output came in the form of a Proteome Discoverer file with the abundance of 
each protein in each sample as a ratio to the pooled sample, from which proteins selected 
from the existing literature and signalling pathway database searches as relating to cell 
survival processes were identified (see Section 2.4.4). These proteins then underwent 
statistical analysis in order to identify those that showed significant changes in expression 
between age groups concordant with the cardiac vulnerability profile during postnatal 
development (see Section 2.8). Selected proteins displayed in Section 3.3 are given as a 
‘mean ratio’ per age group, referring to the abundance of protein in each individual sample 
relative to the pooled sample (abundance in individual sample/abundance in pooled 
sample), from which an average of all samples for each age group was calculated. 
3.2.3 Western blot validation  
The full western blotting methodology has been described in Section 2.5. To summarise, 
remaining sample from tissue extraction and quantification outlined in Section 3.2.1 that 
was not sent for proteomic analysis was instead used to prepare a sample of 0.15mg of 
96 
 
protein in a final volume of 100µl, prepared for gel electrophoresis with the addition of an 
equal volume of loading buffer (Laemmli buffer + βME). Protein samples were run on a Mini-
PROTEAN® TGXTM precast gels and transferred to a PVDF membrane, which in later 
experiments were subsequently stained with Ponceau S solution to produce full lane bands 
(see Section 2.5.4 and Appendix, Figures 103-108), before blocking with milk. Membranes 
were then incubated with antibodies for HSP90, Caveolin-1, Caveolin-3, 14-3-3η, AKT, pAKT, 
β-Catenin, and pβ-Catenin (see table of antibodies in Section 2.1.2), washed with TBST, 
incubated with a secondary antibody, and visualised using the Enhanced 
ChemiLuminescence system. Initial experiments used a GAPDH loading control for 
normalisation of protein bands, but this was subsequently replicated using whole lane 
intensities as identified by Ponceau S staining.  
3.3 Results 
The first proteomics study involved the analysis of extracted proteins from 14-day, 28-day 
and adult rats, before undergoing proteomic and phosphoproteomic analysis (Section 3.2). 
The results collected from the proteomic and phosphoproteomic output will be presented 
separately in Sections 3.3.1 and 3.3.2 below. For figure clarity, P14 and P28 were used to 
represent postnatal day 14 and 28, respectively. 
3.3.1. Effect of postnatal development on survival signalling proteome 
59 proteins were identified and extracted from the proteomic output due to their previously 
reported roles in survival signalling or the apoptotic process. Of these, 32 were found to 
show a statistically significant change in expression with age, 6 of which increased with 
increasing age, with the remaining 26 proteins decreasing with increasing age, as 
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Statistically significant survival signalling proteins.
P14 P28 Adult
Figure 13. Survival signalling related proteins found to change significantly with age. Data are 











Figure 12. Volcano plot of all survival signalling proteins identified in the proteomics, comparing 
fold difference (FD) between the average protein expressions in 14-day old and adult heart samples 
expressed as log2 (x-axis), against the p-value expressed as –log10 (y-axis). The red line indicates a 
cut-off point for statistical significance (p = 0.05). 
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3.3.2 Validation of significantly different survival signalling proteins 
using western blotting  
In order to validate the results of this proteomic output, western blotting was run on the 
same samples, targeting some of the key proteins identified – HSP90, caveolin-1, caveolin-
3, and 14-3-3η. These proteins were selected in part due to previous use and testing of the 
antibodies in our research group, in addition to their reported links to survival signalling 
pathways. Both HSP90 and 14-3-3η have been linked to the stabilisation of Akt and 
augmentation of its activity, with subsequent cardioprotection following I/RI (Wang et al. 
2009, Gurusamy et al. 2006). Caveolins have similarly been linked to cardioprotection and 
the promotion of Akt activity (Tsutsumi et al. 2008, Horikawa et al. 2011), in addition to their 
upstream roles in coordinating the activation of survival signalling pathways at the cell 
membrane (Das et al. 2007).  
Initial western blotting was performed using an antibody for traditional housekeeping 
protein, GAPDH, as the loading control. However, it was found that GAPDH expression 
changed during postnatal development both in the proteomic output and using western blot 
analysis (Appendix, Figures 103-105). An additional housekeeping protein, β-actin also 
yielded the same results (Appendix, Figures 106-107). Therefore, Ponceau S staining was 
used instead as a loading control, as analysis found that the intensity of full lane bands did 
not change significantly between the three age groups (Appendix, Figure 108). Each protein 
tested with western blotting alongside the corresponding results from proteomic analysis 
are shown below (Figures 14-18). The data collected for both the use of GAPDH and full lane 




3.3.2.1 Validation of the expression of HSP90 
HSP90 expression detected by western blotting showed the same pattern of expression 
across the three age groups, with statistically significant differences between 14-day old 
samples and adult samples both with correction using GAPDH and Ponceau S. 
Figure 14. Validation of HSP90 expression. 
A. The expression of HSP90 as detected by 
western blotting, corrected for GAPDH 
(left) in comparison with Ponceau S (right) 
across the 3 age groups. B. The mean 
expression of HSP90 from the proteomic 
output. Western blotting bands alternate 
between the three age groups. Data are 
presented as Mean ± SE (n = 4 for P14, n = 
4 for P28, and n = 4 for adult). * = 
statistically significant difference in 














































































3.3.2.2 Validation of the expression of caveolin-1 (Cav-1) 
While the same overall trend in expression of Cav-1 as detected in the proteomic output was 
seen both with correction using GAPDH expression and correction using whole lane Ponceau 
S intensity, statistical significance was only seen between 14-day old samples and adult 
samples when a GAPDH correction was applied. 
Figure 15. Validation of  caveolin-1 (Cav-1) 
expression. A. The expression of Cav-1 as 
detected by western blotting, corrected 
for GAPDH (left) in comparison with 
Ponceau S (right) across the 3 age groups. 
B. The mean expression of Cav-1 from the 
proteomic output. Western blotting bands 
alternate between the three age groups. 
Data are presented as Mean ± SE (n = 4 for 
P14, n = 4 for P28, and n = 4 for adult). * = 
statistically significant difference in 

















































































3.3.2.3 Validation of the expression of caveolin-3 (Cav-3) 
While Cav-3/GAPDH mimicked the trend in expression across the three age groups seen in 
the proteomic output, albeit with statistical significance only between 14-day old and 28-
day old samples, this trend was not seen when Cav-3 expression was corrected for using 
Ponceau S staining. This may result from the quality of the Cav-3 bands produced. 
Figure 16. Validation of caveolin-3 (Cav-3) 
expression. A. The expression of Cav-3 as 
detected by western blotting, corrected 
for GAPDH (left) in comparison with 
Ponceau S (right) across the 3 age groups. 
B. The mean expression of Cav-3 from the 
proteomic output. Western blotting bands 
alternate between the three age groups. 
Data are presented as Mean ± SE (n = 4 for 
P14, n = 4 for P28, and n = 4 for adult). * = 
statistically significant difference in 



















































































3.3.2.4 Validation of the expression of 14-3-3ƞ 
The trend in expression of 14-3-3η seen in the proteomic output was replicated both with 
GAPDH correction and Ponceau S correction. However, correction using GAPDH produced 
statistically significant differences between 14-day old and 28-day old samples not seen in 
the proteomic output. It is likely that this discrepancy results from the baseline differences 




Figure 17. Validation of 14-3-3η 
expression. A. The expression of 14-3-3η as 
detected by western blotting, corrected for 
GAPDH (left) in comparison with Ponceau S 
(right) across the 3 age groups. B. The mean 
expression of 14-3-3η from the proteomic 
output. Western blotting bands alternate 
between the three age groups. Data are 
presented as Mean ± SE (n = 4 for P14, n = 4 
for P28, and n = 4 for adult). * = statistically 
significant difference in comparison with P14 


















































































3.3.3 Postnatal development and the survival phosphoproteome 
3.3.2.1 Total phosphorylation of select/relevant proteins 
Of an original 53 identified, 35 phosphoproteins linked with survival signalling or apoptosis 
were found to show a statistically significant change in expression with age. Of these, 2 
proteins were found to increase with increasing age, with the remaining 33 proteins 























Volcano plot of survival signalling related proteins
Figure 18. Volcano plot of all survival signalling or apoptosis related phosphoproteins 
expressed as the fold difference (FD) in the expression of each phosphoprotein in adult 
samples/14-day old samples identified in the phosphoproteomic output (with log2 
transformation for proportional representation of both increased or decreased 
expression), displaying each phosphoprotein on an axis of fold difference in mean 
phosphoprotein expression between adults and P14 by the p-value (-log10 
transformation), denoting statistical significance of this difference. The red line indicates a 
cut-off point for statistical significance, with those above the red line displaying statistically 





Figure 19. Survival signalling related phosphoproteins found to change in a statistically 
significant manner with age. Data are presented as Mean ± SE (n = 3 for P14, n = 3 for P28 



































































































































































3.3.2.2 Detection of specific phosphorylation sites of select proteins 
For each statistically significant protein found, the individual phosphosites were extracted 
from Proteome Discoverer as outlined in Section 2.4, excluding those with low confidence 
ratings or that were not present in samples from each group. Each phosphosite was 
subsequently analysed for changes with age, as displayed in Figures 20-25 below. All those 
shown in Figure 21 showed statistically significant changes with age. 
 
The majority of phosphorylation sites detected in the phosphoproteomic output followed 
the overall trend in change with age as that of the total phosphorylated protein, as shown 

















Individual phosphorylation sites of the statistically significant 
survival signalling phosphoproteins.
P14 P28 Adult
Figure 20. Proteins with only one phosphorylation site detected showing statistically 
significant differences with age (P14 vs Adult). Data are presented as Mean ± SE (n = 3 for 

































Individual phosphorylation sites of BCLAF1, with total 
phosphorylated BCLAF1 as a reference.
P14 P28 Adult
Figure 21. The individual phosphorylation sites detected with proteomic analysis and their 
pattern of change with age in comparison with the total phosphorylated protein for BCLAF1. 
Data are presented as Mean ± SE (P14 n = 3, P28 n = 3 and adult n = 4.) * = statistically significant 
























Individual phosphorylation sites of HSP90B, with total 
phosphorylated HSP90B as a reference.
P14 P28 Adult
Figure 22. The individual phosphorylation sites detected with proteomic analysis and their 
pattern of change with age in comparison with the total phosphorylated protein for HSP90-
β. Data are presented as Mean ± SE (P14 n = 3, P28 n = 3 and adult n = 4.) * = statistically significant 


















In the case of Hspa12b, the two separate runs of phosphoproteomics identified exclusively 
either phosphorylation at Ser44 or Ser46. As the only other phosphorylation site present in 
both runs involved dual phosphorylation at both Thr42 and Ser44, which did not fit the 
overall pattern of change with postnatal development seen in the total phosphoprotein, 
analysis was run combining the data for Ser44 and Ser46 from the two runs under the 
possibility that, due to their proximity, this was actually data for the same phosphorylation 
site. The resulting pattern of change in phosphorylation at this site over the course of 






















Individual phosphorylation sites of Prkar1a, with total 
phosphorylated Prkar1a as a reference.
P14 P28 Adult
Figure 23. The individual phosphorylation sites detected with proteomic analysis and their 
pattern of change with age in comparison with the total phosphorylated protein for Prkar1a. 
Data are presented as Mean ± SE (P14 n = 3, P28 n = 3 and adult n = 4.) * = statistically significant 













However, in some cases where multiple phosphorylation sites were detected for a single 
protein, not all were concordant with the overall protein, for example, Ser794 of Tensin 1 

















Individual phosphorylation sites of Hspa12b, with total 
phosphorylated Hspa12b as a reference.
P14 P28 Adult
Figure 24. The individual phosphorylation sites detected with proteomic analysis and their 
pattern of change with age in comparison with the total phosphorylated protein for Hspa12b. 
Data are presented as Mean ± SE (P14 n = 3, P28 n = 3 and adult n = 4.) * = statistically significant 
































Individual phosphorylation sites of Tensin 1, with total 
phosphorylated Tensin 1 as a reference.
P14 P28 Adult
Figure 25. The individual phosphorylation sites detected with proteomic analysis and their 
pattern of change with age in comparison with the total phosphorylated protein for Tensin 1. 
Data are presented as Mean ± SE (P14 n = 3, P28 n = 3 and adult n = 4.) * = statistically significant 










3.3.2.3 Validation of significantly different survival signalling 
phosphoproteins using western blotting 
In order to validate the phosphoproteomic output, western blot analysis was run on the 
same samples to check the trend in expression across the 3 age groups for selected proteins. 
Statistical analysis using Kruskal-Wallis detected significant differences in distribution with 
age for both pβ-catenin normalised with GAPDH and β-catenin normalised with GAPDH, but 
not for pβ-catenin normalised with β-catenin (Figure 26). However, analysis using one-way 
ANOVA (Bonferroni), following confirmation of normal distribution of the samples using the 
Shapiro-Wilk test for normality, did in fact show a statistically significant difference in pβ-
catenin/β-catenin levels between 14-day old and 28-day old samples. This trend correlates 





Analysis of the western blotting data for Akt and pAkt (Figure 27) using Kruskal-Wallis 
showed that there was a statistically significant difference between the age groups for Akt 
normalised with GAPDH, pAkt normalised with Akt, but not pAkt normalised with GAPDH. 



















Figure 26. Comparison of the mean levels of expression of β-catenin (A.) and pβ-catenin (B.) 
between age groups as measured by western blotting, in addition to the mean ratio of pβ-
catenin/β-catenin (C.). Data are presented as Mean ± SE (n = 4 for each group). Antibody 
used was specific for phosphorylation at Ser552. * = statistically significant difference in 
comparison with P14 samples (p < 0.05).  
pβ-catenin/β-catenin 


















































































one outlier from the 14-day old group for Akt/GAPDH, one-way ANOVA (Bonferroni) was 
run. Statistical significance was identified in this case only for Akt/GAPDH, therefore 
conflicting with the phosphoproteomic data for pAkt. It is important to note, however, that 
the antibody used in this case, as well as in most pre-existing research, targets 












Figure 27. Comparison of the mean levels of expression of Akt (A.) and pAkt (B.) between 
age groups as measured by western blotting, in addition to the mean ratio of pAkt/Akt (C.). 
Data are presented as Mean ± SE (n = 4 for each group). Antibody used was specific for 
phosphorylation at Ser473. * = statistically significant difference in comparison with P14 
(p < 0.05). 
pAkt/Akt 


































































However, our phosphoproteomic analysis identified phosphorylation only at Ser129. 
Subsequently, western blot analysis was conducted with an antibody specific for 





















Figure 28. Comparison of the mean levels of expression of Akt (A.) and pAkt (B.) between 
age groups as measured by western blotting, in addition to the mean ratio of pAkt/Akt 
(C.). Data are presented as Mean ± SE (n = 4 for each group). Significant p-values 
labelled (One way-ANOVA, Bonferroni). Antibody used was specific for 
phosphorylation at Ser129. * = statistically significant difference compared with 14-day 

































































As with previous western blotting for Akt/GAPDH expression, 14-day old samples showed 
statistically significantly higher expression than both 28-day old and adult samples. In 
agreement with the phosphoproteomic output, pAkt/GAPDH expression was also higher in 
14-day old samples in comparison with both 28-day old and adult samples. However, 
correction of pAkt expression with Akt expression removed these differences. As multiple 
phosphorylation sites are required for full activation, it may be that western blot analysis 
using antibodies targeting specific sites does not reflect what is seen in total 
phosphoproteomic output, and does not take into account the additive effects of 
phosphorylation at multiple sites. Discrepancies between the western blot data and 
phosphoproteomic output may also result from the fact that the phosphoproteomics only 
looks at phosphorylation level without taking into account a correction for the total protein. 
In this instance, the greater levels of phosphorylation detected at Ser129 in 14-day old 
samples was also found in our western blot data when looking at the expression of 
pAkt/GAPDH alone. The overall lack of difference in pAkt levels when corrected for Akt is 
likely due to fact that samples are from control hearts prior to any injury that would trigger 






This pilot study – using a small number of cardiac samples to measure the survival signalling 
proteome and phosphoproteome – provided evidence that the trends in expression can, for 
the majority of proteins, be confirmed using a totally different technique involving 
antibodies. Furthermore, the analysis found that patterns of change in expression during 
development for the majority of proteins aligned with what would be expected from their 
reported roles in survival signalling and apoptosis in the literature, and the differences in 
vulnerability to I/R injury. It should be noted that the statistical power of this study was low 
(observed power = 0.612) due to the small sample sizes, but was repeated with greater n-
numbers and an additional age group in Chapter 4. 
3.4.1 Expression of survival signalling proteins tends to be higher in 14-
day compared to adults 
3.4.1.1 Target proteins of the RISK pathway show trends in expression with 
either a peak or trough at 14-days of age. 
The majority of proteins found to change significantly in expression over the course of 
postnatal development displayed concordance between their expected role in pro-survival 
or apoptotic signalling events. Some of the most notable proteins identified in the proteomic 
output were those linked to the RISK signalling pathways, including HSP90, which acts as a 
cardioprotective inhibitor of apoptosis following I/R through its upstream regulatory action 
upon the PI3K/Akt pathway (Wang, Peng et al. 2009, Li, Luo et al. 2013), and shows a 
corresponding decrease in expression during postnatal development. Similarly, 14-3-3ƞ, the 
knockout of which leads to GSK3β activation and decreased Akt phosphorylation (Gurusamy, 
Watanabe et al. 2006), caveolin-3, which causes elevated Akt and GSK3β phosphorylation 
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with associated improved recovery and reduced apoptosis following I/R (Tsutsumi, Horikawa 
et al. 2008, Horikawa, Panneerselvam et al. 2011), and HSP27 (HSPB1), a cardioprotective 
protein that results in reduced H2O2 and I/R-induced injury, as well as decreased ROS 
production and increased Akt activity when overexpressed in rat cardiomyocytes (Liu, Zhang 
et al. 2007), all show the highest expression at 14-days of age. Similarly, proteins linked to 
ERK signalling – another component of the cardioprotective RISK pathway – were found to 
be expressed at a greater level in immature hearts, including 14-3-3ζ as well as caveolin-1. 
Caveolin-1 has been shown to dissociate from pro-survival signalling ERK1/2 and associate 
with pro-death signalling p38MAPKα and JNK in angiotensin II pre-conditioned hearts in 
order to sequester a greater level of death promoting pathway components, whilst making 
a greater level of survival signalling components available to the cell (Das, Das et al. 2007). 
14-3-3ζ knockout was found to result in increased mortality and cardiomyocyte apoptosis, 
with an associated inhibition of ERK activation and increased pro-apoptotic JNK and 
p38MAPK activation (Xing, Zhang et al. 2000). MEK5 expression was also shown to be 
greatest in the immature heart, correlating with its pro-survival activity through activation 
of anti-apoptotic ERK5 (Shishido, Woo et al. 2008), and its apparent link to caspase 3 activity, 
which increases following MEK5 deletion (Wang, Merritt et al. 2005). Interestingly, protein 
kinase C delta-binding protein – also known as cavin-3 – was found to be most highly 
expressed at 14-days of age, the biological significance of which raises conflict in terms of 
the involvement of RISK pathway components in the resistance to I/RI seen at this age. 
Whilst non-cardiac-specific papers have demonstrated cavin-3 to be a negative regulator of 
Akt activity through the action of EGR1 and PTEN, it has also been shown to act as a positive 
regulator of ERK signalling at the expense of Akt signalling through the anchoring of caveolae 
to the plasma membrane and subsequently allowing the transduction of activated ERK 
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signalling (Hernandez, Weng et al. 2013). However, it is likely that the Akt-inhibiting action 
of cavin-3 is the more significant in the context of cell survival, as studies have shown that 
knockout of the protein results in increased cell proliferation and increased resistance to 
apoptosis (Hernandez, Weng et al. 2013), as well as the attenuation of pro-apoptotic p53 
signalling (Lee, Byun et al. 2008). The greater expression of cavin-3 at 14-days compared to 
adult hearts therefore shows discordance between its role in apoptosis and the differences 
in vulnerability to I/RI in these age groups. Subsequent monitoring of any changes in its 
expression in samples extracted from hearts following I/R, and the effect of its selective 
inhibition or overexpression on recovery following I/RI, will therefore be required.  
3.4.1.1.2 Higher expression of ETC components in 14-day hearts 
Conflicting roles of the Electron Transport Chain (ETC) component, Cytochrome c oxidase 
(COX), on cell survival have been reported in the literature (Schull, Gunther et al. 2015, 
Hütteman, Helling et al. 2012). It has been stated that deficiency of the protein results in the 
increased activation of ceramide synthase 6, causing the build-up of pro-apoptotic C16 : 0 
ceramide, which leads to accelerated mitochondrial apoptosis following oxidative stress and 
implicates it as an anti-apoptotic protein (Schull, Gunther et al. 2015). However, a 
contrasting role has been described in a study by Hütteman et al. (2012) in which the role of 
COX, due to its importance as the rate-limiting step of the ETC, was described as pro-
apoptotic. Following ischemia, increased intracellular Ca2+ results in hyperactivation of COX 
via loss of allosteric inhibition by ATP and changes in the protein’s phosphorylation state, 
which in turn leads to pathological high mitochondrial membrane potentials, excessive 
reactive oxygen species (ROS) production, release of cytochrome c, and finally apoptosis 
through the subsequent activation of caspases (Hüttemann, Helling et al. 2012). Finally, 
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mitochondrial dysfunction and secondary energy failure occurs as a result of COX and ETC 
hypoactivity during reperfusion, leading to cell death (Hüttemann, Helling et al. 2012). 
Whilst this study was conducted in the brain and not the heart, this mechanism of COX’s role 
in apoptosis fits with our proteomic output for two of the three subunits detected, and may 
indicate that the higher expression of COX in mature hearts in comparison with immature 
hearts results in the greater vulnerability to ischemia/reperfusion injury seen, as these 
hearts are primed for hyperactivation of the ETC and greater levels of subsequent apoptosis. 
However, it is not certain if our findings of a higher expression of subunits such as Mt-co2 
and Cox6a2 in 28-day old and adult hearts in comparison with 14-day old hearts reflects a 
corresponding higher level of activity of the protein, as others have reported greater activity 
of the ETC and COX in immature compared to adult hearts to compensate for the increasing 
energy demands following birth (Johnson and Brown-Borg 2006). It may be that, although 
activity is higher in the immature heart, the lower expression in comparison with adults may 
mean that the mature heart has a greater reserve of inactive protein that can be 
hyperactivated following I/RI, resulting in the greater vulnerability seen. Future steps will 
therefore be required in order to check if these expression levels correspond with activity of 
the protein, and with these changes following simulated I/RI. Alternatively, these contrasting 
reports of COX’s role in apoptosis following I/R may in fact reflect subunit-specific roles, as 
four of the five subunits detected to change significantly in the proteomic output – subunits 
2, 6A1 and 6A2 – and phosphoproteomic output – subunits 6B1 and 7A2 – have been 
described in the literature to contribute to apoptotic or survival pathways. For example, 
subunit 2 is responsible for the transfer of electrons from cytochrome c to the catalytic 
subunit 1 of COX, and has been shown to be upregulated in association with apoptosis-
inducing cytochrome c as well as being induced in HIV infected T cells, with silencing of the 
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subunit leading to decreased levels of apoptosis (Tripathy and Mitra 2010). Similarly, subunit 
6A2 has been linked to the oxidative stress response, associated with increased levels of pro-
apoptotic Bax, and has been suggested to potentially lead to necrosis or apoptosis following 
a cytokine stress response (Adler-Wailes, Guiney et al. 2008). In apparent accordance with 
their pro-apoptotic roles, both subunits were shown to increase in expression over the 
course of postnatal development. In contrast, subunit 6A1 and 6B1 have both been indicated 
to have pro-survival roles (Eun, Woo et al. 2008, Kim, Mori et al. 2015), and were 
subsequently shown to decrease during postnatal development in the proteomic and 
phosphoproteomic output. Subunit 6A1 has been shown to suppress the death-inducing 
activity of Bax, with overexpression of the subunit resulting in decreased Bax-induced 
apoptosis, as well as the generation of ROS, release of cytochrome c, and activation of 
caspase 3 (Eun, Woo et al. 2008). Subunit 6B1 overexpressing cells were shown to have 
greater basal levels of ROS, but greater cell viability following oxidative stress than control 
cells (Kim, Mori et al. 2015). These studies highlight the importance of COX activity, as well 
as that of the individual subunits, to the degree of cardiac injury following I/R as a result of 
their effect on the levels of ROS production and oxidative stress – key mediators of I/RI and 
subsequent cell death. The differential expression of these proteins at different stages of 
development therefore identifies the need for further study into any correlating differences 
in their expression, as well as whether these trends mimic the biphasic profile of cardiac 




3.4.1.1.3 Changes in the expression of HSPB6, TRIM72, Prkcdbp and Cd99 are 
not consistent with their reported role in survival signalling 
Exceptions to the overall concordance of the change in protein expression with postnatal 
development and their role in survival signalling within the proteomic data are HSPB6 and 
TRIM72, which increase with increasing age despite being pro-survival proteins (Fan, Chu et 
al. 2005, He, Tang et al. 2012), in addition to Prkcdbp and Cd99, which are both implicated 
in pro-apoptotic processes and decrease with increasing age (Sohn, Choi et al. 1998, 
Hernandez, Weng et al. 2013). In the case of TRIM72, this may be linked to its apparently 
crucial role in preconditioning. As TRIM72 levels have been shown to decrease following I/R 
or hypoxia/oxidative stress, an effect that has been shown to be prevented following IPC, 
Cao et al. (2010) aimed to address the importance of TRIM72 in IPC. It was found that 
TRIM72 interacts with caveolin-3 and PI3K to activate the RISK pathway, leading to a 
reduction in cell death following I/R or hypoxia/oxygenation, and that deficiency or 
knockdown of the protein resulted in heightened damage, as well as the loss of the 
cardioprotective effects provided by IPC (Cao, Zhang et al. 2010). The lower expression of 
TRIM72 seen in immature hearts in comparison with mature hearts in our proteomic data 
may therefore correlate with the lack of efficacy of IPC in young hearts (Doul, Charvatova et 
al. 2015).   
3.4.1.1.4 PRKAR1A is highly expressed in the young heart 
An additional confounding factor in the comparison between our proteomic data and the 
supposed roles of the identified proteins in the literature is the fact that, in some cases, 
reports as to the effects of these proteins on apoptosis and the response to I/RI are 
conflicting. For example, the cAMP-dependent protein kinase type I-alpha regulatory 
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subunit (PRKAR1A) has been described as having a pro-apoptotic role due to its regulatory 
effects on PKA activity, an important regulator of cell growth and function (Yin, Pringle et al. 
2011). The study showed that knockout of this regulatory subunit resulted in excessive PKA 
activity and tumorigenesis, a finding supported through demonstration that depletion of the 
subunit resulted in increased BCL-XL expression, resistance to apoptosis, and increased PKA 
and MEK/ERK signalling (Basso, Rocchetti et al. 2014). However, knockdown of this protein, 
whilst increasing PKA activity, has also been shown to result in decreased cardiomyocyte 
proliferation and downregulation of key transcription factors required for cardiogenesis (Yin, 
Jones et al. 2008), as well as an increase in the transcription of pro-apoptotic proteins, such 
as members of the BCL-2 family, and increased apoptosis (Gangoda, Doerflinger et al. 2014).  
Alternatively, PKA has been demonstrated to have an effect on sympathetic stimulation via 
phosphorylation of ryanodine receptors and other Ca2+-cycling proteins, with subsequent 
alterations to Ca2+-cycling, increased NCX currents, increased sinoatrial node (SA) node firing 
rate, and therefore increased heart rate (Larsson 2010). As mentioned in Section 1.1.1, 
neonatal heart rates are lower than that of adult rats, with slower Ca2+-cycling and greater 
action potential durations. It is therefore possible that the greater expression of PKA-
regulating PRKAR1A in 14-day old hearts is a reflection of the lower heart rates in this age 
group. Moreover, due to the fact that immature hearts show a greater reliance on Ca2+-influx 
from extracellular sources and the action of the NCX to control Ca2+-cycling, due to the 
underdevelopment of the SR and relatively small contribution of Ca2+-channels at this stage 
of development (Section 1.1.1), high levels of PRKAR1A may also present a protective 
mechanism by which PKA activity is reduced to prevent Ca2+-overload. PKA has been 
suggested to increase NCX activity via upstream phosphorylation targets (Yaniv, Juhaszova 
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et al. 2011), and thus high levels of PRKAR1A may be expressed in order to reduce excessive 
NCX activity in 14-day old hearts. 
The uncertainty as to the exact role of some of the identified proteins makes a definitive 
connection between the levels of their expression with the vulnerability profile to I/RI 
difficult to elucidate, with studies often highlighting tissue-specificity for the role of these 
proteins. In order to address this issue, further work will be required to look at expression 
levels in hearts that have undergone ischemia/reperfusion in order to form a comparison 
with their expression in control hearts, in addition to experiments looking at the activity of 
these proteins and the result of selective inhibition. 
3.4.1.2 Phosphorylated survival signalling and cardioprotection related 
proteins change in expression during development 
3.4.1.2.1 Cardioprotective pHSPB6 expression increases during postnatal 
development 
Whilst most proteins identified in the phosphoproteomic output also correlated with their 
expected role in survival signalling, a notable exception was HSPB6, which was shown to 
increase during postnatal development, a similar trend to that displayed in the non-
phosphorylated proteomic data. This is unexpected, as HSPB6 has been described within the 
literature as possessing a pro-survival and anti-apoptotic role (Fan, Chu et al. 2005, Gusev, 
Bukach et al. 2005), therefore suggesting it should show greater expression in cardiac 
samples taken from 14-day old rats, which show the greatest resistance to I/R injury. 
Furthermore, HSPB6 phosphorylation at Ser16 was shown to increase over the course of 
postnatal development, again contradicting its reported role in the literature, as 
phosphorylation of this site by PKA has previously been shown to be the phosphorylation 
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event required for the cardioprotective effects of HSPB6, with inhibition of Ser16 
phosphorylation resulting in the loss of HSPB6’s cardioprotective effects (Nicolaou, Knoll et 
al. 2008, Qian, Ren et al. 2009). The low levels of phosphorylation at this site in 14-day old 
hearts is further confounded by the detection of phosphorylated AKAP12 in the 
phosphoproteomics, which is reportedly activated to enhance its scaffolding ability by PKA 
(Tao, Wang et al. 2010), and is a member of a protein family suggested to be cardioprotective 
through its vital role in localising PKA within certain regions of the cell in order to direct its 
phosphorylation of substrates such as HSPB6 at Ser16 (Edwards, Scott et al. 2012). However, 
previous research has shown that HSPB6 levels, in addition to levels of Ser16 
phosphorylation, are higher specifically within the ischemic myocardium, with cardiac-
specific overexpression resulting in decreased infarct size and improved recovery of 
contractile performance following I/R, due to the protein’s ability to reduce necrosis and 
apoptosis in cardiomyocytes (Edwards, Scott et al. 2012). This suggests that, as our samples 
were taken from control hearts, the simulation of I/R may result in a reversal of the trend 
detected in the proteomic and phosphoproteomic output, with greater expression of Ser16 
phosphorylated HSPB6 in immature hearts correlating with decreased cell death and 
increased recovery following ischemic insult. It is therefore possible that, as is the case for 
pAkt (Liaw, Hoe et al. 2013), basal levels of the active protein are low in immature hearts, 
allowing for subsequent activation and thus a protective response following damage which 
cannot be mimicked in mature hearts due to baseline high levels. HSPB6 is therefore a 
protein of interest for future experiments, to examine the differences between these age 
groups with samples that have undergone I/R in comparison with those that have not. 
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3.4.1.2.2 Phospho-Cytochrome b-c1 increased in expression during 
development 
HSPB6 comprised one of only two phosphoproteins that increased in expression during the 
course of postnatal development, the other being cytochrome b-c1 subunit 6. However, 
unlike HSPB6, this pattern of change with age does fit with the protein’s reported role in the 
apoptotic process. Cytochrome b- c1 has been implicated as a component of the intrinsic 
apoptotic pathway, triggering this process in order to drive the removal of cells containing 
mitochondria that have begun to produce ROS following an event inducing irreparable 
damage (Dibrova, Cherepanov et al. 2013), in addition to enhancing cytochrome c release 
from the mitochondria in order to accelerate the apoptotic process (Okazaki, Ishibashi et al. 
1998). However, a potentially conflicting role for the protein, as studies looking at the 
cardioprotective effects of preconditioning (PC) and pharmacological inhibition of GSK3β via 
their effect on the mitochondria found that cytochrome b-c1 subunit 6 levels were increased, 
with decreased levels of cytochrome c, suggesting PC results in alteration of ETC components 
that result in cardioprotective effects on mitochondrial function (Wong, Aponte et al. 2010). 
While the low expression of this protein in 14-day old hearts and its apparent link to PC may 
correlate with the lack of efficacy of PC in immature hearts, this study did not provide a true 
cause and effect relationship between cytochrome b-c1 levels and mitochondrial function or 
recovery of the heart post-I/R. Moreover, the biological significance of phosphorylation has 
not yet been reported, meaning it is uncertain as to whether the protein has been detected 
in its active or inactive state.    
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3.4.1.2.3 RISK pathway targeted phosphoproteins change during postnatal 
development 
As with the total proteomic output, several proteins associated with members of the 
cardioprotective RISK pathway were found to change significantly with age during postnatal 
development. For example, HSPA12B has been shown to result in decreased infarct size, as 
well as improved cardiomyocyte survival and cardiac function following I/RI when 
overexpressed or upregulated, with an associated enhancement of PI3K/Akt pathway 
activation (Ma, Lu et al. 2013, Kong, Dai et al. 2016), and abolition of its cardioprotective 
properties following the pharmacological inhibition of PI3K/Akt (Zhou, Qian et al. 2011, 
Kong, Dai et al. 2016). YAP1 (Lin, Zhou et al. 2015), HSPA9 (Li, Yang et al. 2011, Na, Kaul et 
al. 2016), and hNRNP-K (Hutchins, Belrose et al. 2015) have also been implicated as 
mediators or downstream targets of the PI3K/Akt or ERK1/2 signalling within the RISK 
pathway.  
3.4.1.2.4 Pro-apoptotic phospho-proteins decrease in expression during 
development 
Unexpectedly, several reportedly pro-apoptotic proteins displayed greater levels of 
expression at 14-days of age than in adults. For example, BCLAF1 is a transcriptional 
repressor that leads to increased apoptosis and cell death (Kasof, Goyal et al. 1999, 
Haraguchi, Holaska et al. 2004, Wessely, Seidl et al. 2005, Sarras, Alizadeh Azami et al. 2010, 
Berk, Tifft et al. 2013), Tp53i11 is a p53 target gene that promotes apoptosis following 
cellular stress (Liang, Cao et al. 2004, Ise, Han et al. 2005), and Dcaf8, as well as other 
members of its protein family, has been described as a mediator of apoptosis (Tsunekawa, 
Kondo et al. 2013, NCBI 2016). Similarly, ARHGEF2 has been implicated as death promoting 
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through activation of RhoA/ROCK signalling in cardiomyocytes (Chang, Lee et al. 2006, Chang 
and Lee 2006, Huang, Chen et al. 2014, Meiri, Marshall et al. 2014), and MAP4K4 reportedly 
activates the TAK1, JNK and mitochondrial death pathways (Xie, Zhang et al. 2007), in 
addition to mediating pro-apoptotic TNF-α action and inhibiting pro-survival protein YAP via 
phosphorylation of LATS (Meng, Moroishi et al. 2015). In the case of ARHGEF2, 
phosphorylation has been suggested to hold an inactivating effect on functional activity 
(Meiri, Marshall et al. 2014), suggesting it may be highly expressed in its inactive state at 14-
days of age. However, the functional significance of ARHGEF2’s individual phosphosite 
detected by phosphoproteomics is not yet known, an issue that is seen with many of these 
phosphoproteins. As a result, it is uncertain as to whether the data produced involves 
proteins that are functionally active or inactive, making correlation with an effect on cell 
survival and the vulnerability profile to I/RI difficult to determine.  
3.4.1.2.5 Changes in specific phosphorylation sites correlate with total 
phosphoprotein sites 
As mentioned in Section 3.4.2.2, individual phosphorylation sites displayed a predominantly 
concordant pattern of change over the course of postnatal development to that seen in the 
total phosphorylated protein. An exception to this involved a protein for which multiple 
phosphorylation sites were detected; Ser794 of Tensin 1. Whilst these differences may be 
due to interference from other modifications present within the detected peptides, or due 
to differences in confidence ratings, the functional roles of this phosphorylation site has not 
previously been described in the literature. Potentially, those which do not fit the pattern of 
change seen in the total phosphorylated protein, or indeed the other phosphorylation sites 
detected, may do so as a result of a conflicting functional role. As most of the detected 
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phosphorylation sites are more greatly enriched in 14-day old rat hearts, it may be that 
phosphorylation sites such as Ser794 of Tensin 1, which do not follow this pattern of 
expression, are not involved in the protein’s survival signalling activities, or may even be 
repressors of this activity. Further work will be needed to investigate the functional roles of 
such phosphorylation sites. 
3.4.1.2.6 Phospho-Akt levels measured using proteomics did not correlate with 
western blot analysis 
Analysis of the phosphoproteomic output also identified that phosphorylation of the pro-
survival signalling protein, Akt1, at Ser129 was shown to be greater at 14-days, a 
phosphorylation site reported to be phosphorylated by the anti-apoptotic kinase, Casein 
Kinase 2 (CK2) (Di Maira, Salvi et al. 2005), subsequently promoting the catalytic activity of 
Akt1. It should be noted that the pattern of change in pAkt/Akt expression over the course 
of postnatal development obtained from the western blot data showed a complete reversal 
to that seen in the phosphoproteomic output, with the highest levels of pAkt expression in 
adult samples. The reason for this discrepancy between our proteomic data and the western 
blot trends in pAkt expression during postnatal development is uncertain, but may be a 
result of the non-specificity of the antibody to Akt1, which was the isoform detected by 
phosphoproteomic analysis, in addition to the fact that phosphoproteomics only detected 
phosphorylation at Ser129, whereas the antibody used in initial experiments was specific to 
Ser473. Subsequent testing with an antibody specific for phosphorylation at Ser129 did in 
fact show statistically significant changes in abundance across the three age groups that was 
concordant with that seen in the phosphoproteomic output, with the greatest levels of pAkt-
Ser129 in 14-day old samples compared with both 28-day olds and adults. However, 
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correction for total Akt expression removed any statistically significant differences between 
the three age groups. It is therefore likely that discrepancies between the western blotting 
data and phosphoproteomic output result from the fact that phosphoproteomic analysis did 
not account for total protein expression, only looking at the raw abundance of 
phosphorylation at each site to the pooled sample. This correlates with previous reports that 
neonates exhibiting a greater tolerance to I/R also possess a large pool of inactive, non-
phosporylated Akt in comparison with adults, and that adults show greater damage 
following I/R that correlates with decreased expression of Akt (Liaw, Hoe et al. 2013). The 
authors suggest that this “Akt reserve” allows immature hearts to produce a powerful pro-
survival response following I/R through phosphorylation and activation of the inactive Akt 
pool, resulting in a greater tolerance to I/RI than that seen in mature hearts. However, the 
specific phosphorylation site used in this study was not reported by the authors, making 
exact comparison between our findings and their data difficult.  
Antibodies targeting Ser473 are the most predominantly utilised in the literature, with 
phosphorylation at Ser473 often being reported as the key step for Akt activation, whereas 
our phosphoproteomic output did not detect any phosphorylation at Ser473. This apparent 
difference in phosphorylation levels between two reportedly activating phosphosites of Akt 
during postnatal development raises the possibility that it is in fact Ser129 phosphorylation 
that is the more important modification in the context of developmental-related differences 
in survival signalling. However, it will be necessary to further investigate the reason for the 
complete lack of Ser473 detection in the phosphoproteomic output, and whether this is 
merely a reflection of the fact that samples tested were taken from non-stressed hearts 
which likely would not have any need for the activation of survival signalling pathways.  
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3.4.2 Summary & Conclusion  
Proteomic and phosphoproteomic analysis identified a number of proteins linked to survival 
signalling and apoptosis that showed statistically significant changes in expression over the 
course of postnatal development. The trend in expression of the majority of these proteins 
was consistent with their reported roles in cell survival, with most pro-survival proteins 
showing their greatest levels of expression at 14-days of age, and most of those that 
promote cell death showing their greatest levels of expression in adults. Western blot 
validation of selected proteins demonstrated patterns of expression that were by and large 
concordant with that seen in the proteomic output. However, this work does not address 
the biphasic (bell-shaped) profile in response to I/R which involves including younger age 
group compared to 14-day old. Therefore, further proteomic/phosphoproteomic work was 
undertaken to further explore the expression patterns of survival-related proteins in order 
to identify those displaying biphasic profiles of expression, as will be described in Chapter 4.   
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Chapter 4: Developmental Changes in the Cardiac Survival 
Signalling Proteome in relation to vulnerability to cardiac 
insults  
4.1 Introduction 
As discussed in Sections 1.4 and 1.5, pro-survival and anti-apoptotic signalling pathways 
such as RISK-SAFE play a crucial role in the reduction of cell death and subsequent cardiac 
injury following I/RI. Our hypothesis states that, due to their importance in the I/RI response, 
underlying differences in the abundance and activity of these proteins may exist between 
age groups, contributing to the differences in cardiac vulnerability identified over the course 
of postnatal development. In order to address whether differences in the expression and 
phosphorylation state of RISK-SAFE proteins, as well as those known to cross-talk with these 
signalling pathways, may exist at different developmental stages, proteomic and 
phosphoproteomic analysis was utilised using age groups that are known to result in the 
bell-shaped vulnerability profile. Potential proteins of interest were identified through 
literature searches and signalling pathway maps, before statistical analysis to highlight those 
that showed a significant peak or nadir in expression at 14-days of age, coinciding with the 
peak in cardiac resistance to I/RI at this age. Identification of any survival related proteins 
with a pattern of postnatal expression mimicking the profile of cardiac vulnerability would 
therefore provide promising targets for further experimentation as to the effect of their 
inhibition on cardiac injury, and potential differences in the response of hearts from 
different age groups.  
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4.2 Materials & Methods 
4.2.1 Animal groups & sample extraction 
Proteomic and phosphoproteomic analysis was conducted with samples taken from 7-day 
old (n = 4), 14-day old (n = 8), 28-day old (n = 8) and adult (n = 7) rats. Rats were culled as 
outlined in Section 2.2, hearts excised, and the apex removed for flash freezing in liquid 
nitrogen. Tissue then underwent protein extraction and quantification as described in 
Sections 2.4.1 and 2.4.2.  
4.2.2 Proteomic and Phosphoproteomic Analysis 
The full process of proteomic and phosphoproteomic analysis has been described in Section 
2.4.3, but can be summarised as the dilution of the quantified samples mentioned in Section 
4.2.1 with double distilled water to adjust the protein concentration of each sample to 
2mg/ml for sending to the University of Bristol Proteomics Facility, in order for samples to 
undergo Tandem Mass Tag (TMT) analysis (ThermoFisher Scientific, UK). For 
phosphoproteomic analysis, samples underwent an additional phosphopeptide enrichment 
step using a TiO2 column (Section 2.4.3). 
The resulting output came in the form of a Proteome Discoverer file with the abundance of 
each protein in each sample as a ratio to the pooled sample, from which proteins selected 
from the existing literature and signalling pathway database searches as relating to cell 
survival processes were identified (see Section 2.4.4). These proteins then underwent 
statistical analysis in order to identify those that showed significant changes in expression 
between age groups concordant with the cardiac vulnerability profile during postnatal 




 An initial run of proteomic analysis was conducted for survival signalling proteins, with 
western blot validation of the proteomic data, using only 3 age groups; 14-day old, 28-day 
old and adult hearts (Chapter 3). A younger age group is important for testing and 
comparison to the biphasic profile of vulnerability to I/RI. Therefore, protein was extracted 
from the cardiac tissue of 4 age groups, 7-day (n = 4), 14-day (n = 8), 28-day (n = 8) and adult 
(n = 7) rats, and used for proteomic analysis (as described in Section 2.4). From this data, we 
identified relevant proteins presenting with a similar biphasic profile expression mirroring 
that of vulnerability to I/RI for future targeting. For figure clarity, P7, P14 and P28 were used 
to represent postnatal day 7, 14 and 28, respectively. 
4.3.1 Comparison of trends in key survival signalling protein expression 
between the original proteomic output and the new proteomic output. 
Proteins from the original proteomic output were identified in the new proteomic output in 
order to determine which of these – selected for being most highly expressed in 14-day old 
hearts in comparison with adult hearts – also showed a biphasic pattern of expression in the 
new proteomic output. Of the original 59 proteins selected for their role in survival signalling 
– 33 of which showed statistically significant differences in expression between 14-day old 
and adult samples in the first run of proteomics (Section 3.3.1) – only 14 had an overall 
biphasic trend in expression, with only 5 of these showing a statistically significant difference 
in comparison to both 7-day old and adult samples. This new run of proteomic analysis has 
subsequently allowed us to exclude a large number of proteins of interest identified from 
the original proteomic output from further investigation and study, as they do not fit the 
biphasic profile seen in cardiac vulnerability over the course of postnatal development. 
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4.3.2 Do changes in survival signalling proteins during postnatal 
development follow a biphasic profile? 
We identified 659 proteins that were related to survival signalling, either directly within the 
RISK-SAFE pathways or within peripheral/interconnected pathways in all age groups. 
Comparing the 14-day old and adult proteome, we found 468 proteins were expressed at a 
higher level in 14-day old samples, with 37 proteins showing significantly lower expression 
in 14-day old samples (Figure 29).  
However, to match the biphasic profile of vulnerability to I/RI, we focused on proteins which 
also displayed a biphasic profile of expression with age including 7- and 28-days old. The 
Figure 29. Volcano plot of all survival signalling proteins identified in the proteomics (n = 
659), comparing fold difference (FD) between the average protein expressions in 14-day 
old and adult heart samples expressed as log2 (x-axis), against the p-value expressed as –
log10 (y-axis). The red line indicates a cut-off point for statistical significance (p = 0.05) for 
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original proteomic output identified a total of 10,453 proteins, 412 of which demonstrated 
a biphasic profile of expression across the four age groups. Of the 659 survival signalling-
related proteins previously described, 346 were found to exhibit a profile with a peak or 
nadir of protein expression at 14-days, with statistically significant differences between 14-
day old and adult samples. However, of these, only 86 proteins also showed statistically 
significantly differences between 14-day and 7-day old samples. For the purposes of this 
work, only key proteins strongly involved with the RISK-SAFE pathways specifically, 





















































































































Change in expression of Survival Signalling related proteins
P7 P14 P28 Adult
Figure 30. Biphasic profile of key survival signalling related protein expression in the 
proteomic output. All proteins show statistically significant difference between 14-day old 
and adult samples. Proteins with (*) also show statistically significant difference between 
14-day old and 7-day old samples. Data for adult and 28-day old tend to follow similar 













   







4.3.3 Phospho-proteomic Output 
As described in Section 2.4, samples also underwent phosphoproteomic analysis. Of the 
original proteins of interest, selected due to their central role in RISK-SAFE and survival 
signalling and displayed in Section 4.3.2, complete sets of phosphoproteomic data – i.e. 
detected in all three sets and thus all four age groups – were only identified for two proteins; 




Whilst both 7-day old and 14-day old samples showed statistically significantly higher levels 
of pAkt phosphorylation at Ser124 than both 28-day old and adult, no significant difference 
was seen between 7-day old and 14-day old samples.  
Two separate phosphorylation sites were detected for pAMPK-β1, as shown in Figure 32 
below, both of which showed markedly differing trends of abundance between the four age 
groups. Phosphorylation at Ser24 followed the expected trend of statistically significantly 
greater levels in 14-day old samples in comparison to both 28-day old and adult samples. 
Phosphorylation at Ser108 showed statistically significantly greater levels in 28-day old 
Figure 31. The abundance of Akt 
phosphorylation at Ser124 
across the 4 age groups (7-day (n 
= 4), 14-day (n = 8), 28-day (n = 8) 
and adult (n = 7)). * = Statistically 
significant difference in 
comparison with 7-day old 
samples (p < 0.05). # = Statistically 
significant difference in 
comparison with 14-day old 
samples (p < 0.05). Data 
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samples in comparison to all of the other three age groups. The significance of these 




Figure 32. Relative abundance of AMPK-B1 phosphorylation at A. Ser24 and B. Ser108 
across the 4 age groups (7-day (n = 4), 14-day (n = 8), 28-day (n = 8) and adult (n = 7)). 
* = Statistically significant difference in comparison with 14-day old samples (p < 0.05).  
# = Statistically significant difference in comparison with 28-day old samples (p < 0.05). 
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Proteomic and phosphoproteomic analysis show that patterns of change in expression 
during development for the majority of proteins aligned with what would be expected from 
their reported roles in survival signalling and apoptosis in the literature, and the differences 
in vulnerability to I/R injury. A number of key and peripheral survival signalling proteins were 
identified in an initial run of proteomic analysis with only 3 age groups as displaying a gradual 
decrease or increase in expression from 14-days of age to adult (Chapter 3). A second run of 
proteomic analysis including a fourth age group – 7-day old rats – as well as a larger number 
of samples per age group (Section 4.3), switching from the use of the TMT-6plex to TMT-
10plex kit and from the LTQ-Orbitrap Velos Mass Spectrometer (Thermo Fisher) to the 
Orbitrap Fusion Tribid Mass Spectrometer (Thermo Fisher) with greater sensitivity, identified 
a greater number of proteins that are more central to the RISK-SAFE survival signalling 
pathways than those identified in the initial run of proteomics. The addition of the fourth 
age group also allowed for biphasic trends in expression analogous to the cardiac 
vulnerability profile to be identified, with the subsequent exclusion of a number of proteins 
from the initial run that showed a gradual change in expression with postnatal development, 
but not the characteristic biphasic profile of interest. 
4.4.1 RISK-SAFE pathways proteins displayed age-related biphasic 
changes in expression 
As discussed in Section 1.5, the RISK-SAFE signalling pathways play a key role in cell survival 
following ischemic insult, in addition to other overlapping cardioprotective pathways. A 
number of these proteins were subsequently found to display an overall biphasic pattern of 
expression during postnatal development, and for the purposes of this work, Section 4.3 
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focuses on those that either function directly within the RISK-SAFE pathways, or which have 
high degrees of overlap and strong statistical significance (i.e. statistical significance both 
between 14-day old and adult samples, as well as 14-day old and 7-day old samples).  
Members of the RISK pathway with overall biphasic changes in expression included ERK1, 
MEK2, Raf1, H-ras, and K-ras, as well as PI3K subunits, PDK1, Akt1, eNOS, PKG-1, GSK3β and 
PKCε. Similarly, JAK1 and STAT3 of the SAFE pathway also showed a biphasic profile of 
expression. These proteins, while displaying biphasic expression, did not show statistical 
significance between 14-day and 7-day old samples. However, it is uncertain whether this is 
due to the fact that only four 7-day old samples were run, and as a result there was often 
scatter between samples. The apparent overall peak in expression at 14-days of these 
survival signalling proteins supports the hypothesis that they play a causal role in improved 
cardiac vulnerability in this age group.  
The exception to this, however, is GSK3β, which is a known anti-survival signalling protein 
via opening of the mPTP during I/RI (Juhaszova, Zorov et al. 2004, Lal, Ahmad et al. 2015), 
phosphorylation at Serine 9 by Akt and subsequent inactivation of which is believed to be 
required for cardioprotection (Gomez, Paillard et al. 2008). The peak in its expression at 14-
days of age therefore seems to contradict its functional role in cell survival. However, work 
by Zhai et al. (2011) showed that GSK3β had distinct effects on myocardial injury depending 
on which phase of I/R it was activated at. During prolonged ischemia, inhibition of GSK3β 
was found to exacerbate injury, whereas activation lead to suppression of mTOR activity and 
increased autophagy, resulting in decreased infarct sizes. In contrast, GSK3β inhibition 
during reperfusion lead to increased activation of mTOR, decreased autophagy, and a 
subsequent reduction in reperfusion injury (Zhai, Sciarretta et al. 2011). It is therefore 
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possible that 14-day old hearts have a high reserve of GSK3β that can be activated during 
ischemia to reduce ischemic injury, and is subsequently inhibited by other survival signalling 
proteins, such as Akt, during reperfusion for cardioprotection. Further work will be needed 
to look at the expression and phosphorylation states of GSK3β in 14-day old compared with 
adult samples taken following ischemia alone and following reperfusion. 
Upstream of these signalling pathways, caveolins play an important role in co-ordinating 
survival signalling at the cell membrane, and have previously been shown to exert 
cardioprotective roles through knockout and overexpression studies (Das, Das et al. 2007). 
In keeping with this, three isoforms of caveolin (-1, -2 & -3) all displayed a biphasic profile of 
expression, with statistically significant differences between 14-day and both 7-day and 
adult samples. It is therefore possible that enrichment of survival signalling begins even at 
the initial stages of these pathways and their activation via caveolins, or that the caveolins 
themselves may play a direct role in the reduction of I/RI through actions such as binding 
and inhibition of caspase-3 (Sharma et al. 2011), increased association of caveolin-1 with 
pro-apoptotic p38MAPK-α, or decreased association of caveolin-3 with anti-apoptotic 
p38MAPK-β (Das, Gherghiceanu et al. 2008). Moreover, caveolin-3 has also been reported 
to exert cardioprotective effects via the regulation of autophagy during Ischemia and I/R 
(Kassan et al. 2016). In this study, caveolin-3 overexpressing cells were found to have a much 
greater autophagic response during ischemia following treatment with traditional 
autophagy inducing compounds, in addition to co-immunoprecipitation with and 
upregulated expression of autophagic markers such as beclin-1 in comparison with wild type, 
with associated cardioprotection and preservation of mitochondrial function. Knockdown of 
caveolin-3 was subsequently demonstrated to result in a reduction of autophagic marker 
expression following simulated ischemia and I/R, increased apoptosis and apoptotic protein 
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expression, and greater mitochondrial dysfunction (Kassan et al. 2016). This link of caveolin-
3 to autophagy, shared by GSK3β and further proteins to be discussed, indicate the potential 
that this process may be of particular importance in 14-day old hearts.  
As mentioned in Section 1.5.3, AMPK is a cardioprotective protein that monitors cellular 
stress and acts as a subsequent regulator of metabolism, for example through increased 
glucose uptake via GLUT4 (Moussa and Li 2012), the inactivation of which has been shown 
to increase ROS production during reperfusion and decrease resistance of mitochondria to 
mPTP opening, in addition to reduced JNK signalling and increased necrosis (Zaha et al. 
2016). In addition to this, AMPK is believed to play a role in autophagy, which could result in 
a pro-survival response during ischemia via removal of damaged cellular components in the 
stressed environment, and subsequent freeing of nutrients and energy (Paiva et al. 2011). 
Paiva et al. (2011) also report that AMPK activation may preserve both post-reperfusion 
cardiac function and mitochondrial integrity as a result of increased glycolysis, and 
subsequently raised ATP levels in the cell once reperfusion begins. Our proteomic output 
found that both AMPK-α2 and AMPK-β1 were more highly expressed at 14-days of age in 
comparison with both 7-day old and adult samples. AMPK could therefore potentially play a 
role in the decreased vulnerability of this age group to cardiac insult through its range of 
cellular functions, or through its links to members of the RISK-SAFE pathways. Indeed, work 
by Chen et al. (2017) found that Lysophosphatidic Acid (LPA) treatment of 14-day old 
Langendorff perfused hearts resulted in significant improvements in cardiac function and 
infarct size, with decreased CK-MB release and apoptosis, and an associated increase in the 
expression of survival signalling proteins such as Akt, BCL-2, and AMPK.  However, previous 
work has also described AMPK activation as being detrimental during reperfusion (Paiva et 
al. 2011). Therefore, similarly to GSK3β, it will be necessary to look at the differential 
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expression and activation of AMPK in 14-day old and adult samples both post-ischemia and 
post-reperfusion.  
Finally, mTOR showed statistically significant biphasic expression in the proteomic output 
between 14-day old and both 7-day old and adult samples. As previously discussed, mTOR 
activity is reportedly suppressed during ischemia by proteins such as GSK3β and AMPK, in 
order to upregulate autophagy and confer cardioprotection to the heart. However, mTOR is 
also known to be both an upstream activator of and downstream target for activation by Akt 
(Tao et al. 2010), which also displayed an overall biphasic trend in expression in the 
proteomic output. In a study by Kong et al. (2016), overexpression of HSPA12B – which 
although not included in this chapter, also showed a statistically significant biphasic peak in 
expression at 14-days of age in comparison with all other age groups in the proteomic output 
– was shown to reduce infarct size and cardiac dysfunction, with increased cardiomyocyte 
survival. These cardioprotective effects were associated with increased pAkt/Akt, 
pGSK3β/GSK3β, and pmTOR/mTOR ratios, all of which were abolished by the inhibition of 
upstream PI3K activity (Kong et al. 2016). It is therefore possible that the high expression of 
mTOR at 14-days of age could indicate a reserve of the protein kept inactive during ischemia 
by AMPK and GSK3β, and is subsequently activated by Akt during reperfusion. Expression 
and phosphorylation status of mTOR will consequently be tested in post-ischemic and post-
I/R samples in order to further elucidate these potential interactions, as well as any 
differences between 14-day old and adult samples.  
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4.4.2 Phosphoproteomic analysis did not identify biphasic changes in 
the phosphorylation status of survival signalling proteins 
Analysis of the phosphoproteomic output detected only a few proteins with phosphosites 
common across all 4 age groups examined. Firstly, phosphorylation of Akt was detected at 
Ser124, with significant differences only between 28-day old and adult samples in 
comparison with 7-day old and 14-day old samples, therefore showing an overall decrease 
during postnatal development, but not a biphasic change. Ser124 has been reported to be 
constitutively phosphorylated (Iacovides, Johnson et al. 2013), unaffected by 
pharmaceutical inhibition of PI3K and thus independent of the classic phosphorylation axis 
associated with RISK-SAFE signalling (Liao and Hung 2010). It is therefore unlikely that 
differences in levels of Ser124 phosphorylation relate to differences in cardioprotective 
signalling between these age groups, and instead reflect the greater expression of total Akt 
in 7-day old and 14-day old samples, as shown in Section 4.3.1. Indeed, tissue was extracted 
from control hearts in their non-stressed states, and therefore it is not unexpected that 
abundant levels of Akt activating phosphorylation, e.g. at Ser473, were not detected. It 
should be noted that Akt phosphorylation in the first run of phosphoproteomic analysis 
(Chapter 3) identified phosphorylation only at Ser129, not Ser124. The fact that samples 
from both runs of phosphoproteomic analysis were taken from hearts in their control state, 
in addition to the fact both Ser129 detected in the first run and Ser124 detected in the 
second showed the same trends in abundance across the three common age groups tested 
– with 14-day olds showing significantly greater levels of phosphorylation at both sites in 
comparison with 28-day olds and adults – is consistent with these data representing 
phosphorylation at the same site in both runs of analysis. Indeed, previous papers have 
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suggested that current phosphoproteomic methods are limited by the ionisation and 
behaviour of phosphopeptides and phosphate groups during the MS/MS process, with 
subsequent inaccuracies and impairment of the correct identification of individual 
phosphorylation sites (Solari et al. 2015). It is therefore possible that, due to the close 
proximity of the two residues (Ser129 and Ser124), such issues during the process of 
phosphoproteomic analysis itself may have resulted in their incorrect identification, with 
both runs having actually identified phosphorylation at the same site. However, it is not 
possible to say for certain whether this was indeed the case, and which, if either, was 
incorrectly identified. On the other hand, the fact that previously described western blotting 
experiments for Akt phosphorylation at Ser129 (Section 3.3.2.3) did mimic the trend seen in 
the phosphoproteomic output may indicate that phosphorylation at this site was correctly 
identified.  
Similarly, phosphorylation was detected for AMPK at Ser24, but was only significantly 
different between 28-day old and adult samples in comparison with 14-day old samples. 
Ser24 has been shown to be one of several sites involved in the “autophosphorylation 
cascade” triggered by the AMPK-α1 (Mitchelhill, Michell et al. 1997), and whilst not involved 
in the enzymatic activity of AMPK, its phosphorylation is linked to cellular distribution of the 
protein and required for its exportation from the nucleus (Sanz, Rubio et al. 2013). Similarly 
to Akt, it is therefore likely that the trend in abundance of phosphorylation at this site 
reflects the trend in total AMPK-β1 expression shown in Section 4.3.1, as opposed to an 
association to cardioprotective mechanisms in these control hearts. However, it is possible 
that the role of phosphorylation at Ser24 in the cellular localisation of AMPK means that the 
greater levels of phosphorylation at this site in 14-day old samples suggests a larger pool of 
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protein primed for full activation in the event of cellular stress and cardiac injury in this age 
group. 
Phosphorylation of AMPK was also detected at Ser108, again subverting the expected 
biphasic trend in abundance and instead peaking at 28-days of age, with statistically 
significantly greater levels than all 3 of the other age groups. Ser108 has been shown to be 
a target of autophosphorylation located in the glycogen binding region of AMPK-β1 (Iseli, 
Walter et al. 2005), and whilst studies have shown that mutation at this site confers only 
partial disruption of glycogen binding (Polekhina, Gupta et al. 2003), it has also been shown 
that mutation results in a 60% reduction in enzymatic activity of the protein (Warden, 
Richardson et al. 2001). However, due to the pattern of abundance of phosphorylation at 
Ser108 found in the phosphoproteomic output, peaking at 28-days of age, it is unlikely that 
phosphorylation at Ser108 is mechanistically significant to the biphasic differences in cardiac 
vulnerability seen across these four age groups. 
4.4.3 Summary & Conclusion  
A number of RISK-SAFE pathway and survival signalling proteins were identified in the 
proteomic output that demonstrated a pattern of expression consistent with both their 
reported roles in cell survival, and with the biphasic profile of cardiac resistance to I/RI. As a 
result, three key proteins – PKCε, GSK3β, and AMPK – were selected from this data for 
further investigation into the effects of their inhibition on isolated cardiomyocyte 
vulnerability to simulated I/RI, as will be described in Chapter 5.  
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Chapter 5: Targeting of signalling pathways to assess the 
response of isolated cardiomyocytes to cardiac insult  
5.1 Introduction 
Analysis of proteomic data (Section 4.3) identified a number of key survival signalling 
proteins that demonstrated an overall biphasic pattern of expression across the four age 
groups (7-day old, 14-day old, 28-day old, and adult rats) concordant with the differences in 
cardiac vulnerability to I/RI seen. Having thus addressed the first aim of this work – the 
identification of “any changes that occur in survival signalling through changes in the 
expression of pro-survival and apoptosis-related proteins during development” – work to 
address the second aim was subsequently undertaken; “To see if specific inhibition of the 
identified proteins affects the vulnerability to ischemia/reperfusion injury during postnatal 
development in isolated cardiomyocytes.” 
As described in Section 1.5, PKCε and GSK3β are important downstream targets of RISK-SAFE 
signalling, both demonstrating an overall biphasic trend of expression during the course of 
postnatal development in the proteomic output (Section 4.3.1), as shown in Figures 33 and 
34 below. As statistically significant differences in the expression of these two proteins was 
not seen between 7-day old and 14-day old samples, the scatter plots of individual data 
points are included to highlight the overall trend in expression, and the uncertainty 
introduced by the fact that only 4 samples from 7-day old hearts were included in the 
proteomic analysis. In the case of GSK3β particularly, a clear outlier in the 7-day old group 
of samples was identifiable (indicated by a red circle). However, its removal did not alter 
findings of significance between the age groups. An outlier was also detected for PKCε in the 
14 day old samples, removal of which did not affect findings of statistically significant 
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Proteomic output – Mean 
expression of GSK3β by age
7 day 14 day 28 day Adult
Figure 33. A. Biphasic profile of PKCε expression in the proteomic output. * = statistically 
significant difference with P14 (p < 0.05). Data presented as Mean ± SE. B. Plot of PKCε 




Figure 34. A. Biphasic profile of GSK3β expression in the proteomic output. * = statistically 
significant difference with P14 (p < 0.05). Data presented as Mean ± SE.  B. Plot of GSK3β 





























 Analysis of the proteomic output (Section 4.3.1) identified a biphasic trend in the expression 
of AMPK with statistically significant differences between 14-day old samples and all 3 of the 
remaining age groups, therefore showing a strong correlation with the biphasic pattern of 
cardiac resistance to I/RI across these 4 age groups, as shown in Figure 35 below. AMPK has 
an important role in reducing cardiac injury during ischemia and reperfusion, as described 
in Section 1.5.3, combining with its strong biphasic profile of expression to make it a key 
target for further investigation alongside PKCε and GSK3β. Although both PKCε and GSK3β 
did not show statistically significant differences in expression between 7-day old and 14-day 
old samples, the previously discussed limitation of having only 4 samples for the 7-day old 
group, the overall biphasic profile, the importance of both proteins as end targets of survival 
signalling pathways in addition to their links to AMPK in terms of both signalling and 
autophagy (Nishino et al. 2004, Sciaretta et al. 2014), and the availability of previously tested 
inhibitors highlighted them as important targets for these initial studies. 
Figure 35. Biphasic profile of AMPK subunit expression in the proteomic output. * = 












* AMPK (5'-AMP-activated protein kinase
catalytic subunit alpha-2)



























Proteomic Output – Mean expression of AMPK subunits by age 





As a result of these findings, PKCε, GSK3β and AMPK were targeted using the inhibitors 
chelerythrine (Huang, Liu et al. 2010), TWS119 (Jiang, Xiao et al. 2016) and dorsomorphin 
dihydrochloride (Konishi, Haraguchi et al. 2011), respectively, for cell viability studies into 
the potential differential effects of their inhibition on cardiomyocytes isolated from different 
age groups. 
5.2 Materials & Methods 
5.2.1 Cardiomyocyte isolation 
Cardiomyocyte isolation was performed as outlined in Section 2.3, using hearts extracted 
from 14-day old (n = 6), 28-day old (n = 4), and adult (n = 3) rats. As previously described, 
hearts were perfused with an initial buffer containing 750 μM Ca2+ to optimise circulation 
and wash out any remaining blood or clots. This was switched to perfusion with an EGTA 
containing solution to remove any remaining Ca2+, followed by freshly made enzyme solution 
until an optimal softness of the heart was reached, indicating sufficient digestion to provide 
a good yield of isolated cardiomyocytes. Calcium was then gradually reintroduced into cells 
through perfusion with a buffer of 150 μM Ca2+, and sequential addition of 0.5 mM and 1 
mM Ca2+ solutions. The resulting cell solution was separated into two groups; control and 
simulated I/R, the latter receiving an additional 3 mM Ca2+ (for a final concentration of 4 
mM), as well as 20 mM KCl and 0.5 mM H2O2. Cell viability was subsequently measured using 




5.2.2 Protocol for investigating the effect of drugs in an injury model of 
cardiomyocyte suspension 
Cardiomyocyte isolation was performed as outlined in Section 2.3 and 5.2.1 above, using 
hearts extracted from 14-day old (n = 5) and adult (n = 4) rats, and with some changes to the 
protocol. Firstly, solutions B, C and enzymatic solution D were all made from a stock solution 
A containing glucose, as previously described. However, solutions used following enzymatic 
digestion – i.e. solutions E, F and G – were made using a stock of solution A containing no 
glucose. This exclusion of glucose was made as initial experiments demonstrated that the 
presence of glucose in these solutions aided cardiomyocyte survival even in cells undergoing 
simulated I/R, resulting in relatively low drops in cell viability over the 2 hour experimental 
period (see Section 5.3.1 and Figure 36) which subsequently made measurements for 
changes in viability difficult. Previous studies have also discussed the potential issue that 
glucose inclusion in the final solution may affect isolated cardiomyocyte studies due to the 
uptake of glucose by cells and subsequent changes in metabolism (Voigt et al. 2015). 
Secondly, the cell suspension of isolated cardiomyocytes was divided into three groups; one 
as a control group with no further treatments, one as a simulated I/R group (0.5 mM H2O2 + 
an additional 3 mM Ca2+), and one with both simulated I/R and treatment with a specific 
inhibitor selected based on proteomic analysis (5 µM chelerythrine, 5 µM TWS119 or 1 µM 
dorsomorphin dihydrochloride). Elevated K+ concentrations (20 mM) were not used for 
simulated I/R in these experiments in order to limit the effects to the key mechanisms of 
injury traditionally described – oxidative stress and calcium overload. Both TWS119 (Jiang et 
al. 2016) and dorsomorphin dihydrochloride (Konishi et al. 2011, Chen et al. 2010) have been 
tested in cardiomyocytes and Langendorff perfused hearts in previous studies, which 
successfully demonstrated the effective and specific inhibition of our proteins of interest at 
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the concentrations used in these experiments. Similarly, chelerythrine has been 
demonstrated to inhibit PKCε activity in rat hearts at the 5 μM concentration used, as 
determined by the decreased PKCε translocation and abundance in mitochondrial fractions 
(Nunez et al. 2017). However, it is important to note that this inhibitor and concentration is 
not specific for PKCε, and also inhibits other PKC isoforms (Huang et al. 2010), an issue that 
will be discussed further in Chapter 9. Finally, for these experiments, cell viability was 
measured using Trypan blue from the total cell solution as a start viability, then every 30 
minutes for 2 hours. 
5.2.3 Western blot analysis of protein extracted from isolated 
cardiomyocytes 
The full western blotting methodology has been described in Section 2.5. To summarise, 
samples of the isolated cardiomyocyte suspension (Section 5.2.2) from the starting solution 
and from the final solutions of the experimental groups following 2 hours incubation were 
flash frozen in liquid nitrogen at the end of the experiment. Protein was subsequently 
extracted and quantified as outlined in Sections 2.4.1.2 and 2.4.2, and used to prepare a 
sample of 0.15mg of protein in a final volume of 100µl. These samples were then prepared 
for gel electrophoresis with the addition of an equal volume of loading buffer (Laemmli 
buffer + βME), before being run on a Mini-PROTEAN® TGXTM precast gels and transferred to 
a PVDF membrane, which was subsequently stained with Ponceau S solution to produce full 
lane bands (see Section 2.5.4), before blocking with milk. Membranes were then incubated 
with antibodies for PKCε, pPKCε, GSK3β or pGSK3β (see table of antibodies in Section 2.1.2), 
washed with TBST, incubated with a secondary antibody, and visualised using the Enhanced 
ChemiLuminescence system. Ponceau S staining was used as a loading control for 




5.3.1 Vulnerability of isolated cardiomyocytes to simulated I/R in the 
presence of glucose 
Cardiomyocytes were isolated from rat hearts of ages 14-days (n = 6), 28-days (n = 4) and 
adult (n = 3), and viability was measured for each as a percentage of cells without Trypan 
blue staining at each time point (as outlined in Section 2.1). Solutions used for these 
experiments were as described in Section 5.2.1, with inclusion of glucose in the final 
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The mean percentage of viable cells for each group is displayed in Figure 36. These data 
show a greater decrease in the mean percentage of viable cells over time in the experimental 
group undergoing simulated I/RI (0.5 mM H2O2, 20 mM KCl, 4 mM Ca2+) in comparison with 
the control group at each age group. However, this difference is not statistically significantly 
different at 14-days of age. In 28-day old and adult hearts, however, the difference in the 

























Average Cell viability - Adults
Experimental Control
Linear (Experimental) Linear (Control)
C. 
Figure 36. The mean percentage of viable cells over time for control cells compared to cells 
that underwent simulated I/RI by age (A. 14-days, B. 28-days, C. Adult). Data are presented 
as mean ± SE (n = 6 for P14, n = 4 for P28 and n = 3 for adult). * = statistically significant 




5.3.2 Effect of inhibition of selected survival signalling proteins on 
cardiomyocyte viability following simulated I/R at different stages of 
postnatal development. 
Three proteins were selected based on proteomic analysis for further investigation – PKC & 
GSK3β, which are key end effectors of RISK-SAFE signalling, and AMPK, which showed strong 
statistical significance between 14-day old samples and all other age groups – as discussed 
in Section 5.1. Therefore, three selective inhibitors of these proteins were used: 
chelerythrine (5 µM), TWS119 (5 µM) & dorsomorphin dihydrochloride (1 µM). For these 
experiments, the data for which are presented in Figures 37-44, glucose was absent from 
the final solutions, and elevated K+ was not used in the simulated I/R groups (see Section 
5.2.2). The effects of these drugs on cell viability were investigated using a suspension of 
cardiomyocytes (as described in Section 2.3). 
5.3.2.1 Effect of survival signalling protein inhibition on cardiomyocyte 
viability following simulated I/R injury. 
5.3.2.1.1 Differential effects of PKCε inhibition on isolated cardiomyocytes from 
14-day old and adult hearts. 
5.3.2.1.1.1 Effect of chelerythrine treatment on percentage change in cardiomyocyte 
viability. 
The percentage change of viable cardiomyocytes – defined as cells that have not taken up 
trypan blue staining, and expressing the initial viability as 100% – was measured every 30 
minutes for 2 hours in each experimental group, and the results for both 14-day old and 
adult cells are displayed in Figure 37 below. Whilst cardiomyocyte suspensions from adult 
hearts displayed statistically significant differences in viability only between the control 
group (green) in comparison with both the simulated I/R (blue) and simulated I/R with PKC 
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inhibition (red) groups, 14-day old cells showed additional statistically significant differences 
in viability between the simulated I/R and PKC inhibited groups. This shows that inhibition 
of PKC only had an effect on cell viability in cardiomyocytes taken from 14-day old hearts, 























Average percentage change in viability of adult cardiomyocytes























Average percentage change in viability of 14-day old cardiomyocytes
Control Simulated I/R Sim. I/R + Chelerythrine
** 
* 
Figure 37. Time-dependent changes in percentage change of viability of cardiomyocytes 
isolated from 14-day (A) old and adult (B) rat heart incubated in the presence or absence of 
H2O2 or H2O2 + chelerythrine; A. 14-day old hearts (n = 5 per group), control vs. simulated I/R, 
control vs. chelerythrine, simulated I/R vs. chelerythrine. B. Adult hearts (n = 4 per group), control 
vs. simulated I/R, control vs. chelerythrine. * = statistically significant difference with control (p < 









5.3.2.1.1.2 Effect of chelerythrine treatment on percentage change of rod-shaped 
cardiomyocytes. 
Counts were also taken at each time point for the percentage of rod-shaped cardiomyocytes 
alone, treating all rounded cells as no longer viable regardless of staining with trypan blue. 
Calculation of the percentage change in rod-shaped cardiomyocytes showed statistically 
significant differences between experimental groups only in adult cells, with a higher 
percentage retaining their rod-shaped structure in the control (green) group in comparison 
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Average percentage change in rod cells of 14-day old cardiomyocytes
Control
Simulated I/R
Sim. I/R + Chelerythrine
* 
Figure 38. Percentage change in rod-shaped cardiomyocytes over the course of 120 minutes 
in 14-day old and adult rat heart derived cardiomyocytes; control vs. simulated I/R vs. 
chelerythrine treated cardiomyocytes. A. 14-day old hearts (n = 5 per group). B. Adult hearts (n = 4 
per group), control vs. simulated I/R, control vs. chelerythrine. * = statistically significant difference 








5.3.2.1.1.3 Effect of chelerythrine treatment on the expression and phosphorylation 
state of PKCε 
Samples were collected from the cell suspension at the start of the experiment, and again 
at the end for each of the three experimental groups (control, simulated I/R, and simulated 
I/R + chelerythrine), in the form of a cell pellet spun down through microcentrifugation. 
Protein was extracted from these pellets and samples were prepared for western blotting as 
outlined in Section 2.5. These samples were then tested for pPKCε expression, before the 
membrane was stripped and reprobed with an antibody for PKCε, in order to compare the 
effects of simulated I/R as well as treatment with chelerythrine on the expression and 








No statistically significant differences were seen in pPKCε/PKCε expression between the 
experimental groups of cells isolated from either 14-day old hearts or adult hearts. However, 
between the two age groups, pPKCε/PKCε was significantly higher in adults than 14-day old 
cells both in the control and simulated I/R groups. The significance of this is unclear, but may 
reflect the overall higher viability in adult cells than 14-day old cells following isolation. It is 
also important to note that other studies have looked at the translocation of PKC or have 
conducted analysis of protein activity as opposed to phosphorylation state in order to 
examine the efficacy of the drug’s inhibitory effect. In addition to the fact that chelerythrine 
is not a PKCε specific inhibitor, this may explain why no significant differences were detected 
by western blotting. However, the concentration used here has been shown in previous 
studies to be effective in the inhibition of PKCε. 
Figure 39. A. Representative western blot bands for pPKCε and PKCε for each experimental group from 
both 14-day old and adult cardiac samples, with a graph depicting the average ratio of pPKCε/PKCε for 
each age and experimental group. (n = 3 for each group). Data presented as mean ± SE. * = 
statistically significant difference in comparison with corresponding 14-day old group (p < 0.05). B. 




5.3.2.1.2 Effects of GSK3β inhibition on cardiomyocytes from 14-day old and 
adult hearts  
5.3.2.1.2.1 Effect of TWS119 treatment on percentage change in cardiomyocyte 
viability.  
As seen in Figure 40, cardiomyocyte suspensions from adult hearts displayed statistically 
significant differences in percentage change in viability only between the control (green) 
group in comparison with both the simulated I/R (blue) and simulated I/R with TWS119 (red) 
groups. However, 14-day old cells showed additional statistically significant differences in 
viability between the simulated I/R and GSK3β inhibited groups. This shows that inhibition 
of GSK3β only had an effect on cell viability in cardiomyocytes taken from 14-day old hearts, 





























Average percentage change in viability of 14-day old cardiomyocytes







5.3.2.1.2.2 Effect of TWS119 treatment on percentage change of rod-shaped 
cardiomyocytes 
The percentage of rod-shaped cardiomyocytes was significantly different between control 
and TWS119 treated cells, as well as between simulated I/R and TWS119 treated cells, 
whereas there was no difference between Control and simulated I/R cells in 14-day olds. In 
adults, however, only the Control group showed differences to both the simulated I/R and 
TWS119 groups, indicating GSK3β inhibition effected the percentage of rod cells only in 14-




























Average percentage change in viability of adult cardiomyocytes
Control Simulated I/R Sim. I/R + TWS119
Figure 40. Percentage change in viability over the course of 120 minutes in 14-day old and 
adult rat cardiomyocytes; control vs. Simulated I/R vs. TWS119 treated cardiomyocytes. A. 
14-day old hearts (n = 5 per group), control vs. simulated I/R, control vs., simulated I/R vs. 
TWS119. B. Adult hearts (n = 4 per group), control vs. simulated I/R, control vs. TWS119. * 
= statistically significant difference with control (p < 0.05). ** = statistically significant 
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Average percentage change in rod cells of 14-day old cardiomyocytes
Control Simulated I/R Sim. I/R + TWS119
Figure 41. Percentage change of rod-shaped cardiomyocytes over the course of 120 
minutes in 14-day old and adult rat cardiomyocytes; control vs. simulated I/R vs. TWS119 
treated cardiomyocytes. A. 14-day old hearts (n = 5 per group), control vs. TWS119, 
simulated I/R vs. TWS119. B. Adult hearts (n = 4 per group), control vs. simulated I/R, 
control vs. TWS119. * = statistically significant difference with control (p < 0.05). ** = 










5.3.2.1.2.3 Effect of TWS119 treatment on the expression and phosphorylation state of 
GSK3β. 
Samples were collected from the cell suspension at the start of the experiment, and again 
at the end for each of the three experimental groups (Control, Simulated I/R, and Simulated 
I/R + TWS119), in the form of a cell pellet spun down through microcentrifugation. Protein 
was extracted from these pellets and samples were prepared for western blotting as 
outlined in Section 2.5. These samples were then tested for pGSK3β expression, before the 
membrane was stripped and reprobed with an antibody for GSK3β, in order to compare the 
effects of simulated I/R as well as treatment with TWS119 on the expression and 
























No statistically significant differences were detected between any age or experimental 
groups. This likely results from the need for splitting and running samples on two separate 
gels, and resulting scatter in results, in addition to issues with the collection of cell pellets 
and subsequent extraction of proteins from these samples at the end of the experiment 
when cell viability is very low. Protein concentration in these samples was low, and 
subsequently produced weak bands which may not have provided sufficient resolution to 
identify differences in expression, particularly when attempting to detect phosphorylated 
proteins. However, the concentration of inhibitor used in these experiments has been 
demonstrated to effectively inhibit GSK3β in previously published works. 
Figure 42. A. Representative western blot bands for pGSK3β and GSK3β for each 
experimental group from both 14-day old and adult cardiac samples, with a graph 
depicting the average ratio of pGSK3β /GSK3β for each age and experimental group. (n = 
3 for each group). Data presented as mean ± SE. B. Boxplot representation of the 













5.3.2.1.3 Differential effects of AMPK inhibition on isolated cardiomyocytes 
from 14-day old and adult hearts.  
5.3.2.1.3.1 Effect of dorsomorphin dihydrochloride treatment on percentage change in 
cardiomyocyte viability. 
As seen in Figure 43, cardiomyocyte suspensions from adult hearts displayed statistically 
significant differences in percentage change in viability only between the control (green) 
group in comparison with both the simulated I/R (blue) and simulated I/R with dorsomorphin 
(red) groups. However, 14-day old cells showed additional statistically significant differences 
in viability between the simulated I/R and AMPK inhibited groups. This shows that inhibition 
of AMPK only had an effect on cell viability in cardiomyocytes taken from 14-day old hearts, 
whereas adult cells were unaffected by AMPK inhibition. 




























Average percentage change in viability of 14-day old cardiomyocytes







5.3.2.1.3.2 Effect of dorsomorphin dihydrochloride treatment on percentage change of 
rod-shaped cardiomyocytes. 
The percentage change of rod-shaped cardiomyocytes was significantly different between 
control and dorsomorphin treated cells, as well as between simulated I/R and dorsomorphin 
treated cells, whereas there was no difference between control and simulated I/R cells in 
14-day olds. In adults, however, only the control group showed differences to both the 
simulated I/R and dorsomorphin groups, indicating AMPK inhibition effected the percentage 
of rod cells only in 14-day olds. 




























Average percentage change in viability for adult cardiomyocytes 
Control Simulated I/R Sim. I/R + Dorso.
* 
Figure 43. Percentage change in viability over the course of 120 minutes in 14-day old and 
adult rat heart derived cardiomyocytes; control vs. simulated I/R vs. dorsomorphin treated 
cardiomyocytes. A. 14-day old hearts (n = 5 per group), control vs. simulated I/R, control vs. 
dorsomorphin, simulated I/R vs. dorsomorphin. B. Adult hearts (n = 4 per group), control 
vs. simulated I/R, control vs. dorsomorphin. * = statistically significant difference with 








As previously mentioned, difficulty in collecting sufficient cells to form a pellet as a result of 
the very low cardiomyocyte viability at the end of incubation, often meant having an 
insufficient protein concentration for detection in western blotting. However, previous 
studies have demonstrated the efficacy of this concentration of dorsomorphin 
dihydrochloride in inhibiting AMPK activity (Konishi, Haraguchi et al. 2011). Western blotting 
























Average percentage change in rod cells of 14-day old cardiomyocytes























Average percentage change in rod cells of adult cardiomyocytes
Control Simulated I/R Sim. I/R + Dorso.
* 
Figure 44. Percentage change of rod-shaped cardiomyocytes over the course of 120 minutes 
in 14-day old and adult rat heart derived cardiomyocytes; control vs. simulated I/R vs. 
dorsomorphin treated cardiomyocytes. A. 14-day old hearts (n = 5 per group), control vs. 
dorsomorphin, simulated I/R vs. dorsomorphin. B. Adult hearts (n = 4 per group), control vs. 
simulated I/R, control vs. dorsomorphin. * = statistically significant difference with control (p < 










5.4.1 Simulated I/R decreases viability in adult & 28-day old, but not 14-
day old cardiomyocytes  
Simulation of ischemia/reperfusion injury in isolated cardiomyocytes found that there was 
no statistically significant difference in the resulting percentage cell viability between the 
experimental and control groups in 14-day old cardiomyocytes, whereas a statistically 
significant change was found in both 28-day old and adult cardiomyocytes. The absence of 
a statistically significant difference at 14-days is consistent with previous reports of a greater 
resistance to injury from I/RI injury at this age (Modi and Suleiman 2004). Moreover, the 
bell-shaped pattern of resistance reported – in which recovery following I/R markedly 
decreases at 28-days, and subsequently further in adults – appears to be mimicked in this 
data. As previous work into differences in resistance to I/RI have predominantly been 
conducted in whole hearts, the fact that a similar vulnerability profile can be seen in isolated 
cardiomyocyte samples that do not contain the same interacting factors found in the whole 
heart is significant. It should be noted that for direct statistical comparison of the viabilities 
of the experimental and control groups at the end of the experimental procedure, viability 
counts were treated as having been taken at exactly the same time point, whereas in reality 
there was a 20 minute delay between the measurements taken for the experimental group 
to those of the control group. It is therefore possible that the degree and significance of the 
differences as reported by statistical analysis have been underestimated.  
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5.4.2 Inhibition of differentially expressed proteins altered vulnerability 
of 14-day old, but not adult cardiomyocytes to simulated I/R 
5.4.2.1 Inhibition of PKC  
As previously mentioned, PKC was chosen for targeting in isolated cardiomyocyte viability 
studies due to its overall biphasic pattern of expression with postnatal development in the 
proteomic output, and due to the fact that it is a key end effector of survival signalling 
pathways such as RISK-SAFE. Inhibition of PKC with chelerythrine had a statistically 
significant effect on percentage viability of cardiomyocytes in 14-day old hearts only, but not 
in percentage rod-shaped cells in either age group. The fact that inhibition of PKC only 
seemed to effect 14-day old cardiomyocytes, at which age expression was greatest over the 
course of postnatal development, indicates that there is a potential causative mechanism 
linking the action of PKC and its greater expression to the associated greater resistance to 
cardiac insult at this age.  
Active PKCε is known to translocate to the sarcolemma and mitochondria from the cytosol, 
an effect seen following preconditioning in both the whole heart and in cultured neonatal 
rat cardiomyocytes (Inagaki et al. 2006). It is believed that this translocation allows PKCε to 
interact with KATP-channels present at both sites, although the mitochondrial form is 
believed to be more relevant in cardioprotection (Gross and Peart 2003, Light et al. 1996). 
Work has shown that in rabbit hearts, treatment with a PKC activator resulted in reduced 
infarct size, an effect that was lost with use of a KATP-channel inhibitor (Miura et al. 2000). 
However, similarly to our findings and those of others on the effect of chelerythrine in adult 
hearts, Miura et al. (2000) found that the use of a PKC inhibitor, in this case calphostin, did 
not affect infarct size.  
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PKCε has also been shown to interact with the mPTP, preventing its opening and subsequent 
water and solute entry, mitochondrial swelling, outer membrane rupture, release of 
intermembrane cytochrome c, and apoptosis (Inagaki et al. 2006). Baines et al. (2003) 
demonstrated that PKCε is able to directly interact with components of the mPTP, for 
example, through phosphorylation of VDAC1 and the resulting inhibition of pore opening 
(Kerner et al. 2014). While incubation of isolated cardiomyocytes with PKCε and cardiac 
specific expression of active PKCε resulted in greater interaction between PKCε and mPTP 
components, as well as inhibition of mPTP opening and reduced Ca2+-induced mitochondrial 
swelling, expression of inactive PKCε did not have an effect on pore opening (Baines et al. 
2003). This mimics the lack of effect seen with PKC inhibition via chelerythrine treatment 
frequently reported, but whether such findings would be the same in the more injury 
resistant 14-day old heart is uncertain. Our findings in isolated cardiomyocytes showed that 
chelerythrine did indeed have a negative effect on cell viability, and may indicate that the 
greater expression of PKCε in 14-day old hearts correlates with a greater dependence on 
PKCε activity. Interestingly, three isoforms of VDAC (-1, -2, and -3) were all found to be most 
highly expressed in 14-day olds, with statistically significant differences compared to both 7-
day old and adult hearts. This presents the possibility that a greater expression of VDAC in 
these hearts makes them more reliant on the activity of PKCε to phosphorylate and inhibit 
pore opening. Indeed, Zhang et al. (2012) showed that the cardioprotective effects of 
urantide following I/RI, associated with increased pAkt levels and BCL-2:Bax ratios, were lost 
following treatment with either chelerythrine or the PI3K-Akt inhibitor, LY294002. As their 
previous work had demonstrated no effect on I/RI with chelerythrine treatment alone 
(Zhang et al. 2005), it is possible that PKC inhibition and thus the effect of chelerythrine only 
effects survival and the response to cardiac insult in a situation where PKC expression or 
168 
 
activity is already elevated, which may provide an explanation as to why the drug was only 
effective in 14-day old hearts. Further work will be required to examine the effects of 
chelerythrine in 14-day old, Langendorff-perfused whole hearts. 
5.4.2.2 Inhibition of GSK3β  
GSK3β was chosen for targeting in isolated cardiomyocyte viability studies due to its overall 
biphasic pattern of expression with postnatal development, in addition to its role as a key 
end effector of survival signalling pathways such as RISK-SAFE. TWS119 treatment resulted 
in a statistically significant drop in cardiomyocyte percentage viability in 14-day olds, an 
effect that was also seen in the percentage of rod-shaped cells. However, this occurred in 
neither percentage viability nor percentage rod-shaped cells in adults. These results 
therefore demonstrate a putative link between the greater expression of GSK3β in 14-day 
olds in comparison with adult hearts, implicating GSK3β as a potentially causal protein in the 
greater resistance to cardiac insult seen in 14-day old hearts. Whilst this may appear 
surprising due to previous reports that GSK3β activity is detrimental to cardiomyocytes 
following I/RI, and that inhibition via pharmacological means or via phosphorylation by Akt 
is cardioprotective (Das et al. 2008), the majority of these studies have been focused on the 
adult heart, or in neonatal cardiomyocytes cultured prior to the 14-day peak in resistance to 
cardiac injury. As GSK3β is known to actually provide a cardioprotective effect during 
ischemia (discussed in Section 1.5.3), it is possible that this ischemia-specific role is more 
prominent in 14-day old hearts, and that inhibition of GSK3β results in the loss of this 
protection, leading to decreased cardiomyocyte viability in this age group. However, 
targeting of GSK3β in our isolated cardiomyocyte work employs chronic inhibition, as 
TWS119 is added to the cell suspension and left to incubate, whereas Langendorff studies 
169 
 
will wash out the drug, usually prior to ischemia. It will therefore be necessary to investigate 
the effect of GSK3β inhibition in the whole heart, and to examine the expression and 
phosphorylation states of samples taken from Langendorff perfused hearts following 
ischemia alone and following I/R.  
5.4.2.3 Inhibition of AMPK  
AMPK was chosen for targeting in isolated cardiomyocyte viability studies due to its strong 
biphasic pattern of expression, with statistical significance between 14-day old and both 7-
day and adult hearts, as well as its previously discussed cardioprotective properties (Section 
5.1.3), and overlap with RISK-SAFE signalling pathways. Inhibition of AMPK with 
dorsomorphin dihydrochloride resulted in a statistically significant drop in both 
cardiomyocyte percentage viability and the percentage of rod-shaped cells in 14-day olds, 
but not adults. Furthermore, the percentage of rod-shaped cells was found not to differ 
between control and simulated I/R cardiomyocytes in 14-day olds, whereas cells with 
simulated I/R in addition to dorsomorphin treatment had a significantly lower percentage 
than both. In adults, however, the percentage of rod-shaped cells was significantly lower in 
both the simulated I/R alone and simulated I/R with dorsomorphin groups compared to 
control, whereas these groups did not differ from one another. This supports the hypothesis 
that a greater expression of survival signalling related proteins in the 14-day old hearts 
confers greater resistance to cardiac insult, as inhibition of such proteins appears to confer 
a negative effect on viability not seen in adult hearts where basal AMPK expression is lower. 
Of particular interest is AMPK’s link to PKCε – the result of inhibition of which is discussed in 
Section 5.4.2.1 – in the setting of iPreC. Nishino et al. (2004) found that iPreC resulted in 
increased AMPK activity following translocation of PKCε to the cell membrane, and that this 
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effect of iPreC on AMPK activity was lost following pre-treatment with PKC inhibitors, 
including chelerythrine. This study implies that AMPK-mediated cardioprotection is PKCε-
dependent, and may be a contributing factor to our findings that chelerythrine treatment 
effected cardiomyocyte viability only in 14-day old cells, but not adults. However, whilst 
PKCε was found to translocate from the cytosol even in non-iPreC regions of the heart, these 
regions did not display greater AMPK activity (Nishino et al. 2004). The authors suggest that 
this may be due to the lack of the elevated AMP levels that accompany iPreC required for 
AMPK activation, raising interesting implications in the context of immature hearts. It has 
previously been reported that there is a lack of efficacy of iPreC in neonatal hearts (Doul et 
al. 2015, Schmidt et al. 2014), which may suggest that 14-day old hearts have an additional 
mechanism or signalling influence that allows for elevated AMPK activity, thus rendering 
iPreC redundant. Whether these findings hold true in the whole heart requires further 
investigation.  
5.4.3 Isolated cardiomyocytes respond differently to stress than intact 
hearts 
Contrary to what is seen in the whole heart, cardiomyocytes isolated from 14-day old hearts 
with simulated I/RI appeared to have a similar, if not greater, drop in percentage viability 
over the 2 hour experimental procedure in comparison with adults, in addition to a very 
dramatic decrease in the percentage of rod-shaped cells. While this seems to contradict 
reports that 14-day old hearts have a greater resistance to cardiac insult than adults, it is 
likely that these differences are due to the process of enzymatic digestion itself, which may 
be more harmful to 14-day old cardiomyocytes and indeed tended to yield a smaller number 
of cells that would quickly lose their rod shaped morphology and become rounded, but 
remain viable. Furthermore, this transition from a rod to rounded morphology seemed to 
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be exacerbated by the process of filtering the cardiomyocyte suspension and the subsequent 
stepwise increase of Ca2+ concentration in these 14-day old cells, suggesting the digestion 
process may have increased their sensitivity to Ca2+ loading. 
Initial proof of model studies (Section 5.3.1) actually found that, in comparison with 28-day 
olds and adults, 14-day old cardiomyocytes were the only age group not to show a 
statistically significant difference in viability over the two-hour experimental period between 
control and simulated I/RI groups. However, as the decrease in cell viability following 
simulated I/RI across all three age groups was not very dramatic, our standard laboratory 
protocol for cardiomyocyte viability studies subsequently switched to perfusion with a non-
glucose or sodium pyruvate containing solution following enzymatic digestion. This may 
have had a greater effect on 14-day olds, especially as it is known that hearts switch from 
predominantly glycolysis based metabolism during the neonatal period to predominantly β-
oxidation based as they transition into adulthood (Lopaschuk and Jaswal 2010), and may 
therefore contribute to these differences in response to insult seen between isolated 14-day 
old cardiomyocytes and the intact 14-day old heart.  
5.3.4 Summary & Conclusion 
Inhibition of PKCε, GSK3β and AMPK – which showed biphasic patterns of expression in the 
proteomic output correlating with the cardiac vulnerability profile to I/RI – all resulted in 
significant decreases to cardiomyocyte viability following I/RI in 14-day old, but not adult 
hearts. This is consistent with our hypothesis that these proteins, due to their role in cell 
survival and peak expression at 14-days of age, may play an important part in the underlying 
mechanism conferring heightened cardiac resistance to I/RI in this age group. Further work 
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was therefore undertaken to see if such age-dependent effects of inhibition on cardiac injury 
could be replicated in the whole heart, as will be described in Chapter 6.  
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Chapter 6: Targeting survival signalling pathways and 
vulnerability of intact adult and neonatal hearts to I/R 
6.1 Introduction 
A number of key survival signalling proteins that demonstrated an overall biphasic pattern 
of expression across the four age groups, concordant with the differences in cardiac 
vulnerability to I/RI, were identified in the proteomic analysis (Section 4.3). One of the key 
proteins found was AMPK, which demonstrated a biphasic trend in expression with 
statistically significant differences between 14-day old samples and all 3 of the remaining 
age groups. As AMPK has an important role in reducing cardiac injury during ischemia and 
reperfusion (Section 1.5.3), a biphasic profile of expression that correlates with changes 
cardiac resistance to I/RI, as well as having demonstrated the effect of its inhibition on 
isolated cardiomyocytes from different age groups (Section 4.3.3.1.3), the two first aims of 
this work have already been addressed:  
1. “To identify any changes that occur in survival signalling through changes in the 
expression of pro-survival and apoptosis-related proteins during development.”  
2.  “To see if specific inhibition of the identified proteins affects the vulnerability to 
ischemia/reperfusion injury during postnatal development in isolated 
cardiomyocytes.” 
This chapter therefore looks to address the third and fourth aims of this work; “To see if 
specific inhibition of the identified proteins affects the vulnerability to ischemia/reperfusion 
injury during postnatal development in whole hearts” and “To identify any changes that may 




6.2 Materials & Methods 
6.2.1 Protocol for ischemia/reperfusion experiments in the whole heart 
Langendorff perfusion was performed as described in Section 2.6, using 14-day old (n = 6), 
adult (n = 6) rats. Hearts were removed, cannulated on a Langendorff apparatus and 
perfused with Krebs-Henseleit solution for a period of stabilisation, prior to a 30 minute 
period of global ischemia, and 60 minutes of reperfusion. Effluent was collected before 
ischemia and at 1, 5, 10, 20, 30 and 60 minutes of reperfusion for use in creatine kinase 
measurements. As tissue was taken from the left ventricular wall and processed for electron 
microscopy (Section 8.3), TTC staining for infarct sizes was not performed. The creatine 
kinase data for these experiments are presented in Section 6.3.1 below. 
6.2.2 Protocol for ischemia/reperfusion experiments with drug wash-
out prior to ischemia 
Langendorff perfusion was performed as described in Section 2.6 and 6.2.1 above, using 14-
day old (control n = 5, dorsmorphin dihydrochloride n = 5) and adult (control n = 5, 
dorsmorphin dihydrochloride n = 5) rats. However, for these experiments, a control heart 
and dorsomorphin dihydrochloride treated heart were perfused simultaneously for 
comparison. Inhibitor treated hearts were stabilised for 5 minutes, followed by 15 minutes 
of perfusion with Krebs-Henseleit buffer containing dorsomorphin dihydrochloride (1μM), 
before switching back to non-drug treated Krebs-Henseleit buffer to wash-out any remaining 






As previously described, effluent was collected prior to ischemia and at 1, 5, 10, 20, 30 and 
60 minutes of reperfusion for use in creatine kinase measurements. Following the final 
effluent collection, perfusion of the heart was switched to TTC solution (Section 2.6.4) for 
10 minutes in order to stain for regions of infarction. Hearts were then incubated at 37°C in 
PBS for 5 minutes, frozen for 20 minutes, and cut into thin cross-sectional slices. These slices 
were stored at 4°C in 4% formalin overnight, before transfer into PBS to be stored until 
scanning. Slices were scanned, dried and weighed, then analysed for percentage infarct size 
as described in Section 2.6.4. The data for these experiments are presented in Section 
6.3.2.1. 
6.2.3 Protocol for experiments with drug present throughout ischemia  
Langendorff perfusion was performed as described in Section 2.6 and 6.2.2 above, using 14-
day old (control n = 5, dorsomorphin dihydrochloride n = 4) and adult (control n = 3, 
Figure 45. Experimental design for ischemia/reperfusion experiments with 




dorsomorphin dihydrochloride n = 4) rats. However, for these experiments, dorsomorphin 
dihydrochloride was not washed out prior to ischemia. Instead, inhibitor-treated hearts 
underwent a 10 minute period of stabilisation before perfusion with a Krebs-Henseleit 
solution containing 1μM dorsomorphin dihydrochloride for 5 minutes. Flow was then halted 
for 30 minutes of global ischemia as previously described, and the rest of the experiment 
conducted as described in Section 6.2.2 above. The full protocol for both experimental 
groups is outlined in Figure 46 below. 
 
6.2.4 Western blot analysis of extracted tissue 
The full western blotting methodology has been described in Section 2.5. To summarise, 
protein samples were extracted and quantified (Sections 2.4.1.1 and 2.4.2) from the apex of 
control hearts and hearts that had been treated with dorsomorphin dihydrochloride 
following the ischemia/reperfusion protocol outlined in Figure 46 above. Samples were 
Figure 46. Overview of the experimental design for ischemia/reperfusion 




appropriately diluted to a final concentration of 0.15mg protein in a final volume of 100μl 
with double distilled water, and prepared for gel electrophoresis with the addition of an 
equal volume of loading buffer (Laemmli buffer + βME). These samples were loaded onto a 
Mini-PROTEAN® TGXTM precast gels and transferred to a PVDF membrane, stained using 
Ponceau S solution to produce full lane bands (see Section 2.5.4), before blocking with milk. 
Membranes were then incubated with antibodies for AMPK, pAMPK, mTOR, pmTOR, Akt, 
pAkt, PKCε, pPKCε, GSK3β, pGSK3β, BAC, BCL-2, or Mfn1 (see table of antibodies in Section 
2.1.2), washed with TBST, incubated with a secondary antibody, and visualised using the 
Enhanced ChemiLuminescence system. The resulting blots were analysed using ImageJ or 
Image Studio Lite as described in Section 2.5.6, and corrected using full lane intensities 







6.3.1 Effect of I/R injury on isolated hearts from 14-day old and adult 
rats 
In order to examine the differences in the degree of cardiac injury during reperfusion 
following ischemia during postnatal development, hearts from 14-day old (n = 6) and adult 
(n = 6) rats were extracted, cannulated, and perfused with Krebs-Henseleit solution, as 
described in Section 2.6. Effluent was collected during the reperfusion period for 
measurements of creatine kinase release, small sections of the apex were taken at 20 
minutes for later protein extraction. 
Creatine kinase release was measured in effluent samples collected pre-ischemia, following 
stabilisation (0 minutes), then at 1, 5, 10, 20, 30, and 60 minutes into reperfusion. 
Absorbance for each sample was measured using a spectrophotometer (Section 2.6.3) and 
converted into units/L, as plotted in Figure 47A below. From this, a corrected value from the 
wet weights of the hearts were calculated (Figure 47B), as well as a corrected area under 
the curve (Figure 47C). 
In order to assess the differences in cardiac injury between the two age groups, statistical 
analysis was performed for creatine kinase released at each time point in 14-day old samples 
compared with adult samples. 14-day old samples were shown to have peak creatine kinase 
release at 1 minute reperfusion, higher than that seen in adults, both uncorrected and 
corrected for wet heart weight. However, this difference was only statistically significant 
following correction for weight. In both the corrected and uncorrected (age: p < 0.05, time: 
p < 0.05, age*time: p < 0.05 for both) data, creatine kinase levels were then shown to 
increase to levels significantly higher in adults than in samples collected from 14-day olds 
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over the remaining course of reperfusion. Statistically significant differences following post 
hoc tests with a Bonferroni correction are indicated in Figures 47A and 47B (* = p < 0.05). 
Area under the curve was significantly higher in adults than 14-day olds. The lower creatine 
kinase released following 1 minute of reperfusion in 14-day olds, and the subsequently 
higher levels in adult samples from 5 minutes reperfusion onwards, indicates a greater 
degree of cardiac injury in the adult hearts in comparison with 14-days old.  
  
Figure 47. Time-dependent CK 
release during reperfusion from 
14-day old and adult hearts  
shown as absolute values (A), 
corrected for weight (B) and 
total release (AUC) (C). Data 
shown as Mean ± SE 
(n=6/group). * = statistical 
significance compared with 14-





























































6.3.2 Effect of selected survival signalling proteins inhibition on injury 
following I/R in adult and 14-day old hearts. 
A statistically significant biphasic change in AMPK expression was detected by proteomic 
analysis (Section 4.3), thus highlighting this protein as a potential component of the 
underlying mechanism behind biphasic changes in resistance to cardiac injury seen during 
postnatal development. Following experiments to identify any effects of AMPK inhibition on 
cell viability in isolated cardiomyocytes (Section 5.3.2), further experiments were 
undertaken to examine the effects of inhibiting this protein using dorsomorphin 
dihydrochloride in the whole heart, to better take into account additional factors that are 
excluded when looking at individual cardiomyocytes. 
6.3.2.1 Effect of pre-ischemic treatment with an AMPK inhibitor on whole 
hearts 
In order to test the effect of AMPK inhibition on whole hearts, 14-day old and adult rats were 
culled, hearts excised and subsequently cannulated onto a Langendorff setup (Section 2.6). 
Non-control group hearts were perfused with dorsomorphin dihydrochloride for 5 minute 
before washout with Krebs-Henseleit buffer prior to ischemia, as outlined in Section 6.2.2.  
6.3.2.1.1 AMPK inhibition and creatine kinase release post I/R 
As previously described in Section 6.3.1, effluent was collected at set time points during 
reperfusion (Section 6.2.2) and creatine kinase levels at each timepoint were measured for 
both control and dorsomorphin dihydrochloride treated hearts in order to compare the 
degree of cardiac injury between the two groups.  
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14-day old  
Tests of Within-Subjects Effects showed that the difference between the means is not 
statistically significant (treatment: p > 0.05, time: p < 0.05, treatment*time: p > 0.05), 
indicating creatine kinase release was not significantly altered by treatment of hearts with 
dorsomorphin dihydrochloride, as shown in Figure 48. 
 
Adult 
Tests of Within-Subjects Effects showed that the difference between the means is not 
statistically significant (treatment: p > 0.05, time: p < 0.05, treatment*time: p > 0.05), 
indicating creatine kinase release was not significantly altered by treatment of hearts with 
dorsomorphin dihydrochloride. 
Figure 48. CK release 
during reperfusion 
following 30 minutes 
ischemia in 14-day old 
hearts ± pre-treatment 
with dorsomorphin 
dihydrochloride, 
corrected for wet weight 
of the heart. Data 
presented as Mean ± SE. 
(n = 5/group).  
Figure 49. CK release 
during reperfusion 
following 30 minutes 




corrected for wet weight 
of the heart. Data 
presented as Mean ± SE. 





































6.3.2.1.2 AMPK inhibition and infarct size post I/R 
Cardiac injury was assessed in both age groups using TTC staining (Section 2.6.4), with any 
regions lacking brick red staining measured as areas of infarction. Figure 50 below shows 
that in 14-day old hearts, dorsomorphin dihydrochloride treatment followed by drug wash 
out prior to ischemia did not produce a statistically significant difference in infarct size in 
comparison with the control group, indicating inhibition of AMPK did not result in a 





This was also the case in adult hearts (Figure 51), where no statistically significant difference 




Figure 50. Infarct size measurements in 14-day old hearts following I/RI with or without 
AMPK inhibitor pre-treatment. (Top) Representative example images of control (A) and 
dorsomorphin dihydrochloride (B) treated hearts stained with TTC. (Bottom) The 
differences in infarct size between 14-day old hearts following I/R with or without 
dorsomorphin dihydrochloride pre-treatment. Data presented as mean ± SE (C) and 


































6.3.2.2 Effect of AMPK inhibition during ischemia on reperfusion injury 
The data above showed no statistically significant differences in injury when hearts were 
treated with AMPK inhibitor, dorsomorphin dihydrochloride, when added and washed out 
prior to ischemia. Therefore, these experiments were repeated, without washout of the drug 
prior to ischemia, as outlined in Section 6.2.3. 
6.3.2.2.1 Effect of AMPK inhibition during ischemia on creatine kinase release. 
As previously described, effluent was collected at set time points during reperfusion (Section 
6.2.3) and creatine kinase levels at each timepoint were measured for both control and 
dorsomorphin dihydrochloride treated hearts in order to compare the degree of cardiac 
injury between the two groups.  
Figure 51. Infarct size measurements in adult hearts following I/RI with or without AMPK 
inhibitor pre-treatment. (Top) Representative example images of control (A) and 
dorsomorphin dihydrochloride (B) treated hearts stained with TTC. (Bottom) The 
differences in infarct size between adult hearts following I/R with or without 
dorsomorphin dihydrochloride pre-treatment. Data presented as mean ± SE (C) and 
































14-day old: Creatine kinase Release Corrected for Heart Weight 
While peak creatine kinase levels and Area Under Curve (AUC) values were not significantly 
different between the two groups, creatine kinase released over the course of reperfusion 
was shown to be statistically significantly different between control and dorsomorphin 
dihydrochloride treated hearts by two-way repeated measures ANOVA analysis (age: p < 
0.05, time: p < 0.05, age*time: p < 0.05). Subsequent post hoc tests with a Bonferroni 
correction showed significant differences between control and dorsomorphin 
























Figure 52. CK release from 14-day old hearts during reperfusion following 30 minutes 
ischemia with or without dorsomorphin dihydrochloride treatment during ischemia, 
corrected for wet weight of the heart. Data presented as mean ± SE. (control: n = 5. 
dorsomorphin: n = 4). * = statistically significant difference in comparison with control 




Adult: Creatine kinase release corrected for heart weight 
No statistical significance was seen between control and dorsomorphin treated hearts in 
terms of peak creatine kinase release, AUC values, two-way repeated measures ANOVA 
analysis of creatine kinase released over the 60 minute course of reperfusion, as well as 
comparison of creatine kinase levels at each time point between the two experimental 
groups. Whilst this suggests that perfusion of hearts with dorsomorphin dihydrochloride 
does not make a difference to the degree of injury seen in adult hearts, it is important to 
note that, as mentioned previously, a large degree of variation was seen between 
measurements due to the reagent used to measure creatine kinase, which may have 
affected these results. This will be further discussed in Section 6.4.  
Figure 53. CK release from adult hearts during reperfusion following 30 minutes ischemia 
with or without dorsomorphin dihydrochloride treatment during ischemia, corrected for 
wet weight of the heart. Data presented as mean ± SE. (Control: n = 3. Dorsomorphin: 

























6.3.2.2.2 Effect of AMPK inhibition on infarct size 
Cardiac injury was assessed in both age groups using TTC staining (Section 2.6.4), with any 
regions lacking brick red staining measured as areas of infarction. In 14-day old hearts 
(Figure 54), a statistically significant difference was seen between the mean infarct sizes of 
the control group and dorsomorphin treated group (p = 0.005), indicating inhibition of AMPK 
throughout ischemia did result in a significant increase in cardiac injury in 14-day old hearts. 
In adult hearts (Figure 55), however, no statistically significant difference was seen between 
the mean infarct sizes of the control group and dorsomorphin treated group (p = 0.253), 
indicating inhibition of AMPK throughout ischemia did not result in a significant increase in 
cardiac injury in adult hearts. It should be noted, however, that infarct was measured as any 
region of the heart without “brick-red” staining, and it may be that measurement of more 
extremely infarcted regions of tissue – i.e. those stained white – separately may show a 
significant difference between the two experimental groups in adults.  
 
* 
Figure 54. Infarct size measurements in 14-day old hearts following I/RI with or without AMPK 
inhibitor treatment during ischemia. (Top) Representative example images of control (A) and 
dorsomorphin dihydrochloride (B) treated hearts stained with TTC. (Bottom) The differences in 
infarct size between 14-day old hearts following I/R with or without dorsomorphin dihydrochloride 
treatment. Data presented as mean ± SE (C) and boxplot (D). * = statistically significant difference 


































6.3.2.2.3 Effect of AMPK inhibition during ischemia on the expression and 
phosphorylation state of key survival signalling proteins. 
In order to further investigate the signalling mechanisms underlying differences in the 
degree of cardiac injury seen in 14-day old and adult hearts following ischemia/reperfusion 
Injury, and the specific effect of AMPK inhibition on these two age groups, the apex of 
control, post-ischemia, post-ischemia/reperfusion, and post-ischemia/reperfusion + 
dorsomorphin dihydrochloride perfused hearts were collected. Tissue was homogenised and 
quantified as described in Section 2.4.1 and 2.4.2 before preparation for western blotting 
(Section 2.5). Due to the number of experimental groups required to be run simultaneously 
for each age group, and limitations in the number of samples that could be run per gel due 
to lane configurations, two separate gels had to be run for each protein tested. Each gel was 
Figure 55. Infarct size measurements in adult hearts following I/RI with or without AMPK 
inhibitor treatment during ischemia.  (Top) Representative example images of control (A) and 
dorsomorphin dihydrochloride (B) treated hearts stained with TTC. (Bottom) The differences in 
infarct size between adult hearts following I/R with or without dorsomorphin dihydrochloride 































also run with a pooled reference sample to act as a standard between each run, which was 
used to produce a ratio of sample/pooled sample for each. 
6.3.2.2.3.1 Effect of AMPK inhibition on pAMPK & AMPK expression 
To ensure the efficacy of dorsomorphin dihydrochloride inhibition of AMPK, samples were 
tested for phosphorylation of AMPK.  
 
While no statistically significant differences were seen between corresponding experimental 
groups, a clear trend demonstrating the expected drop in pAMPK detection in the 
dorsomorphin dihydrochloride treated group was seen in comparison to all other 
experimental groups in both 14-day old and Adult samples. Effective inhibition of AMPK in 
this experimental group can thus be inferred. Furthermore, as expected due to the reported 
cardioprotective signalling properties of active AMPK during ischemia and cardiotoxic 
properties during reperfusion, the bands show that in 14-day old samples, there is an overall 
higher level of phosphorylated and active AMPK in the ischemic group than the reperfused 
Figure 56. Effect of 
AMPK inhibition on 
pAMPK/AMPK. Mean 
pAMPK/AMPK levels 
in 14-day old and 
adult rat hearts either 
in control, following 
ischemia, I/R, or I/R + 
dorsomorphin 
dihydrochloride 
treated groups. Data 
presented as mean ± 


















group. In adults, however, stronger bands for phosphorylated AMPK were seen in the 
reperfused group than ischemic groups. The lack of statistical significance likely results from 
technical restrictions in terms of the number of samples that could be run per gel and 
subsequent comparison of protein expression between gels, thus resulting in substantial 
scatter of values. This will be discussed further in the limitations section (Section 9.2). 
6.3.2.2.3.2 Effect of AMPK inhibition on pmTOR & mTOR expression 
Due to the known role of AMPK as an upstream regulator of mTOR via inhibition of other 
members of the mTORC1 complex, samples were analysed using western blot to assess any 
changes to mTOR expression or phosphorylation following AMPK inhibition.  
 
 
Similarly to pAMPK expression, no statistically significant changes in pmTOR/mTOR levels 
were detected by western blot, likely due to a large scatter in values resulting from the 
necessity of running multiple gels, as will be discussed in limitations (Section 9.2). However, 
Figure 57. Effect of AMPK 
inhibition on 
pmTOR/mTOR.  (Top) 
Representative western 
blot bands for each 
experimental and age 
group. (Bottom) Mean 
pmTOR/mTOR levels in 
14-day old and adult rat 
hearts either in control, 
following ischemia, I/R 
alone, or I/R + 
dorsomorphin 
dihydrochloride treated 
groups. Data presented as 




















as can be seen from the images themselves, pmTOR levels appear to be greater in the 
dorsomorphin dihydrochloride treated group, particularly in adult samples where no protein 
was detected in control, ischemia or I/R groups. This greater expression in the dorsomorphin 
dihydrochloride treated groups correlates with inhibition of AMPK, which usually works to 
inhibit the action of mTOR during ischemia in a cardioprotective manner. The importance of 
this will be further discussed in Section 6.4.3. 
6.3.2.2.3.3 Effect of AMPK inhibition on pAKT & AKT expression  
As a key component of the survival signalling related RISK pathway, as well as its link to AMPK 
activity and signalling, the expression and phosphorylation state of AKT was measured by 









Figure 58. Effect of AMPK 
inhibition on pAKT/AKT.  
(Top) Representative 
western blot bands for 
each experimental and 
age group. (Bottom) 
Mean pAKT/AKT levels in 
14-day old and adult rat 
hearts either in control, 
following ischemia, I/R 
alone, or I/R + 
dorsomorphin 
dihydrochloride treated 
groups. Data presented 

















No statistically significant difference was seen in pAKT/AKT expression. However, blots 
showed visually that both pAKT and AKT levels were greater in 14-day old samples in 
comparison with adult samples, and that in AMPK inhibited dorsomorphin dihydrochloride 
treated groups in both 14-day old and adult hearts showed particularly high levels of both 
protein forms across the four experimental groups.  
6.3.2.2.3.4 Effect of AMPK inhibition on pPKCε & PKCε expression  
 PKCε is an important endpoint of the survival signalling related RISK pathway, as well as 
closely linked to AMPK activity and signalling. Therefore, the expression and 
phosphorylation state of PKCε was measured by western blotting from samples to identify 










However, no statistically significant differences were seen in pPKCε/PKCε expression 
between age groups or experimental groups.  
Figure 59. Effect of AMPK 
inhibition on pPKCε/PKCε.  
(Top) Representative 
western blot bands for 
each experimental and 
age group. (Bottom) 
Mean pPKCε/PKCε levels 
in 14-day old and adult 
rat hearts either in 
control, following 
ischemia, I/R alone, or 
I/R + dorsomorphin 
dihydrochloride treated 
groups. Data presented 


















6.3.2.2.3.5 Effect of AMPK inhibition on pGSK3β & GSK3β expression 
GSK3β is an important endpoint of the survival signalling related RISK pathway, in addition 
to being a cardioprotective protein when active during ischemia, whilst being cardiotoxic 
during reperfusion in a similar mechanism to AMPK. Therefore, the expression and 
phosphorylation state of GSK3β was measured by western blotting to identify any changes 
caused by AMPK inhibition.  
 
Statistically significant differences in pGSK3β/GSK3β were seen only between dorsomorphin 
dihydrochloride treated adult hearts and dorsomorphin dihydrochloride treated 14-day old 
hearts (p < 0.05), as well as inhibitor treated adult hearts and adult hearts that had 
undergone ischemia alone (p < 0.05). As phosphorylation at Ser9 indicates inactivation of 
the protein, this suggests that AMPK inhibition results in the inhibition of GSK3β in adult 
hearts, but not 14-day old hearts. The importance of this will be discussed further in Section 
6.4.5. 
Figure 60. Effect of AMPK 
inhibition on 
pGSK3β/GSK3β.  (Top) 
Representative western blot 
bands for each experimental 
and age group. (Bottom) 
Mean pGSK3β/GSK3β levels 
in 14-day old and adult rat 
either in control, following 
ischemia, I/R alone, or I/R + 
dorso. dihydrochloride 
treated groups. Data 
presented as mean ± SE (n = 
3/group). Statistically 
significant difference in 
comparison with; * = 
corresponding 14-day old 
group (p < 0.05). # = 




















6.3.2.2.3.6 Effect of AMPK inhibition on BAX & BCL-2 expression 
BAX and BCL-2 are commonly used measures of cell death and therefore indicators of the 
degree of cardiac injury. The expression and ratio of these two proteins was therefore 
analysed by western blot in order to identify any potential changes following the inhibition 
of AMPK. The data for BAX and BCL-2 as corrected by Ponceau S staining are shown below 
in Figure 61 & Figure 62 respectively. Figure 63 shows representative examples of western 
blot bands for both proteins by age and experimental group, as well as a graphical 
representation of the mean BAX/BCL-2 ratios.  
 
 
* * * 
* 
Figure 62. Mean BCL2 levels 
in 14-day old and adult rat 






groups. Data presented as 
mean ± SE (n = 3/group). 
Figure 61. Mean BAX levels 
in 14-day old and adult rat 
hearts either in control, 
following ischemia, I/R, or 
I/R + dorsomorphin 
dihydrochloride treated 
groups. Data presented as 
mean ± SE (n = 3/group). * 
= statistically significant 
difference in comparison 
with corresponding 14-day 
























Both BAX and BCL-2 expression, as well as BAX/BCL-2 ratio, were visibly greater in 14-day 
old samples than adult samples across all four experimental groups. Statistical significance 
was seen in BAX expression between all 14-day old experimental groups in comparison with 
all adult groups (p < 0.05), in addition to greater BAX/BCL-2 ratios in all 14-day old samples 
in comparison with their corresponding experimental group in adults (p < 0.05), i.e. 
P14_Control vs. Adult_Control.  This greater expression of both proteins in 14-day olds was 
also seen in the proteomic output of control samples, and suggests that this overall higher 
expression of pro-apoptotic BAX and cardiotoxic higher BAX/BCL-2 ratio seen in all 14-day 
old groups in comparison with adults may not allude to a physiologically relevant to the 
response to ischemia and reperfusion and subsequent increased cardiac injury in this age 
group, as it is already seen in control, non-stressed hearts. This will be further discussed in 
Section 6.4.6. 
Figure 63. Effect of AMPK 
inhibition on BAX/BCL-2.  
(Top) Representative 
western blot bands for each 
experimental and age group. 
(Bottom) Mean BAX/BCL2 
levels in 14-day old and adult 
rat either in control, following 
ischemia, I/R alone, or I/R + 
dorsomorphin 
dihydrochloride treated 
groups. Data presented as 
mean ± SE (n = 3/group). 
Statistically significant 
difference in comparison 
with; * = corresponding 14-
day old group (p < 0.05). # = 
P14_Control (p < 0.05). ¥ = 























Whilst no differences could be seen between the experimental groups in terms of BAX/BCL-
2 levels in adult samples, which may result from overall low expression and weak bands of 
BAX and BCL-2 in these samples, 14-day old samples showed an expected higher pro-
apoptotic BAX/BCL-2 level in samples from hearts that underwent I/R both with (p < 0.05) 
and without (p < 0.01) dorsomorphin dihydrochloride perfusion than control hearts. Hearts 
that underwent ischemia alone, however, showed no statistically significant increase in 
BAX/BCL-2 levels in comparison to control. 
6.3.2.2.3.7 Effect of AMPK inhibition on Mfn1 expression 
Mfn1 was identified in the proteomic output as showing an overall biphasic profile of 
expression during postnatal development, and is an important component of the 
mitochondrial fusion process (Sections 7.3.4 & 7.1.2.3). Due to the importance of 
mitochondrial fusion and fission in cardiomyocyte injury and cell death, in addition to Mfn1’s 
biphasic pattern of expression, western blot analysis was undertaken in order to identify any 
changes in expression that occurred following inhibition of AMPK.  
Figure 64. Effect of 
AMPK inhibition on 
Mfn1.  (Top) 
Representative western 
blot bands for each 
experimental and age 
group. (Bottom) Mean 
Mfn1 levels in 14-day 
old and adult rats either 
in control, following 
ischemia, I/R alone, or 
I/R + dorsomorphin 
dihydrochloride treated 
groups. Data presented 










Whilst no statistically significant differences were seen in Mfn1 expression between either 
the experimental groups or age groups, bands were visually consistently weaker in the adult 
groups – as supported by the lower expression of Mfn1 in adult samples in the proteomic 
output (Section 7.3.4) – and also appeared to be weaker in the 14-day old control groups. 
The significance of this will be further discussed in Section 6.4.7. 
6.4 Discussion 
Initial studies into differences in the response to I/RI of Langendorff perfused 14-day old and 
adult hearts, using the measurement of creatine kinase (CK) release, found that, despite an 
initial peak at 1 minute of reperfusion, 14-day old hearts had statistically significantly lower 
levels of CK released over the course of reperfusion than adults. This was seen both using 
values for AUC, an indicator of total CK release, as well as with direct comparisons of CK 
concentration at each time point between the two age groups. Following the initial peak in 
CK release at 1 minute in 14-day olds, there was a subsequent decrease over the course of 
reperfusion, with levels returning to those seen pre-I/RI by approximately 10 minutes of 
reperfusion. In adults however, despite showing significantly lower levels of CK than 14-day 
olds at 1 minute of reperfusion, there was a subsequent increase in CK concentration 
peaking at approximately 5-10 minutes of reperfusion, remaining at this level for the 
duration of the reperfusion period. This indicates a greater degree of injury in adults than 
14-day olds by the end of the reperfusion period, correlating both with the greater infarct 
size seen in adult control compared to 14-day old control hearts in subsequent TTC staining 
experiments (Section 6.3.2.1.2 and 6.3.2.2.2), as well as the greater resistance of 14-day 
olds to I/RI seen in the postnatal vulnerability profile (Section 1.4.2). The reason behind the 
initial peak in 14-day CK levels is uncertain, but may indicate an initial stress response at the 
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early stages of reperfusion which trigger survival signalling mechanisms in order to 
subsequently protect the heart from injury.  
6.4.1 AMPK inhibition increased the vulnerability of 14-day old, but not 
adult hearts, to I/RI 
Perfusion of whole hearts with AMPK inhibitor, dorsomorphin dihydrochloride, had no effect 
on the degree of cardiac injury in either age group when washed out prior to ischemia 
(Section 6.3.2.1). However, when left in hearts for the duration of ischemia, a statistically 
significant increase in infarct size was seen in 14-day old, but not adult hearts, in 
concordance with the age dependent differences on the effect of AMPK inhibition seen in 
isolated cardiomyocytes (Section 5.3.3.1.3). These findings therefore support the hypothesis 
that AMPK, which displayed a statistically significant biphasic peak in expression at 14-days 
of age in the proteomic output, may play a role in the resistance to ischemia/reperfusion 
injury seen in this age group. Due to the importance of AMPK activity to cardioprotection 
specifically during ischemia (Section 1.5.3), it is possible that the mechanism underlying the 
decreased vulnerability of 14-day old hearts to cardiac injury focuses upon signalling events 
that occur prior to reperfusion, priming the heart to reduce cell death upon the restoration 
of blood flow. The lower expression of AMPK in adult hearts may therefore reflect the lack 
of efficacy of AMPK inhibition in increasing infarction size in comparison with 14-day olds, 
as it does not play as important a role in cardioprotection in this age group.  
However, creatine kinase levels showed no statistically significant changes in either age 
group following treatment with dorsomorphin dihydrochloride. It should be noted that the 
original creatine kinase experiments in Section 6.3.1 were performed using a subsequently 
discontinued form of reagent (see Section 2.1.1), and subsequent creatine kinase 
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measurements (Section 6.3.2) were performed with a supposedly equivalent product (see 
Section 2.1.1) provided in smaller bottles. These bottle sizes meant that multiple bottles had 
to be made up for each round of measurements, and appeared to result in a greater variation 
in creatine kinase values than those seen with the original product. This may contribute to 
the lack of statistical significance seen. As a result of this, the determination of cardiac injury 
has focused on infarct sizes, as determined by TTC staining. However, previous studies have 
shown that dorsomorphin dihydrochloride does in fact result in the attenuation of 
cardioprotective methods through the inhibition of AMPK and AMPK-dependent autophagy 
in adult rat hearts (Kosuru, Cai et al. 2018, Zeng, He et al. 2018), in conflict with our data. 
This may be due to the fact that, in contrast to these studies, work in this project was 
conducted on hearts that had not undergone any other treatments or cardioprotective 
measures. Alternatively, it may result from the methodology of infarct determination used, 
as in this work, any areas not stained a brick red colour were measured as infarcted regions 
in order to be able to compare with 14-day old hearts, which do not tend to produce the 
clear white regions of infarcted tissue often reported, and instead a light pink, likely due to 
the resistance hearts of this age group have to ischemia/reperfusion injury. It is possible that 
measurements of the white regions of infarcted tissue alone may in fact show a significant 
difference in infarct size between control and dorsomorphin dihydrochloride treated hearts. 
Due to these difficulties in quantification and comparison between the two age groups, 
future work may benefit from expanding the determination of cardiac injury to include 




6.4.2 AMPK inhibition does not cause significant changes in pAMPK 
expression  
No statistically significantly significant changes in AMPK phosphorylation were seen 
following treatment with AMPK inhibitor, dorsomorphin dihydrochloride, between 14-day 
old and adult samples, or between samples taken at different experimental points. However, 
it is likely that this is due to expected variance and scatter resulting from the need to run 
samples on two separate gels. Indeed, as previously mentioned (Section 6.3.2.2.3.1), a clear 
difference in band intensity could be seen visually between experimental groups, supported 
by differences in the mean levels of pAMPK/AMPK, with lower levels of phosphorylated and 
thus active AMPK in dorsomorphin treated groups demonstrating successful inhibition of the 
protein and efficacy of the inhibitor. Moreover, a higher overall level of pAMPK/AMPK was 
seen in the 14-day old ischemic group in comparison with the reperfused group. This 
corresponds with the reported cardioprotective role of AMPK during ischemia specifically, 
and its damaging effects during reperfusion. Conversely, adult samples showed stronger 
bands for pAMPK in the reperfused group in comparison with samples taken from hearts 
that had undergone ischemia alone. This may suggest that these adult hearts display a 
pattern of AMPK activation over the course of ischemia and reperfusion that is actually 
detrimental to the heart and increases cardiac injury, whereas 14-day old hearts do in fact 
follow the cardioprotective process of AMPK activation. It is also possible that an additional 
pro-survival protein or proteins may act to promote activation of AMPK during ischemia, and 
subsequently deactivate it during reperfusion in 14-day old hearts.  
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6.4.3 AMPK inhibition does not cause significant changes in mTOR and 
AKT phosphorylation levels 
While no statistically significant differences were seen in pmTOR/mTOR levels between any 
of the experimental or age groups, clear differences could be seen in band intensities 
between these groups. Notably, adult samples showed no detectable mTOR or pmTOR 
bands, except for in hearts treated with dorsomorphin dihydrochloride. The absence of 
detectable bands in the control, post-ischemic, and I/R groups of adult hearts could relate 
to the fact that proteomic analysis indicated low levels of mTOR expression in adults, 
especially compared to 14-day olds, coupled with the fact that successful detection of both 
the total and phosphorylated forms of the protein in these western blot experiments was 
difficult, requiring long exposure times and often producing high levels of background.  
Indeed, antibody reviews from the manufacturer’s (CST) website discussed difficulties in 
obtaining bands when loading 20 μg of protein, only detecting clear bands when using 30 μg 
of protein. However, these factors do not account for the fact that treatment with 
dorsomorphin dihydrochloride appeared to increase the actual expression of mTOR, with 
detectable bands only in these treated hearts.  While AMPK is known to inhibit mTOR activity 
via phosphorylation of its mTORC1 binding partners (Shaw 2009), the ability of AMPK to 
effect mTOR expression is uncertain. However, studies have demonstrated that inhibition of 
AMPK in the context of tumour cells – where its antagonism of mTOR activity is again a 
critical component of suppressing tumour cell growth – does in fact result in alterations in 
the gene expression of a range of proteins, indicating an important role for AMPK in 
transcription (Zhou et al. 2009). It is therefore possible that AMPK has an inhibitory role on 
mTOR gene expression in adult rat hearts that is alleviated upon AMPK inhibition with 
dorsomorphin dihydrochloride.  
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As mentioned in Section 6.3.2.2.3.2, pmTOR bands were visually much stronger in samples 
taken from hearts that had undergone AMPK inhibition throughout ischemia. Most notably, 
protein bands were detected very faintly if at all in control, ischemia and I/R groups, but 
showed clear bands in dorsomorphin dihydrochloride treated groups. This is concordant 
with the fact that AMPK is a known inhibitor of the mTORC1 complex, of which mTOR is a 
key component, in order to promote cellular energy conserving processes such as autophagy 
and thus increase ATP availability, leading to reduced cardiac injury during  ischemia 
(Moussa and Li 2012). While AMPK is not reported to directly interact with mTOR itself, it is 
known to phosphorylate other members of the mTORC1 signalling pathway, including 
mTORC1 inhibitor TSC2 (Gwinn and Shaw 2010) and mTOR binding partner, Raptor (Shaw 
2009). The phospho-site, Ser2481, targeted by western blotting in Section 6.3.2.2.3.2 is an 
autophosphorylation site commonly used to demonstrate an intact mTOR signalling 
pathway, meaning the greater levels of pmTOR/mTOR in AMPK inhibited hearts may 
represent an alleviation of AMPK-mediated inhibition of mTOR and mTORC1 activity. 
However, this difference was not as distinct between 14-day old experimental groups, with 
bands for pmTOR & mTOR detectable in all four experimental groups, and the mean levels 
of pmTOR/mTOR displaying no clear trends across the four experimental groups. As 
previously mentioned, this may result from the large scatter of data points due to the 
running of samples on separate gels, as visually stronger bands were seen in AMPK inhibited 
hearts in a similar manner to adult samples. It is also important to note that blots using these 
pmTOR and mTOR antibodies (Section 2.1.2) consistently presented with non-specific bands 
and high levels of background noise, meaning the accuracy of measured band intensities 
may also have been negatively affected by the quality of the blots themselves. 
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Conversely to AMPK, Akt is a known activator of mTOR and mTORC1 signalling through the 
phosphorylation and inactivation of mTOR inhibitors TSC2 and PRAS40 (Hahn-Windgassen, 
Nogueira et al. 2005), and through promotion of IKKα-mediated phosphorylation and 
activation of mTOR (Dan, Ebbs et al. 2014). Again, contrary to AMPK, Akt has been shown to 
work during reperfusion as opposed to ischemia, inhibiting “deleterious autophagy” 
(Panisello-Roselló, Lopez et al. 2018) and subsequent apoptosis via activation of mTORC1 
during this stage of I/RI, conferring cardioprotection. This role of AKT would therefore 
suggest that changes in pAkt/Akt levels would correlate with pmTOR/mTOR following 
inhibition of AMPK. However, our data showed that pAkt/Akt was greater in 14-day old 
hearts treated with dorsomorphin dihydrochloride, whereas there was no clear difference 
in adult dorsomorphin dihydrochloride treated hearts in comparison to the other 
experimental groups, contrasting the trends seen in pmTOR/mTOR levels. The importance 
of this remains uncertain, as despite these overall trends in differences in phosphorylation 
state were seen, with visually clear differences in band intensities between these groups, no 
statistically significant difference was seen in pAkt/Akt expression, again likely due to the 
large scatter resulting from the need to separate the samples into two gels.  
Studies have traditionally reported opposing mechanisms of cardioprotection by AMPK and 
Akt dependent on the phase of I/RI during which they are active, in addition to reports that 
Akt actually functions to inhibit AMPK via phosphorylation of its α1 subunit at Ser458 and its 
α2 subunit at Ser491 with subsequent inhibition of AMPK-activating phosphorylation at 
Thr172 (Qi and Young 2015). However, recent studies investigating the underlying signalling 
mechanisms of cardioprotective compounds such as PLCA and activation of the κ-opioid 
receptor have shown that AMPK and Akt are actually both activated and work synergistically 
in order to confer cardioprotection (Lee, Ku et al. 2015, Zhang, Zhou et al. 2018). It is possible 
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that the greater levels of pAkt/Akt in 14-day old dorsomorphin dihydrochloride treated 
hearts may reflect an attempt to compensate for inhibition of AMPK. Further work will be 
needed to examine the full mechanisms and interactions between AMPK and Akt specifically 
during cardiac I/RI, as existing publications often discuss conflicting reports as to whether 
these two proteins work upstream or downstream of one another (Qi and Young 2015, 
Zhang, Zhou et al. 2018), as well as whether they function synergistically or during different 
phases of I/RI in order to confer cardioprotection (Lee, Ku et al. 2015, Panisello-Roselló, 
Lopez et al. 2018). 
Finally, it is important to note that previously published work has in fact shown that 
dorsomorphin dihydrochloride actually inhibits Akt and mTOR, inducing autophagy in 
treated cells despite inhibition of AMPK (Vucicevic, Misirkic et al. 2011, Liu, Chhipa et al. 
2014), which appears to directly contradict our findings. However, these studies were all 
conducted in cancer cell lines, meaning tissue and cell-type specific differences may account 
for the contrasting effects of dorsomorphin dihydrochloride on Akt and mTOR activation. 
6.4.4 AMPK inhibition does not cause significant changes in PKCε 
phosphorylation  
Similar to AMPK, mTOR and Akt, the levels of pPKCε/PKCε did not show any statistically 
significant changes following AMPK inhibition, nor between the other experimental or age 
groups. However, some clear differences could be identified between the experimental and 
age groups based on their means. For example, levels of phosphorylated PKCε appeared to 
be greater in 14-day old hearts following I/R than adult hearts following I/R, which correlates 
with the cardioprotective role of PKCε and the greater resistance of 14-day old hearts to I/RI 
than adults. pPKCε expression also appeared to be greater in adult hearts treated with 
204 
 
dorsomorphin dihydrochloride than the other three adult experimental groups. This 
apparent increase in active PKCε in AMPK inhibited groups is somewhat unexpected, as PKCε 
is reported to function upstream as an activator of AMPK, for example, during IpreC 
((Jackson, Escobar et al. 2018)(Nishino et al., 2004)), and would therefore be unaffected by 
AMPK inhibition. The reason for this apparent increase is therefore uncertain, but may 
suggest a mechanism by which there is an increase in PKCε activity as an attempt to 
compensate for the loss of AMPK activity. Further investigation of this issue will be required 
in future work in order to elucidate the reason for these differences, as well as to examine 
changes in the localisation of PKCε within the cell. 
6.4.5 AMPK inhibition induces changes in GSK3β phosphorylation only 
in adult hearts 
Inhibition of AMPK resulted in statistically significant differences in pGSK3β/GSK3β levels 
only in adult hearts, with dorsomorphin dihydrochloride treated hearts showing significantly 
higher levels of pGSK3β/GSK3β in comparison with dorsomorphin dihydrochloride treated 
14-day old hearts, as well as in comparison with adult hearts that had undergone ischemia 
alone. As the phosphosite examined by these western blotting experiments (Ser9) is known 
to indicate an inactive form of the protein (Lal, Ahmad et al. 2015), it is possible that this 
indicates a mechanism by which inhibition of AMPK inhibition results in a correlating 
inhibition of GSK3β in adult, but not 14-day old hearts. While 14-day old hearts did show a 
statistically significant increase in infarct size following dorsomorphin dihydrochloride 
treatment not seen in adult hearts, the overall infarct size did remain significantly lower in 
both control and inhibitor treated 14-day old hearts in comparison with adults (Section 
5.3.2.1.2). The activity of both AMPK and GSK3β are reported to be cardioprotective during 
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ischemia via inhibition of mTORC1 (Gwinn and Shaw 2010), which may suggest that, while 
AMPK is an important protein in mediating cardioprotection in 14-day old hearts, activation 
of GSK3β may in fact help to compensate for the loss of AMPK-induced autophagy during 
ischemia, maintaining the relatively low infarct sizes seen in this age group in comparison 
with adult hearts. This correlates with previous experiments looking at the inhibition of 
GSK3β in isolated cardiomyocytes (Section 5.3.2.1.2), in which cardiomyocyte viability was 
only decreased by TWS119 treatment in 14-day old hearts, with adults showing no change 
in viability. This highlights the importance of GSK3β to cardioprotection in 14-day old hearts, 
and therefore may support a potential mechanism by which it works synergistically with 
AMPK in this age group. The significantly higher levels of phosphorylated and inactivated 
GSK3β in dorsomorphin dihydrochloride treated adult hearts compared to 14-day old hearts 
may indicate that any potential compensatory activity is not present in this age group, or 
that in adult hearts, AMPK may in fact have an activating role that is lost following 
dorsomorphin treatment, leading to the greater levels of Ser9 phosphorylation. Notably, 
phosphorylated Akt – which is known to phosphorylate and thus inhibit GSK3β at Ser9 – did 
not appear to be significantly higher in adult hearts treated with dorsomorphin 
dihydrochloride (Section 6.3.2.2.3.3), indicating the higher levels of Ser9 phosphorylation in 
this group did not result from greater Akt activity. Conversely, PKCε phosphorylation did 
appear to be higher in adult hearts following AMPK inhibition, which was not seen in 14-day 
old hearts, which may suggest that greater PKCε activity in this group resulted in increased 
phosphorylation of GSK3β. Indeed, previous work has stated that PKCε works upstream of 
GSK3β in a complimentary manner to Akt (Hunter et al. 2007). However, these relationships 
are currently only correlative, and further work will be needed in order to establish whether 
they do indeed represent a novel mechanism by which GSK3β remains active in the absence 
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of AMPK activity only in 14-day old hearts, or whether it merely pertains to the fact that 
phosphorylation and inactivation of GSK3β at Ser9 by Akt during reperfusion has previously 
been shown to be cardioprotective (Lal, Ahmad et al. 2015), alongside the correlating lack 
of a statistically significant increase in infarct size in adult hearts following dorsomorphin 
dihydrochloride treatment.  
6.4.6 BAX expression and BAX/BCL-2 was higher in 14-day olds 
compared to adults 
BAX expression was found to be statistically significantly greater in 14-day old samples from 
all four experimental groups in comparison with corresponding adult groups, a trend that 
was also seen in the proteomic output from control hearts. BCL-2 expression showed no 
statistically significant differences between any age or experimental groups, but had clearly 
stronger bands in all four 14-day old experimental groups in comparison with adults. As 
could be seen in the representative blots presented in Section 6.3.2.2.3.6, the BCL-2 
antibody was relatively weak, producing a high degree of background that may have affected 
the accuracy of these measurements. As with previously discussed proteins, these samples 
were run on two separate gels, which likely further affected the accuracy of these 
measurements and contributed to the scatter of data points seen for BCL-2. 
A commonly used measure of cardiac injury and cell death is the ratio of BAX/BCL-2 to 
indicate the relative levels of pro-apoptotic to pro-survival protein. Western blotting showed 
that all four experimental groups had statistically significantly greater levels of BAX/BCL-2 in 
14-day olds in comparison with their corresponding adult groups. Whilst no significant 
differences were seen between adult experimental groups, 14-day old samples showed 
greater levels of BAX/BCL-2 in both hearts that underwent I/R alone and in hearts that 
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underwent I/R with the addition of AMPK inhibition compared to control hearts. 
Furthermore, hearts that underwent I/R alone also showed statistically significantly higher 
levels of BAX/BCL-2 in comparison with hearts that had undergone ischemia alone. These 
differences in comparison with both control and ischemic hearts correlates with the fact that 
the majority of cardiac injury and cell death is triggered upon reperfusion. The lack of 
difference between adult experimental groups appears to contradict the large infarct sizes 
seen in adult hearts following I/RI, but may once again relate more to the methodology and 
quality of the bands produced, as both BAX and BCL-2 bands were very weak in adult 
samples, with high degrees of background for BCL-2 in particular. This may also explain the 
lack of statistically significant differences in BAX/BCL-2 between I/R alone and I/R with 
dorsomorphin dihydrochloride treatment, despite significantly higher percentage infarct 
sizes in dorsomorphin dihydrochloride treated hearts in 14-day olds.  
Whilst high BAX expression and BAX/BCL-2 levels are traditionally used as indicators of cell 
death and cardiac injury (Shen, Zhou et al. 2017, Liu 2018), our data have shown that in both 
proteomic analysis and western blotting, control levels of BAX expression and BAX/BCL-2 are 
already elevated in 14-day old hearts with statistical significance in comparison with adult 
hearts. Previous work by Liaw et al. (2013) showed a similar change in the expression of BAX, 
BCL-2 and BAX/BCL-2 levels from neonatal to adult hearts that correlates with biphasic 
changes in resistance to I/RI. Whilst the authors also noted these paradoxically high levels 
of BAX in 14-day old hearts with the greatest resistance to cardiac injury, they suggested 
that this is merely balanced out by correlating high levels of BCL-2 (Liaw, Hoe et al. 2013). 
However, in both data presented by Liaw et al. and data presented in this work, adult hearts 
were found to show significantly lower levels of both BAX and BAX/BCL-2 than 14-day old 
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hearts.  The reason behind these greater levels of pro-apoptotic protein even in control 
hearts is uncertain, possibly suggesting an alternate mechanism by which BAX primes the 
immature heart for I/RI, and will require further investigation. Future work may benefit from 
examining any differences in 14-day old BAX and BAX/BCL-2 levels compared to adult 
samples using alternate assays in order to confirm this significantly higher level present in 
control hearts is consistent across several different methodologies.  
6.4.7 AMPK inhibition does not alter Mfn1 expression 
No statistically significant differences were seen in the expression of Mfn1 between the two 
age groups or four experimental groups. However, western blotting bands showed visually 
stronger Mfn1 bands in 14-day old samples, with proteomic analysis showing a similarly 
higher expression of Mfn1 in 14-day old hearts compared to adults (Section 6.3.6). Control 
hearts also appeared to display weaker bands than both hearts undergoing I/R and I/R with 
dorsomorphin dihydrochloride treatment in particular, a trend that appeared to be stronger 
in 14-day old samples than adult samples. Skewing of the balance between mitochondrial 
fusion and fission towards fusion is known to be cardioprotective (Ong, Kalkhoran et al. 
2015), with overexpression of fusion proteins Mfn1 and Mfn2 in cardiac cell lines that have 
undergone simulated I/RI resulting in reduced cell death, and an associated inhibition of 
mPTP opening (Ong, Subrayan et al. 2010). Whilst the higher expression of Mfn1 seen in 14-
day old hearts both in proteomic and western blot analysis correlate with the reported 
cardioprotective effects of mitochondrial fusion and Mfn1 overexpression, no clear 
difference was seen in hearts treated with an AMPK inhibitor. It is therefore unlikely that 
any cardioprotective mechanisms provided to 14-day old hearts by AMPK involve direct 
effects on mitochondrial fusion or Mfn1.  
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6.4.8 Summary & Conclusion  
Inhibition of AMPK showed significant effects on cardiac infarct size in 14-day old, but not 
adult hearts, and only when inhibition was sustained throughout ischemia. These findings 
support the hypothesis that the biphasic peak in expression of AMPK at 14-days of age in 
the proteomic output reflects a key role of the protein in the mechanism that confers 
greatest resistance to I/RI to 14-day old hearts. The lack of such an effect in hearts that 
underwent AMPK inhibitor pre-treatment, with washout of the drug prior to ischemia, 
highlights the importance of AMPK activity specifically during ischemia, and correlates with 
previous reports of its cardioprotective function (Section 1.5.3). Whilst western blot analysis 
did not identify any statistically significant changes in related survival signalling proteins, 
overall trends and visible differences in band intensities were present, and it is likely that 
the lack of significance was due to experimental limitations in the number of samples that 
could be run concurrently. These data implicate AMPK as a potentially causal protein to the 
biphasic cardiac vulnerability profile seen in rat hearts, and therefore highlight it as a target 
for future research and investigation.  
Having identified AMPK and a number of other survival signalling related proteins as 
biphasically expressed during postnatal development, and therefore potentially linked to the 
mechanism underlying the biphasic pattern of cardiac resistance to I/RI in rat hearts, the 
next section of work looks to identify any correlating changes in other survival signalling 
related structures. To do this, differences in the morphology of mitochondria – a critical end 
target of survival signalling pathways – and their response to I/RI in 14-day old and adult 
hearts will be examined, as well as any differences in other structures linked to survival 
signalling, such as caveolae and MVBs.  
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Chapter 7: Structural cardiac differences during development: 
implications for cardioprotection 
7.1 Introduction 
Thus far, the first four aims of this work have been addressed, with the identification of 
proteins showing biphasic patterns of expression during postnatal development, as well as 
testing the effects of targeted inhibition of such proteins during I/RI and the effect of this on 
the expression of other survival signalling related proteins. This chapter therefore focuses 
on the fifth aim: 
To identify differences in cardiomyocyte structure and ultrastructure that may influence the 
response to I/RI at different stages of development, including: 
iv.  blood vessel dimensions, cardiomyocyte hypertrophy and sarcomere lengths   
v. caveolae, multivesicular body (MVB) and exosome abundance 
vi.  mitochondrial subpopulation morphology and distribution 
These changes will be investigated for specific comparison of 14-day old with adult hearts in 
order to address this fifth aim, and to provide data on control hearts with which to make 
comparisons with post-ischemic and post-I/R hearts for the sixth aim (Chapter 8).  
7.1.1 Key cardiac structures implicated in survival signalling 
As discussed in Chapter 1, multiple changes occur in the structure of cardiac tissue over the 
course of postnatal development. This includes growth via hypertrophy of existing myocytes 
as opposed to growth via hyperplasia over the course of development (Section 1.2), with an 
associated switch from dependence on extracellular sources in early stages of development 
– for example, a reliance on Ca2+ influx via the NCX – to intracellular sources in adult 
cardiomyocytes – for example, Ca2+-cycling dependent on SR. The development of cardiac t-
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tubules during postnatal development are understood to facilitate signalling to inner regions 
of the cardiomyocyte as hypertrophic growth occurs (Hong and Shaw 2017), and perfusion 
to these regions from extracellular sources is no longer as effective as it is in the smaller and 
narrower cells seen in early stages of development. However, it is possible that these 
changes in cardiomyocyte morphology also leave them more vulnerable to ischemic insult, 
as blood supply and the perfusion of nutrients and signalling molecules to and throughout 
cells may be decreased as a result of this hypertrophy. We therefore examined the 
characteristics of blood vessels in 14-day old and adult hearts, as well as the morphology of 
isolated cardiomyocytes from different age groups, in order to determine whether 
hypertrophic changes are accompanied by an associated increase in blood vessel sizes to 
support the greater supply needs of the adult myocardium. 
7.1.2 Key cardiac ultra-structures implicated in survival signalling  
7.1.2.1 Caveolae  
Caveolin-1, -2 and -3 were all found to show biphasic profiles of expression during postnatal 
development in the proteomic output (Section 4.3.1), peaking at 14-days of age. As 
discussed in Section 4.4.2, these proteins play an important role in cardioprotection, in 
addition to being important components of the structure of the membrane 
subcompartments, caveolae (Couet, Belanger et al. 2001). Caveolae play important roles in 
cell signalling, both through the roles of Caveolins – which are able to interact with other 
intracellular signalling molecules to promote cell survival (Sharma et al. 2011, Das, 
Gherghiceanu et al. 2008) as well as cardioprotective autophagy during ischemia (Kassan et 
al. 2016) – and through their own ability to compartmentalise and localise key proteins for 
rapid signal transduction (Lisanti, Scherer et al. 1994). As a result, these structures were 
212 
 
identified in electron micrographs obtained from 14-day old and adult samples (Section 
7.2.3) in order to compare their abundance between the two age groups, as well as with 
samples that have undergone ischemia (Chapter 8). 
7.1.2.2 Exosomes and MVBs 
Exosomes, transported in MVBs (Figure 65), have been reported to carry a number of 
microRNAs, signalling molecules and Heat Shock Proteins (HSP) known to promote cardiac 
survival (Waldenstrom and Ronquist 2014). In particular, research has demonstrated that 
exosomes trigger protective signalling and reduced cell death through HSP70 carried by 
exosomes, which in turn activate ERK and p38MAPK via TLR4, resulting in HSP27 
phosphorylation and subsequent cardioprotection in rat models of I/RI (Vicencio, Yellon et 
al. 2015). Due to the apparent importance of these structures in promoting cell survival 
following I/RI, electron micrographs were checked for the presence and abundance of 
putative MVBs, in order to identify any differences between 14-day old and adult samples 
that may reflect differences in cardiac vulnerability to injury between these two age groups. 
Moreover, the proteomic output was analysed for the presence of commonly used exosome 







Figure 65. Electron micrograph 
examples of MVBs containing 
exosomes (marked with arrows) 
(image taken from (Sahoo, 
Klychko et al. 2011)) 
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It should be noted that identification of such vesicles and distinguishing them from other 
similar structures, such as caveolae and autophagosomes, was difficult when using electron 
micrographs alone. Due to the visual similarities between such structures, other studies have 
reported using additional methods such as staining for specific markers of these vesicles in 
order to definitively and correctly identify them, an additional step that will be necessary in 
our future work. 
7.1.2.3 Mitochondria 
In comparison with the typical morphology of mitochondria in control hearts (Figure 7, 
Section 1.6), those that have undergone the fusion process possess a much more elongated 
morphology, whereas those that have undergone fission appear much more fragmented and 
rounded (Figure 66). 
  
Mitochondrial fusion proteins – Mfn1, Mfn2 and Opa1 – and fission proteins – Drp1 and Fis1 
– play central roles in mitochondrial morphology, allowing the switch from elongated 
networks of mitochondria to the more fragmented phenotype that arises following fission 
(Ong and Hausenloy 2010). As mentioned in Section 6.4.7, skewing the balance between 
Figure 66. Electron micrograph examples of A. elongated mitochondria characteristic of 
fusion, and B. fragmented and round mitochondria indicative of fission (following 20 




mitochondrial fusion and fission towards fusion is known to be cardioprotective (Ong, 
Kalkhoran et al. 2015), with the overexpression of proteins such as Mfn1 and Mfn2 that 
promote mitochondrial fusion resulting in reduced cell death, and an associated inhibition 
of mPTP opening (Ong, Subrayan et al. 2010). Furthermore, it has been demonstrated that 
cellular stress can trigger ‘hyperfusion’ in order to provide a protective response and reduce 
injury, requiring Opa1 and Mfn1, and correlating with the increased production of 
mitochondrial ATP in order to deliver resistance to cellular stress (Tondera, Grandemange 
et al. 2009). Conversely, excessive mitochondrial fission has been shown to result in the 
production of unhealthy fragmented mitochondria with reduced function, greater 
susceptibility to mPTP opening, and subsequent increased cell death (Maneechote, Palee et 
al. 2017). Studies that have employed inhibitors of fission protein Drp1 in the context of I/RI 
demonstrated that prevention of its activation resulted in the reduction of mitochondrial 
fragmentation and swelling, and the prevention of cardiomyocyte death, as well as the 
reduction of mitochondrial ROS and improvement of LV developed pressure in Langendorff 
perfused hearts (Sharp, Fang et al. 2014).  
Due to the importance of mitochondria as the end target of the RISK-SAFE signalling 
pathways, the functional differences between the three mitochondrial subpopulations 
(Section 1.6), and the cardioprotective roles of fusion proteins, electron micrographs from 
14-day old and adult hearts were used to analyse any potential differences in morphology 
between the two age groups, as well as any differences in the relative abundance of each 
mitochondrial subpopulation. Additionally, proteomic data (described in Chapter 4) was 
used to identify any differences in the expression of fusion and fission proteins. 
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7.2 Materials & Methods 
7.2.1 Histology 
The full methodology of histological sample preparation and analysis has been described in 
Section 2.7.1. To summarise, hearts from 14-day old (n = 4), 28-day old (n = 5), and adult (n 
= 5) rats were flushed with Krebs-Henseleit buffer and cut to remove the apex and any excess 
tissue. The remaining heart sections were placed into tubes of fixative solution for 24 hours, 
before washing with phosphate buffer and processing. This involved dehydrating the tissue 
to allow the infiltration of paraffin wax. Processed tissue was then embedded in paraffin wax 
and placed onto an ice block to solidify the wax. Tissue was then sectioned to a thickness of 
5µm and mounted onto a microscope slide. These slides were then left overnight to dry out 
in a 37°C oven, before staining for blood vessels with Elastic Van Gieson. Images were taken 
and analysed to obtain measurements for the largest vein and artery present as a complete 
cross-section in each region of the heart (left ventricle, right ventricle and interventricular 
septum), for comparison of the size of the largest vessels by age group and localisation.  
7.2.2 Cardiomyocyte isolation & cell size determination 
A sample of cardiomyocytes isolated in Section 5.3.1 were taken for the measurement of 
their widths and lengths, in order to compare the average dimensions of cells between the 
three age groups – 14-day old (n = 3 hearts and 60 cells), 28-day old (n = 4 hearts and 52 
cells) and adults (n = 3 hearts and 97 cells). These sizes were measured using a light 
microscope with a grid-lined slide. Each cell length and width were measured by the number 
of squares spanned on the grid, and converted from this number into an actual size in 
micrometres using the scale 1 square = 0.01mm. 
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7.2.3 Electron microscopy 
The full methodology for preparation and analysis of electron micrographs has been 
described in Section 2.7.2. To summarise, hearts were removed from 14-day old (n = 3) and 
adult (n = 3) rats and placed directly into ice cold cardioplegic solution, before cannulation 
via the aorta and perfusion with cardioplegia. This was then repeated with EM fixative 
solution, following which hearts were cut into small cubes taken from the left ventricular 
wall, left in the fridge overnight in fixative, and transferred into phosphate buffer to be sent 
for processing. Images were taken in several regions of each heart at a range of 
magnifications, from which measurements of mitochondrial area, length, width, as well as 
the area of cardiomyocyte covered, were taken for each of the three mitochondrial 
subpopulations. These images were also analysed for the length of sarcomeres, abundance 
of caveolae, and abundance of putative exosome containing MVBs.  
7.2.4 Proteomic Analysis 
The full process of proteomic and phosphoproteomic analysis has been described in Section 
2.4.3 and 4.2.2. From the proteomic output described in Chapter 4, with samples from 7-
day old (n = 4), 14-day old (n = 8), 28-day old (n = 8) and adult (n = 7) rats, proteins involved 
in mitochondrial fusion and fission, as well as those linked to exosome signalling or as 
exosome markers, were extracted. These proteins were then analysed for any statistically 




7.3.1 Cardiac structural changes during postnatal development 
Hearts from three age groups, 14-day olds (n = 4), 28-day olds (n = 5), and adult (n = 5), were 
extracted from rats, and processed for histology as outlined in Section 2.4.1. The slides 
produced were analysed, locating the largest veins and arteries in each section of the heart 
(right ventricle RV, left ventricle LV and interventricular septum IVS), and taking the 
dimensions and area for each. Representative examples of the largest vessels are given in 
Figure 67 & 68 below.  
P28. 
Figure 67. Examples of large veins in each section of the heart by age, labelled for width 







The areas of the largest veins in different regions of the heart were measured and the data 
shown in Figure 69A. Figures 69B & 69C show the areas of the largest arteries in each region 
of the heart, as well as the areas of their corresponding lumen. Comparison of these vessel 
sizes found no statistically significant difference between the three age groups in neither 
veins, arteries, nor the area of the arterial wall itself. 
 
 
Figure 68. Examples of large arteries in each section of the heart by age, labelled for width 







However, statistical significance was found between 14-day old and both 28-day old and 
adult rats for the ratio between the area of the elastic lamina of the arterial wall and the 
area of the whole vessel, as shown in Figure 70A. Whilst this significance was not found in 
the right ventricle (not shown), arteries from the interventricular septum did display a 
statistically significant difference between 14-day old and adult hearts (Figure 70B). 
 
  
Figure 69. Graphical summary of the mean 
areas for the largest veins (A), arteries (B) 
and arterial lumens (C) in each sample, by 
section of the heart (LV, RV or IVS) and 
age. Data are presented as Mean ± SE (n 
= 4 for 14-day old, n = 5 for 28-day olds 







7.3.2 Cardiomyocyte hypertrophy during development 
Following the isolation of cardiomyocytes from the hearts of 14-day old, 28-day old, and 
adult rats, the sizes of these isolated cells were measured using a grid-lined slide (as 
described in Section 2.1.5). Example images of cells isolated from the different age groups 







Figure 70. Differences in the elastic layer of the arterial wall/total vessel area ratio 
between age groups for the left ventricle (A) and the interventricular septum (B). 
Significant p-values are labelled. Data are presented as Mean ± SE (n = 4 for 14-day 
olds, n = 5 for 28-day olds and n = 5 for adult). * = statistically significant difference in 






Cardiomyocyte dimensions were measured for cells from 3 different hearts for each age 
group, the averages of which are shown in Figure 72. A statistically significant difference was 
found between the 3 age groups in terms of both the length and width of the isolated 
cardiomyocytes.  
 

















Cell dimensions of isolated 
cardiomyocytes by age.
Length Width
Figure 72. Comparison of the length 
and width measurements of 
cardiomyocytes obtained from cell 
isolation between age groups. Data 
are presented as Mean ± SE (n = 3 
for 14-day old, n = 3 for 28-day old 
and n = 3 for adult). * = statistically 
significant difference in comparison 
with 14-day old average length (p < 
0.05). # = statistically significant 
difference in comparison with 14-







Figure 71. Isolated cardiomyocytes 
from a 14-day old heart (left), a 28-
day old heart (right), and an adult 
heart (bottom), with non-viable 
cells stained with Trypan Blue for 





7.3.3 Changes in cardiomyocyte ultrastructure during development 
7.3.3.1 Changes in sarcomere length during postnatal development 
Average sarcomere length was statistically significantly lower in 14-day old than adult hearts 
in control, pre-ischemic samples (p < 0.05). This corresponds to the fact that cardiomyocytes 
undergo hypertrophy of existing cells during postnatal development, with associated 























Average Sarcomere Length 
Figure 73. Graph to show average sarcomere length in control 14-day old and adult rat hearts. 
* = statistically significant difference compared to 14-day old samples (p < 0.05). (P14 n = 3 




7.3.3.2 Changes in the abundance of caveolae during postnatal development 
The number of caveolae present at cardiomyocyte membranes per/µm was statistically 
significantly higher in 14-day old hearts in comparison with adult hearts (p < 0.0001).  This 

























Average number of caveolae per/μm
Figure 74. Comparison of caveolae abundance in 14-day old and adult hearts. (Top) 
Representative electron micrographs of caveolae in 14-day old (right) and adult (left) heart. 
(Bottom) Mean number of caveolae present at the cardiomyocyte cell membrane per/µm in 14-
day old and adult rat hearts. * = statistically significant difference in comparison with P14 (p < 0.05). 






7.3.3.3 Changes in MVB & exosome abundance during postnatal 
development 
7.3.3.3.1 Proteomics of proteins reported to be involved in exosome signalling 
As mentioned in the introduction, MVBs and exosomes are known to be linked to 
cardioprotective signalling, reducing the degree of myocardial injury seen following 
ischemia/reperfusion through activation of survival signalling pathways. We therefore 
examined our proteomic output for proteins involved in these signalling pathways, as well 
as commonly used exosome markers, CD63 and Tsg101. TLR4 and CD63 were not detected 
across all 4 age groups of the proteomic output, and subsequently could not be analysed. 
Results for the remaining proteins with full sets of proteomic data are shown below.   
The majority of proteins showed a progressive increase – HSP70-1a & p38MAPK-MAPK12 – 
or decrease – HSP70-13, HSP70-14, HSP70-4, ERK2 & HSP27 – in expression over the course 
of postnatal development, as opposed to a biphasic pattern of expression, indicating they 
are unlikely to play a role in the biphasic changes to cardiac vulnerability seen over these 
age groups. Conversely, two of the members of the HSP70 family – HSP70-12a & HSP70-12b 
– believed to be carried by exosomes and stimulate cardioprotective signalling via TLR4 did 
show a statistically significant biphasic trend in expression, highlighting them as potentially 
important proteins underlying postnatal changes in response to ischemia/reperfusion injury. 
The remaining proteins involved in this cardioprotective pathway – ERK1 & p38MAPK-
MAPK14 – as well as reported exosome marker TSG101 were also shown to have an overall 
biphasic trend in expression. However, ERK1 and TSG101 did not show statistically significant 
differences in expression between 7-day old and 14-day old samples, and p38MAPK-
MAPK14 did not show any statistically significant changes in expression between these age 
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groups. As a result, the importance of these proteins’ roles in biphasic cardiac vulnerability 
changes is uncertain.  
 
As this proteomic output was produced from whole tissue samples, future work will need to 
further examine the role of these proteins in exosome function and their cardioprotective 
properties, possibly through staining – IHC or Immunogold staining – in order to establish 
whether those proteins showing statistically significant biphasic expression specifically do so 
within or in association with exosomes, or whether they change in cardiac tissue as a whole. 
Figure 75. Changes in the expression of key exosome-related proteins and downstream 
signalling targets during postnatal development, as detected by proteomic analysis. Data are 
presented as Mean ± SE ((7-day (n = 4), 14-day (n = 8), 28-day (n = 8) and adult (n = 7)) * = statistically 
significant difference compared to 14-day old samples (p < 0.05). # = statistically significant 






































































Changes in Exosome Related Protein Expression During 
Postnatal Development



































7.3.3.3.2 Effect of postnatal development on the abundance of MVBs & 
exosomes in control hearts 
Examination of Electron Micrographs taken from control hearts found numerous putative 
MVBs with large circular exosomes in 14-day old hearts, which were much rarer in adult 
hearts. It is possible that this reflects a greater abundance of these cardioprotective vesicles 
present in 14-day old hearts prior to injury that primes them for activation of survival 
signalling pathways upon cardiac insult, corresponding to their greater resistance to 
ischemia/reperfusion injury. This corresponds to the detection of survival signalling related 
proteins in the proteomic output from control hearts with a greater expression in 14-day old 





Figure 76. Representative images of putative MVBs containing exosomes in cardiac 




7.3.4 Changes in mitochondrial fission and fusion protein expression 
during development 
As mentioned in Section 7.1.2.3, mitochondrial fission and fusion play an important role in 
the survival of cardiomyocytes following ischemia/reperfusion injury. Therefore, the 
proteomic output was checked for the presence and expression of proteins related to these 
processes in control hearts, in order to identify any differences that may exist over the 
course of postnatal development prior to cardiac insult that could potentially prime hearts 
and confer greater resistance to injury. The data was checked for commonly reported 
mitochondrial fission and fusion proteins, and those that had complete sets – i.e. were 
present across all three runs of proteomic analysis and thus all four age groups – were 
analysed for statistically significant differences in expression across the four age groups, as 




















Mean expression of mitochondrial Fission or Fusion related proteins 
during postnatal development.
P7 P14 P28 Adult
Figure 77. Changes in expression of mitochondrial fission & fusion related proteins at 
different stages of postnatal development, as detected in the proteomic output. Data are 
presented as Mean ± SE. (7-day (n = 4), 14-day (n = 8), 28-day (n = 8) and adult (n = 7)) * = 
statistically significant difference compared to 14-day old samples (p < 0.05). # = statistically 










No statistically significant differences were seen in the expression of Mfn2 or Drp1 across 
the four age groups, and differences in Opa1 expression were only seen between 7-day old 
samples and both 14-day old and adult. As a result, it is likely that these proteins do not play 
a role in potential differential mitochondrial fission or fusion responses to 
ischemia/reperfusion injury in 14-day old hearts that may contribute to their improved 
resistance to cardiac injury. However, a biphasic trend in expression was seen in the fusion 
protein Mfn1 and fission protein Fis1, with a statistically significant difference between 7-
day old and 14-day old samples only in the case of Fis1.  
7.3.5 Changes in mitochondrial morphology during postnatal 
development 
The morphological characteristics of each mitochondrial subpopulation are displayed in 
Figure 78 & 79, with statistical analysis conducted for comparison of the subpopulations 
within each age group. Further statistical analysis was run to compare the morphology of 
the subpopulations between the age groups, as shown in Figure 80.  
Statistically significant differences in morphology were seen predominantly between 
Interfibrillar (IF) mitochondria in comparison with the two other subpopulations in 14-day 
old hearts, with both a significantly greater area and lower roundness than Perinuclear (PN) 
and Subsarcolemmal (SSL) mitochondria. All three subpopulations significantly differed in 
Aspect Ratio (AR), with PN showing a value closest to 1.0, and IF showing a value furthest 













Figure 79. Adult cardiac mitochondrial morphometry by subpopulation. * = statistically 
significant difference in comparison with IF mitochondria (p < 0.05). # = statistically significant 
difference in comparison with PN mitochondria (p < 0.05). Turquoise = Interfibrillar (IF), Blue 
= Perinuclear (PN), Purple = Subsarcolemmal (SSL). IF n = 671, PN = 122, SSL n = 243. 
 
Figure 78. 14-day old cardiac mitochondrial morphometry by subpopulation. * = statistically 
significant difference in comparison with IF mitochondria (p < 0.05). # = statistically significant 
difference in comparison with PN mitochondria (p < 0.05). Turquoise = Interfibrillar (IF), Blue 




In adult hearts, statistical significance was only seen between IF and SSL mitochondria in 
terms of their mean area. Similar to 14-day old hearts, the AR for IF differed from both PN 
and SSL, with a value furthest from 1.0. All three subpopulations were shown to differ in 
roundness, with IF showing the lowest measure of roundness of the three subgroups. 
Direct comparisons between the two age groups (Figure 80) showed that all of the 
morphological characteristics measured for each of the three subpopulations – with the 
exception of IF length – were significantly different. In all three subpopulations, adult 
mitochondria had a greater mean area, as well as both a greater degree of roundness and 
an AR closer to 1.0 than 14-day olds.  
  
Figure 80. Differences in mitochondrial morphological between 14-day old and Adult hearts, 
by mitochondrial subpopulation. * = statistically significant difference in comparison 
with 14-day old hearts (p < 0.05). (n = 3 hearts/age group) 













7.3.6 Changes in mitochondrial subpopulation distribution during 
postnatal development. 
In order to examine the relative numbers of each mitochondrial subpopulation present in 
the myocardium, and how this differs between the two age groups, the area of the 
cardiomyocyte, as well as the collective area of the cardiomyocyte covered by each 







































































A. Average percentage of cardiomyocyte area covered by mitochondria. 












































































Figure 81. Mitochondrial subpopulation distribution in 14-day old and adult hearts. A. 
Percentage of cardiomyocyte covered by mitochondria and mitochondrial 
subpopulations. B. Average number of each mitochondrial subpopulation in a 100µm² 
area of cardiomyocyte, calculated as: area (µm²) of mitochondria subpopulation covering 
cardiomyocyte/average area of an individual mitochondrion of that subpopulation. * = 
statistically significant difference with P14. C. Graph comparing the relative percentages 
of each mitochondrial subpopulation covering a region of cardiac tissue between the two 
age groups. Yellow segment indicates percentage of the cardiomyocyte area free of 
mitochondria. D. Graph depicting the relative percentages of number of each 
mitochondrial subpopulation per 100µm² area of cardiomyocyte by age group. E. Graph 
depicting relative numbers of each mitochondrial subpopulation per 100µm² area of 
cardiomyocyte by age group. (P14 n = 3 hearts, 7 sections. Adult n = 3 hearts, 6 sections)  
 
C. 
D. E. Percentage of each mitochondrial 
subpopulation per 100µm² 
Number of each mitochondrial 
subpopulation per 100µm² 
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A greater proportion of the cardiomyocyte was covered by mitochondria in adults (44%) 
compared with 14-day old (35%). Of these areas, only 8% of the 14-day old cardiomyocyte 
was comprised of IF in comparison with 33% in adults. However, 14-day olds showed a 
greater percentage of PN in cardiomyocytes than adults (19% vs. 4%), but a similar 
proportion of SSL. A similar trend in distribution was seen when calculating the number of 
each mitochondrial subpopulation, with 14-day olds having the greatest number of PN per 
100µm² and adults having the greatest number of IF. In addition to this, 14-day olds were 
also found to have a greater number of SSL in comparison with adults (17 mitos/100µm² vs. 
9 mitos/100µm²). The significance of these differences in distribution will be discussed in 
Section 7.4. 
7.4 Discussion 
7.4.1 Gross cardiac structural changes during development 
Analysis of cell dimensions following isolation of cardiomyocytes from 14-day old, 28-day 
old and adult rat hearts found a statistically significant increase in both cell length and width 
during postnatal development (p < 0.0001 for both measurements). These findings are 
consistent with current knowledge of the switch from hyperplasic growth to hypertrophic 
growth at postnatal day 4 in rats (Olivetti, Anversa et al. 1980), as increasing heart mass is 
supported by the increasing size of individual, pre-existing cardiomyocytes.  
While there does appear to be an upward trend in both vein and artery size during postnatal 
development, the large range of values of cross-sectional area in each group and within each 
region of the heart resulted in a large standard error, and the lack of statistical significance 
between these factors. Whether this lack of statistical significance is due to the small sample 
numbers used, the fact that only the largest vessel from each sample was measured, or is in 
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fact of true physiological relevance is uncertain. Previous reports have described that the 
increasing blood supply needed to support the growing myocardium during postnatal 
development is supported by the proportional growth of capillaries, whereas the coronaries 
may not in fact increase with increasing heart size, resulting in increased coronary vascular 
resistance with age (Hudlicka and Brown 1996).  
There also appears to be a non-statistically significant pattern in vessel size between the 
regions of the heart. Both veins and arteries appear to be largest in the left ventricle (LV) 
and smallest in the interventricular septum (IVS), with the exception of veins at 14-days of 
age which are largest in the IVS, and arteries in the adult samples which are again largest in 
the IVS, although only marginally. This finding correlates with the respective roles of each 
region of the heart in cardiac function and the circulatory system, as the LV is responsible 
for sustaining contraction sufficient to pump blood from the heart to the entire body, and 
as such would require a greater substrate and metabolite supply in order to support the 
higher muscle mass and energy demands than those required by the IVS or right ventricle 
(RV). It is likely that the exceptions found are due to methodological issues in terms of 
selection of the vessels for measurement, in addition to the relatively low sample numbers, 
as a single anomalous result would be capable of altering the average and pattern of change 
in vessel size of the whole age group or heart section. Indeed, a full cross-sectional vein could 
only be found in the LV of one out of the four 14-day old samples. Notably, the ratio of the 
elastic arterial wall area to total vessel area was statistically significantly higher in 14-day old 
hearts than adults in the IVS as well as the 28-day old hearts in the LV. The significance of 
this is uncertain, but may reflect a morphological response of the arteries at this age to the 
increasing coronary vascular resistance, increasing cardiac output and progression towards 
functional and structural maturity at 21 postnatal days (Wu and Wu 2009). 
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7.4.2 Caveolae abundance and caveolin-1, -2 and -3 expression is higher 
in 14-day old compared to adult hearts 
Concordant with the greater expression of caveolin-1, -2 and -3 in the proteomic output 
(Section 4.3.2), the abundance of caveolae was significantly greater in 14-day old hearts than 
adult hearts. As discussed in Section 7.1.2.1, caveolae and caveolins play important 
cardioprotective roles during I/RI through localisation of important survival signalling 
proteins at the cell membrane to facilitate faster signal transduction, as well as through the 
signalling properties of caveolins themselves. Therefore, this greater abundance of caveolae 
in 14-day old samples therefore suggests a potential underlying contribution of these 
structures, as well as associated caveolins, to the greater resistance to I/RI seen in hearts of 
this age group. Future work examining cardiac ultrastructure would be required to see if the 
abundance of caveolae in 7 day old hearts also mimics the trends of caveolin-1, -2 and -3 
expression seen across the four age groups. 
7.4.3 MVB and exosome associated protein expression is higher in 14-
day old hearts compared to adults 
Similar to caveolae, the abundance of putative MVBs was greater in 14-day old hearts than 
adult hearts. This was supported by proteomic analysis, which found that the expression of 
commonly used exosome marker, TSG101, had a biphasic profile, peaking at 14-days of age. 
It should be noted, however, that the difference between 14-day old and 7-day old samples 
was not statistically significant, but may result from the relatively low number of samples 
analysed in the 7-day old group. A number of other proteins linked to exosome signalling 
also showed an overall biphasic profile of expression, including two isoforms of HSP70 – with 
statistically significant differences between 14-day old samples and all three age groups – as 
236 
 
well as ERK1, which showed statistically significant differences only between 14-day old 
samples in comparison with 28-day old and adult samples. While this correlates with the 
greater number of putative MVBs identified in the 14-day old myocardium, these signalling 
proteins do also play important roles in survival signalling in their own right (Section 1.5), 
and may therefore display this pattern of expression independently of exosomes.  
Quantitative analysis of MVB and exosome abundance was not performed in this case, due 
to the uncertainty in accurately identifying and distinguishing MVBs from other vesicles of a 
similar morphology and appearance. While the majority had a clear morphology similar to 
the example given in Section 7.1.2.2, with large circular structures located within MVBs, a 
number had intermediate phenotypes, or ones that appeared similar to structures that have 
previously been presented as both MVBs/exosomes (Waldenstrom, Genneback et al. 2012) 
and autophagasomes (Martin, Xu et al. 2011). As a result, future work would benefit from 
the use of exosome markers in order to conclusively identify MVBs and therefore quantitate 
potential differences between age groups. Such investigation would also need to apply this 
to 7-day old samples to confirm that trends in abundance also follow the biphasic profile 
seen in cardiac vulnerability to I/RI. 
7.4.4 Proteomic analysis of fission and fusion proteins showed age-
related biphasic changes in both Mfn1 and Fis1 expression 
Proteomic analysis of mitochondrial fusion and fission proteins identified only two that 
showed an overall biphasic profile of expression; Mfn1 and Fis1. Whilst Mfn1 expression only 
showed statistical significance between 14-day old in comparison with 28-day old and adult 
samples, statistical significance was seen between 14-day old samples and all three age 
groups in the case of Fis1. This biphasic expression of both a pro-fusion and pro-fission 
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protein (Section 7.1.2.3) indicates no clear bias in favour of one process over the other in 
control hearts, but could indicate that there is a balance between the two that may provide 
cardioprotection during I/RI. It will be important to examine this in post-ischemic samples 
and to look at activation of these proteins in future work in order to better elucidate the 
functional relevance of these patterns of expression. 
7.4.5 Morphology of mitochondrial subpopulations is altered during 
postnatal development 
7.4.5.1 All three mitochondrial subpopulations were smaller and less 
rounded in 14-day old hearts compared with adults 
Previous work by Kalkhoran et al. (2017) showed that, in adult hearts, IF mitochondria are 
more elongated and less spherical than both PN and SSL, with SSL displaying a somewhat 
intermediate morphology between the other two subpopulations. While the authors found 
that SSL were similar in area to IF, but more akin to PN in terms of their sphericity, our work 
actually found that, in adults, only IF and SSL differed significantly in area, and that SSL – not 
PN – had the smallest area. Furthermore, our data showed that all three subpopulations 
differed significantly from one another in roundness, although only IF differed in AR from 
the two other subpopulations, with SSL showing the greatest degree of roundness as 
opposed to PN. Lower AR and greater roundness are suggested to result in mitochondria 
that are less branched, therefore interacting more with surrounding mitochondria as they 
do not extend into other regions, a phenotype attributed to PN (Kalkhoran et al. 2017). 
However, we found that, while PN did have the lowest AR, SSL had the greatest roundness 
in adults. This may relate to the theory that PN and SSL are more linked to cellular signalling 
due to their localisation at the cell membrane or around the nucleus, suggesting their 
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morphology allows for greater inter-mitochondrial signalling.  In 14-day olds, the differences 
in morphology of the mitochondrial subpopulations more closely resembled those reported 
by Kalkhoran et al. (2017), with IF possessing a significantly greater area than both of the 
other subpopulations, PN and SSL displaying significantly higher roundness than IF, and PN 
showing an AR significantly lower than both IF and SSL.  
Comparisons between the two age groups showed that, as expected, all subpopulations had 
a significantly greater area in adults compared with 14-day olds. However, adults also 
displayed a lower AR and greater roundness in all three subpopulations in comparison with 
14-day olds. The significance of these differences is uncertain, but may imply a greater 
degree of local interaction between adult mitochondria, as opposed to communication and 
potentially signalling that extends to other regions of the cardiomyocyte. It will also be 
important to see how these morphological characteristics alter following ischemia and 
reperfusion.  
7.4.5.2 Perinuclear mitochondria are present in higher numbers and density 
in 14-day compared to adult 
Previous reports describe neonates as having more “homogenous networks” (Kuzmicic et al. 
2011) of mitochondria distributed around the sarcolemmal membrane and nucleus, in 
contrast with the more distinct regions of mitochondria and greater density situated 
between the myofibrils seen in adults. In keeping with this, samples taken from 14-day old 
hearts displayed a much less organised distribution of mitochondria within cardiomyocytes, 
often presenting difficulty in finding clear areas of IF for measurements. The majority of 
mitochondria in 14-day olds – expressed as a percentage area of the cardiomyocyte covered 
by mitochondria – were PN (19% vs. 4% in adults), whereas the majority of adult 
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mitochondria were IF (33% vs. 8% in adults). Whilst the greater proportion of IF is to be 
expected in order to support contraction for the increased energy demands in adults, the 
significance of a higher proportion of PN in 14-day olds is uncertain, but may relate to their 
described role as providers of energy for gene transcription (Hwang and Kim 2013). 
The importance of mitochondrial localisation to the nuclear region is supported by work 
reporting the effect of autologously derived mitochondria transplantation in the context of 
I/RI (Masuzawa et al. 2013). The authors reported that injection of these mitochondria into 
ischemic regions of the heart resulted in decreased CK release, troponin-I, apoptosis, and 
infarct size 4 weeks post-surgery, with the recovery of normal contraction within 10 minutes 
of reperfusion. Transplanted mitochondria were found to have been internalised within 2-8 
hours, with an associated increase in cell viability, improved post-infarct cardiac function, 
and enhanced O2 consumption. Further investigation of the localisation of these 
mitochondria showed that, in neonatal rat cardiomyocytes, mitochondria were internalised 
to the PN region following 24 hours of incubation (Masuzawa et al. 2013). These findings 
again suggest a potential link between the localisation of mitochondria to the nucleus and 
improved cardiac outcomes following I/RI, and may indicate that the greater proportion of 
mitochondria at this site in 14-day olds relates to their resistance to cardiac insult.  
7.4.6 Summary & Conclusion 
The abundance of both cardioprotective caveolae and MVBs was greater in 14-day old 
samples than adults, indicating a potential contribution to the greater resistance to I/RI seen 
in 14-day old hearts. Characterisation of both mitochondrial morphology and subpopulation 
distribution between the two age groups identified clear differences upon which further 
comparisons with post-ischemic samples can be built (Chapter 8).  
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Chapter 8: The effect of I/R on Cardiac Ultrastructure in adult 
and 14-day old hearts 
8.1 Introduction 
Having characterised differences between control 14-day old and adult hearts in the 
abundance and morphology of cardiac ultrastructures (Chapter 7), Chapter 8 looks to 
address the sixth aim of this work; “To observe any changes that may occur in the 
cardiomyocyte structure and ultrastructure following ischemic insult and reperfusion.” Data 
was collected from post-ischemic and post-I/RI samples from both age groups, and 
measurements taken for comparison both between age groups following cardiac injury, as 
well as to compare measurements with those obtained from control hearts within each age 
group.  
8.2 Materials & Methods 
8.2.1 Electron microscopy of post-ischemic hearts 
The full methodology for preparation and analysis of electron micrographs has been 
described in Section 2.7.2, and the protocol of Langendorff perfusion for global ischemia in 
Section 2.6.1. To summarise, hearts were excised, cannulated onto Langendorff apparatus 
and perfused with Krebs-Henseleit solution for a period of stabilisation, prior to a 30 minute 
period of global ischemia. Hearts were then removed from the cannula, and small cubes of 
tissue taken from the left ventricular wall, left in the fridge overnight in fixative, and 
transferred into phosphate buffer to be sent for processing. Images were taken in several 
regions of each heart at a range of magnifications, from which measurements of 
mitochondrial area, length, width, as well as the area of cardiomyocyte covered, were taken 
for each of the three mitochondrial subpopulations. These images were also analysed for 
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the length of sarcomeres, abundance of caveolae, and abundance of putative exosome 
containing MVBs.  
8.2.2 Electron microscopy of post-I/R hearts 
Electron microscopy of hearts post-I/R was conducted for 14-day old (n = 3) and adult (n = 
3) hearts as described in Section 8.2.1. For these hearts, however, an additional 60 minute 
period of reperfusion was performed following the 30 minutes of global ischemia. At the end 
of reperfusion, hearts were cut down and cubed sections of tissue taken for processing, as 
previously described.  
8.3 Results 
8.3.1 Effect of ischemia on sarcomere length 
Average sarcomere length was statistically significantly lower in 14-day old than adult hearts 
in pre-ischemic samples, but significantly greater in post-ischemic samples. Comparison of 
pre- vs. post-ischemic samples within each age group showed that average sarcomere length 
decreased in both 14-day old (p < 0.0001) and adult (p < 0.0001) hearts, due to 





Reflective of the differences seen in sarcomere length between the two age groups 
described above, 14-day old samples appeared to show a slightly smaller decrease in 
average sarcomere length following ischemia than adult samples (31% vs. 38%), potentially 
indicating a relatively lower degree of hypercontracture in this age group and less severe 
response to ischemia.   
Figure 82. Representative images of sarcomere lengths in pre- vs. post-ischemic samples, 




















































Figure 83. Average sarcomere lengths of 
pre- vs. post-ischemic hearts in 14-day old 
and adult samples. Data presented as mean 
± SE. * = statistically significant difference 
compared to 14-day old samples (p < 0.05). 
#  = statistically significant difference 
compared to pre-ischemic samples (p < 
0.05). (A). Percentage change in sarcomere 
length from pre- to post-ischemic samples 
in 14-day old vs. adult hearts (B). (P14 n = 
3 hearts, 1080 sarcomeres. Adult n = 3 





8.3.2 The effect of ischemia on caveolae abundance in adult and 14-day 
old hearts 
As mentioned in Section 7.3.3.2, the number of caveolae in control hearts is statistically 
significantly higher in 14-day old samples in comparison with adults (p < 0.001), in line with 
the higher levels of expression of Caveolin-1, -2 & -3 in 14-day old hearts detected by 
proteomic analysis. While this trend continues to be true post-ischemia, a statistically 
significant difference was not seen between the two age groups. 
Figure 84. Electron micrograph examples showing the differences in average caveolae 
number between pre- & post-ischemic hearts, both in 14-day old and adult samples. 





Whilst the number of caveolae per μm decreased following ischemia in both 14-day old and 
adult samples, this reduction was only statistically significant in 14-day old samples (p < 
0.001). However, the average number of caveolae in post-ischemic 14-day old samples 
remains higher than that seen in adults both pre- & post-ischemia (1.9 caveolae/µm vs. 1.5 




























Average number of caveolae per μm
Pre-Ischemia Post-Ischemia
Figure 85. Graph showing the average number of caveolae per µm in pre-ischemic tissue in 
comparison with post-ischemic tissue, and between 14-day old and adult hearts. Data 
presented as Mean ± SE. * = statistically significant difference between P14 & adults (p < 
0.05). # = statistically significant difference between pre- & post-ischemia (p < 0.05). (P14 n 








8.3.3 Effect of ischemia and reperfusion on MVB and exosome 
abundance in 14-day old and adult hearts  
8.3.3.1 Effect of ischemia  
Examination of Electron Micrographs taken from post-ischemic hearts found what appeared 
to be fewer clear MVBs, with large circular exosomes, in 14-day old post-ischemic hearts 
compared to control hearts. This could be due to many of those present in control hearts 
subsequently being exported from the myocardium during ischemia to trigger 
cardioprotective signalling. Indeed, the number of vesicles outside of the myocardium itself 
and between cardiomyocytes, as well as within the myofibres themselves as smaller 
structures reported to be free exosomes (Sahoo and Losordo 2014), seem to have increased 
following ischemia in 14-day olds. However, without exosome and MVB specific markers, it 
is difficult to determine precisely what these structures are and whether they are indeed 
excreted exosomes or MVBs previously seen in the myocardium possessing cardioprotective 
signalling properties. 
Figure 86. Representative images of putative MVBs containing exosomes in cardiac sections 








The number of putative MVBs and exosomes appears to remain low in adult samples 
following ischemia, and 14-day old samples continue to exhibit a greater number of these 
vesicles than adults. This supports the theory that these reportedly cardioprotective and 
survival signalling promoting vesicles are present in higher quantities in 14-day old than 
adult myocardium, and may therefore be related to the greater resistance to cardiac injury 
seen at this stage of postnatal development. 
8.3.3.2 Effect of reperfusion following ischemia  
Following reperfusion, the cardiomyocytes themselves appeared to have a much lower 
number of MVBs than seen in control hearts (Section 7.3.3.3), both in 14-day old and adult 
tissue. However, extracellularly there appeared to be large regions filled with vesicles and 
particulates, which may reflect released exosomes and related signalling particles resulting 
from the export of MVBs from the cardiomyocytes post-I/R. Consistent with this, a greater 
number of these MVBs were identified towards the cardiomyocyte membranes and 
extracellularly, suggesting efflux of these vesicles out of cardiomyocytes potentially to 
trigger survival signalling pathways. Moreover, a number of these putative MVBs were 
detected within or around other cells adjacent to the cardiomyocytes, which may suggest 
that, following their export out of cardiomyocytes, they are able to interact with and possibly 
recruit other cell types to areas of cardiac injury to promote healing, as will be discussed 




Similarly to control and post-ischemic hearts, 14-day old samples appeared to have a greater 
number of these putative MVBs characterised with large, circular exosomes within each 
vesicle in comparison with adult samples. While adult samples did exhibit a number of 
vesicles containing smaller particulates, as seen in Figure 87 above, they did not appear to 
contain the larger, circular components most commonly reported in existing literature as 
exosomes (Section 7.1.2.2).  
  
Figure 87. Representative images of putative MVBs containing exosomes in cardiac 









8.3.4 The effect of ischemia on mitochondrial subpopulations in adult 
and 14-day old hearts  
8.3.4.1 Changes in subpopulation distribution 
In order to examine the relative numbers of each mitochondrial subpopulation present in 
the myocardium, and how this differs between the two age groups following ischemia, the 
area of cardiomyocyte, as well as the collective area of the cardiomyocyte covered by each 
subpopulation, were measured. 
  
A greater proportion of the cardiomyocyte was covered by mitochondria in adults (61%) 
compared with 14-day old (52%). Of these areas, only 14% of the 14-day old cardiomyocyte 
was comprised of IF in comparison with 48% in adults. However, 14-day olds showed a 
greater percentage of PN in cardiomyocytes than adults (29% vs. 4%), but a similar 
proportion of SSL. These patterns of mitochondrial subpopulation abundance between the 
two age groups mimics that seen in control hearts (Section 7.3.8), although with increased 
percentages in the total area of the cardiomyocyte covered by mitochondria, likely resulting 















































Figure 88. The average percentage of cardiomyocyte covered by mitochondria, by 
mitochondrial subpopulation. Data presented as Mean ± SE. * = statistically significant difference 




Collected data for pre- vs. post-ischemic hearts in terms of the percentage of the 
cardiomyocyte area covered by each mitochondrial subpopulation was subsequently 
analysed for any changes in their relative abundance following ischemia (Figure 90). 
Statistically significant differences in the distribution of mitochondrial subpopulations 
following ischemia was seen only in adult hearts, with an increase in the percentage of 
Figure 90. Comparison of the relative abundance of each of the three mitochondrial subpopulations in 
14-day old and adult hearts, pre- vs. post-ischemia. Data is presented as mean ± SE. * = statistically 
significant difference in comparison with pre-ischemic hearts (p < 0.05). (n = 3 hearts/group. Pre-
ischemic: P14 n = 7 cardiomyocytes, adult = 6 cardiomyocytes. Post-ischemic: P14 n = 3 


































Distribution of Mitochondrial Subpopulations: Pre- vs. Post-Ischemia 
Figure 89. Charts comparing the relative percentages of each mitochondrial subpopulation covering 
a region of cardiac tissue between the two age groups. (P14 n = 3 hearts, 3 cardiomyocytes. Adult 
n = 3 hearts, 4 cardiomyocytes). Yellow segment indicates percentage of the cardiomyocyte 
cross-sectional area free of mitochondria. 
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cardiomyocyte covered by IF mitochondria increasing from 33% in pre-ischemic to 48% in 
post-ischemic hearts (p < 0.01). However, it is possible that this change results from an 
increase in the size of individual mitochondria due to swelling as opposed to changes in the 
number of IF mitochondria, as the percentage of the other two subpopulations did not 
appear to change significantly, and it is unlikely that new mitochondria were generated post-
ischemia. Similarly, 14-day old PN mitochondria – which are the most abundant 
subpopulation in this age group – showed a substantial increase in percentage post-
ischemia, again likely owing to swelling of pre-existing mitochondria. 
8.3.4.2 Changes in morphology  
The morphological characteristics of each mitochondrial subpopulation were measured 
using ImageJ, with statistical analysis run for comparisons both within (Figure 91 & 92) and 
between (Figure 93) the two age groups. 
Figure 91. Mitochondrial morphometry in 14-day old hearts following 30 minutes ischemia by 
subpopulation. Data presented as Mean ± SE. * = statistically significant difference in comparison 
with IF mitochondria (p < 0.05). # = statistically significant difference in comparison with PN 
mitochondria (p < 0.05). Turquoise = Interfibrillar (IF), Blue = Perinuclear (PN), Purple = 









Following ischemia, the area of IF mitochondria were significantly greater than both PN and 
SSL mitochondria in 14-day old hearts. While ischemia seemed to remove any of the previous 
differences in roundness seen between the three subpopulations, the AR of all three differed 
from one another, with PN possessing an AR closest to 1.0, and IF possessing an AR furthest 
from 1.0.  
In adult hearts, all three subpopulations differed from one another in terms of area and AR, 
with PN possessing the smallest area and an AR closest to 1.0, while SSL had the greatest 
area and IF had an AR further from 1.0. IF also had the lowest measurement of roundness, 
whereas PN and SSL did not significantly differ from one another. 
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Figure 92. Mitochondrial morphometry in adult hearts following 30 minutes ischemia by 
subpopulation. Data presented as Mean ± SE. * = statistically significant difference in 
comparison with IF mitochondria (p < 0.05). # = statistically significant difference in comparison 
with PN mitochondria (p < 0.05). Turquoise = Interfibrillar (IF), Blue = Perinuclear (PN), Purple = 





Comparisons between the two age groups showed that, whilst IF had the greatest area, 
length and width in adults, as well as an AR furthest from 1.0, these mitochondria did not 
differ in roundness between the two age groups. In contrast, excluding the length of PN 
mitochondria, PN and SSL differed in each measurement between the two age groups, with 
smaller areas, AR closest to 1.0, and lower measurements of roundness in 14-day olds 
compared with adults. The greater roundness of adult PN and SSL mitochondria following 
ischemia may indicate a greater degree of mitochondrial fission in adults, with subsequent 
fragmented and rounded morphology (Ong and Hausenloy 2010).  
 
In order to assess the differences in changes to mitochondrial morphology following 
ischemia, analysis was performed to identify statistically significant differences between the 
three mitochondrial subpopulations within each age groups (Figure 94). In both age groups, 
Figure 93. Mitochondrial morphological differences between P14 and Adult hearts, by 
mitochondrial subpopulation. Data presented as Mean ± SE. * = statistically significant 
difference in comparison with 14-day old hearts (p < 0.05). (n = 3 hearts/age group. P14: 














all three mitochondrial subpopulations showed significantly increased area, length, width, 
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Figure 94. The average differences in mitochondrial morphometry following ischemia, by 
age group. Data presented as Mean ± SE. * = statistically significant difference with pre-
ischemic hearts (p < 0.05). (n = 3 hearts/group.) 
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To compare post-ischemic morphological changes between the two age groups, the 
percentage change of each measurement from pre-ischemic to post-ischemic values was 
calculated. All three subpopulations showed a greater increase in area post-ischemia in 14-
day old hearts, with the most dramatic change seen in PN (92% increase vs. 40% increase 
in area). In both age groups, however, the percentage change in PN roundness was similar 
(7% vs. 5%), becoming closer to 1.0 post-ischemia. In all three subpopulations, both age 
groups displayed a drop in AR towards 1.0, with an approximately 10% greater drop in 14-






Overall, post-ischemic changes in mitochondrial morphology, such as area, appeared to be 
more dramatic across all three subpopulations in 14-day old hearts than in adults. 
8.3.4.3 Changes in intercristae space following ischemia 
Following ischemic injury, mitochondrial swelling is known to occur as a result of factors such 
as an acidic cellular pH, breakdown of creatine phosphate and depletion of ATP levels, 
resulting in the disruption of the mitochondria and its functional abilities (Schmiedl et al. 
1993). Indicators of swelling include an increase in the area of mitochondria, as well as 
disruption of the mitochondrial matrix and larger intercristae spaces. To assess the 
differences in this form of mitochondrial disruption, and the differences in the effect of 
ischemia on mitochondrial swelling between the two age groups, electron micrographs were 
analysed using ImageJ, highlighting regions within the mitochondria where the cristae were 
Figure 95.  Comparison of percentage changes in mitochondrial morphology, calculated 
as the pre-ischemic to post-ischemic percentage change, between the two age groups for 




no longer condensed, and intercristae spaces could be seen. Figure 96 shows an example of 
post-ischemic IF in 14-day old and adult hearts.   
 
Intercristae spaces post-ischemia were greater in samples taken from adult hearts in 
comparison with 14-day old hearts, both in terms of the mean area of intercristae spaces 
(µm²) (p < 0.001) and the percentage of the total mitochondrial area comprised of 
intercristae spaces (p < 0.001). This indicates a greater degree of mitochondrial disruption 
and swelling in adult mitochondria, and therefore more substantial cardiac injury in this age 




Figure 96. Examples of differences in mitochondrial swelling post-ischemia between the 
two age groups, as indicated by the size of intercristae spaces. Central (green) and right 













As no significant differences were seen in the sizes of intercristae spaces between the three 
different mitochondrial subpopulations, only data from IF mitochondria has been included 
to demonstrate the age-dependent differences following ischemia.  
Figure 97. Changes in intercristae spaces compared with the total area of the mitochondria, 
by age group. Data presented as Mean ± SE. * = statistically significant difference compared 
to 14-day old hearts (p < 0.05). (n = 3 hearts/age group. P14 n = 8 fields, 36 mitochondria. 
Adult = 10 fields, 52 mitochondria). 
 
Figure 98. Intercristae spaces in interfibrillar mitochondrion comprised of, by age group. 
Data presented as Mean ± SE. * = statistically significant difference compared to 14-day 
old hearts (p < 0.05). (n = 3 hearts/age group. P14 n = 8 fields, 36 mitochondria. Adult = 
















Mean area of intercristae spaces & Mean total mitochondrial area




































8.3.4.4 Changes in intercristae spaces following ischemia and reperfusion 
As described in Section 8.3.4.5, mitochondria were assessed for the degree of mitochondrial 
disruption and swelling through measurement of the percentage of the mitochondrial area 
made up by intercristae spaces, in this case in samples taken from hearts following 
ischemia/reperfusion. 
 
Similarly to post-ischemic samples, intercristae spaces post-I/R were greater in samples 
taken from adult hearts in comparison with 14-day old hearts, both in terms of the mean 
area of intercristae spaces (µm²) (p < 0.001) and the percentage of the total mitochondrial 
area comprised of intercristae spaces (p < 0.05). This indicates a greater degree of 
mitochondrial disruption and swelling in adult mitochondria, and therefore more substantial 
cardiac injury in this age group than in 14-day olds. No statistically significant differences 
were seen in intercristae spaces between post-ischemic and post-I/R mitochondria.   
Figure 99. Examples of differences in mitochondrial swelling post-I/R between the two age 
groups, as indicated by the size of intercristae spaces. Central (green) and right hand 


















Mean area of intercristae spaces & Mean total mitochondrial area
MEAN area of intercristae spaces MEAN total mito area
Figure 101. The mean percentage of each mitochondrion comprised of intercristae spaces, 
by age group. Data presented as Mean ± SE. * = statistically significant difference 
compared to 14-day old hearts (p < 0.05). (n = 3 hearts/age group. P14 n = 4 fields, 19 

































Mean intercristae space as percentage of total mitochondrial area
* 
Figure 100. The mean area of intercristae spaces compared with the total area of the 
mitochondria, by age group. Data presented as Mean ± SE. * = statistically significant 
difference compared to 14-day old hearts (p < 0.05). (n = 3 hearts/age group. P14 n = 4 





8.4.1 Changes in mitochondrial morphology and intercristae spaces 
during ischemia indicate less damage in 14-day olds compared to adults 
Following ischemia, the pattern of differences in mitochondrial morphology between the 
two age groups remains similar, with adult mitochondria possessing a greater area and 
higher roundness than 14-day old mitochondria. However, calculation of the percentage 
changes in mitochondrial morphology showed that 14-day olds seemed to have the greatest 
increase in area, roundness, and decrease in AR across all three subpopulations in 
comparison with adults. Despite this, intercristae spaces were smaller in 14-day olds, 
indicating that although there appeared to be a greater degree of mitochondrial swelling in 
14-day olds, there was less disruption to mitochondrial ultrastructure, indicating these 
mitochondria likely remain relatively healthy and functional in comparison with adults. 
Moreover, the smaller increase in mitochondrial area in adults may indicate a greater degree 
of fission than that seen in 14-day olds, and further work will be conducted to analyse 
indicators of mitochondrial fission. The incidence of mitochondrial fission will be important 
to identify in our two age groups, as mitochondrial fission is known to be harmful in the 
context of I/RI, with adult mitochondria exhibiting increased indicators of fission also 
showing an increased probability of mPTP opening (Kuzmicic et al. 2011). Furthermore, 
inhibition of mitochondrial fission has been shown to protect cardiomyocytes against I/RI 
(Ong et al. 2010), with specific inhibition of pro-fission protein, Drp-1, resulting in a greater 
number of mitochondria able to maintain their elongated morphology, inhibition of mPTP 
opening, and a resulting decrease in infarct size.  
Whilst only focusing on IF and SSL, Kuzmicic et al. state that, in the context of diabetic 
cardiomyopathy, the majority of mitochondrial abnormalities tend to occur in IF, meaning 
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there is a drop in metabolic activity that causes mechanical deficiency in these hearts. In our 
adult samples, there is a greater degree of disruption in IF mitochondria – as illustrated by a 
larger percentage of the mitochondrial area being comprised of intercristae spaces – in 
comparison with 14-day olds. Combined with the fact that, as discussed in Section 4.4.2, 
adults have a much higher proportion of IF mitochondria in comparison with 14-day olds, 
this suggests it is possible that the greater vulnerability of this subpopulation, in addition to 
its dominance in the adult heart, may contribute to the reduced resistance of this age group 
to I/RI, and that the higher numbers of PN in 14-day olds confer some sort of 
cardioprotection in turn.  
Kalkhoran et al. (2017) found that all three subpopulations exhibited increased sphericity 
following ischemia, as was the case for both age groups in our work. However, the authors 
state that an increase in area was seen only in PN, whereas all three subpopulations showed 
an increase in area in both our 14-day and adult samples. Nevertheless, other morphological 
features were shown to be altered post-ischemia, such as increased indicators of 
fragmentation in IF, a loss of elongated morphology in SSL, and decreased AR in PN 
(Kalkhoran et al. 2017). H2O2-mediated injury in neonatal cardiomyocytes results in 
increased roundness of the mitochondria as a result of disruptions to Ca2+-handling and loss 
of the mitochondrial membrane potential (Akao et al. 2003), and while all three 
subpopulations did show increased roundness following ischemia, PN showed the smallest 
increase in both age groups. Whilst IF showed a 53% increase in roundness in 14-day olds 
compared with 27% in adults, and 16% compared with 8% in SSL mitochondria, PN only 
showed a 7% increase in 14-day olds and 5% in adults. Whether this is a result of a high 
starting roundness compared to other subpopulations even in control hearts, or whether 
this greater roundness is in some way protective to the heart, is uncertain. However, the 
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fact that this subpopulation appears to show the least drastic alterations in roundness 
following ischemia, and is also the most prevalent form in the 14-day old heart, may indicate 
that the predominance of this more resistant subpopulation in 14-day olds links to the 
reduced cardiac vulnerability in this age group. Interestingly, the greatest difference in 
percentage increase of area between the two age groups existed within PN, at more than 
double in 14-day olds (92% vs. 40%). Whilst SSM show a similar percentage increase in area 
(86%) to PN in 14-day olds, there is a much smaller difference in comparison with adults 
(62%). IF showed a lesser degree of swelling, with a 25% increased area in adults and 37% 
increase in 14-day olds, contrasting findings by Kalkhoran et al. which state that IF and SSL 
did not show any significant increase in area. However, it should be noted that this study 
used only a 20 minute period of ischemia, whereas hearts underwent 30 minutes ischemia 
in our work. Whether discrepancies between our findings and previous reports result from 
this difference in the ischemic period remains to be seen, but further work will need to be 
conducted, with an increase in n-numbers, to ensure that these trends hold true. 
Furthermore, it will be important to analyse mitochondrial morphology following 
reperfusion to see whether there are signs of recovery closer to control measurements, or 
further fragmentation and fission.  
8.4.2 Mitochondrial disruption following I/R is greater in adult hearts 
The data showing the change in mitochondria after I/R are similar to the changes seen after 
ischemia alone (as discussed in Section 8.4.1) where adult hearts showed larger intercristae 
spaces than those seen in 14-day old hearts. No significant differences were seen between 
post-ischemic and I/RI hearts within each age group, indicating the full extent of 
mitochondrial swelling does occur during ischemia. These data demonstrate that 
mitochondrial disruption is greater in adults than 14-day old hearts during both ischemia 
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and reperfusion, and that mitochondria in 14-day old hearts seem to maintain a more 
healthy and functional state following I/RI, potentially contributing to the greater resistance 
to cardiac injury seen in this age group.  
8.4.3 Abundance of MVBs was higher in 14-day olds than adults with or 
without cardiac insult 
As shown in Section 7.3.3.3, control 14-day old hearts had a greater number of MVBs 
present within cardiomyocytes themselves in comparison with adult samples. Whilst this 
difference in MVB abundance between 14-day old samples and adults appeared to remain 
following both ischemia and reperfusion, there appeared to be fewer within cardiomyocytes 
than that seen in control hearts. A potential explanation for this could be that many MVBs 
are present in control hearts, and that these are either exported from cardiomyocytes 
following ischemia and reperfusion to target and release transported exosomes directly into 
recipient cells, release free exosomes into the extracellular space to bind with receptors of 
target cells, or are released as free exosomes within the myofibres themselves to trigger 
cardioprotective signalling (Ailawadi, Wang et al. 2015). Although the nature of electron 
micrographs as a snapshot of molecular events is limiting, the drop in number of MVBs 
within cardiomyocytes themselves, particularly in 14-day old hearts, seemed to correspond 
to the presence of MVBs that appeared to be localised around other cell types, suggesting 
they may have been exported from the myocardium to target and recruit such cells. Previous 
studies have indeed suggested that exosomes may be able to signal to and mobilise stem 
and progenitor cells following I/RI in order to facilitate the repair and remodelling of 
damaged myocardium (Sahoo and Losordo 2014). Furthermore, exosomes have been 
demonstrated to be mediators of the cardioprotective effects of remote-iPC (RIPC), with 
depletion of exosomes or targeting and silencing of its components resulting in the loss of 
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the infarct size reducing effect of RIPC (Barile, Moccetti et al. 2017). As previously 
mentioned, iPreC has been shown to be ineffective in providing cardioprotection to the 
immature heart, which raises the possibility that these hearts already possess high levels of 
survival signalling pathway proteins ready for activation, in addition to a greater number of 
exosome containing MVBs in control hearts that can be released upon cardiac injury. In 
order to further investigate the potential role of MVBs and exosomes in the resistance of 14-
day old hearts to I/RI, future work would require the use of exosome specific staining or 
quantitative methods with the inclusion of samples from 7-day old hearts.  
8.4.4 The abundance of caveolae decreased post-ischemia only in 14-
day old hearts 
In-line with previous studies, the number of caveolae present in cardiomyocytes following 
ischemia decreased in comparison with control hearts in both age groups, although this 
difference was not statistically significant in adult samples. This may result from the difficulty 
in finding clear sections within samples from which these counts could be taken in adult 
samples, resulting in a relatively low number of fields of measurement. However, both pre- 
and post-ischemic samples from 14-day old hearts showed a greater number of caveolae 
than adults, which is consistent with previous reports that treatments preventing the loss of 
caveolae following I/R result in cardioprotection and decrease myocardial injury (Hu, Zhang 
et al. 2017).  
8.4.5 Ischemia was associated with a decrease in sarcomere length 
Sarcomere lengths were statistically significantly decreased following ischemia both in 14-
day old and adult samples, in-line with the hypercontracture of cardiomyocytes that occurs. 
However, adult cardiomyocytes displayed significantly shorter sarcomere lengths in 
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comparison to 14-day old cardiomyocytes, despite being higher in pre-ischemic samples, 
indicating a greater degree of hypercontracture in adult hearts post-ischemia. As 
hypercontracture occurs as a result of ATP-depletion and Ca2+-overload following cardiac 
insult, with greater degrees of hypercontracture shown to be associated with larger regions 
of necrotic contraction bands in infarcted tissue (Ruiz-Meana and Garcia-Dorado 2009), 
these findings indicate greater damage in adult hearts following ischemia, and that 14-day 
old hearts require longer than the implemented 30 minute period of ischemia in order to 
sustain equivalent degrees of myocardial injury. 
8.4.6 Summary & Conclusion 
The presence of cardioprotective structures such as MVBs and caveolae was found to be 
greater in 14-day old samples than adults following ischemia and reperfusion in a similar 
manner to control hearts, correlating with the greater resistance to cardiac injury seen in 
14-day olds. Similarly, analysis of mitochondrial morphology and disruption found that adult 
samples displayed a greater degree of injury and mitochondrial dysfunction than 14-day old 
samples. These findings therefore indicate a greater resistance of mitochondria to cardiac 
injury, as well as a potential mechanism of cardioprotection through the greater abundance 
of MVBs and caveolae in 14-day olds. Future work will need to replicate these measurements 
in 7-day old samples in order to confirm that these differences also follow the biphasic 
profile seen in cardiac vulnerability over the course of postnatal development.  
Chapter 9: Summary, Limitations & Future Work 
9.1 Summary of work 
The key findings of this work revolve around the identification of a number of central survival 
signalling-related proteins that demonstrated a biphasic profile of expression over the 
267 
 
course of postnatal development, correlating with the cardiac vulnerability profile across 
these age groups. This included important RISK-SAFE signalling proteins, such as Akt and 
PKCε, that are commonly discussed in the context of I/RI in the heart and demonstrated an 
overall biphasic trend, as summarised in Figure 102. However, it is important to note that 
statistically significant differences in expression between 7-day old and 14-day olds was not 
seen in Akt, PKCε, and a number of other RISK-SAFE related proteins – labelled ‘trend’ in blue 
(Figure 102) – with the lack of significance in comparison with 7-day olds likely resulting from 
the small sample number (n = 4) for this age group. It will therefore be important in future 
work to increase the sample size for these 7-day old hearts, in order to further investigate 
whether or not a true biphasic profile exists for these proteins, thus implicating them as 
causative in the vulnerability profile to I/RI seen across these four age groups.  
In contrast, AMPK, which is linked to cell survival and interacts with a number of RISK-SAFE 
signalling proteins, was found to demonstrate a biphasic profile of expression with statistical 
significance between 14-day old hearts in comparison with 7-day old, 28-day old and adult 
hearts. Due to its known cardioprotective effects in the context of I/RI, through the 
upregulation of autophagy during ischemia as well as through its reported ability to inhibit 
mPTP opening during reperfusion, AMPK became the focus of experiments investigating the 
effect of its inhibition on both cardiomyocyte viability and infarct size in Langendorff 




In both isolated cardiomyocytes and whole heart perfusion, AMPK inhibition resulted in a 
significant decrease in cardiomyocyte viability and increase in infarct size in 14-day olds, but 
not adults. This supports the hypothesis that its peak in expression in 14-day old hearts 
relates to a potential role in the mechanism underlying the greater resistance of 14-day old 
hearts to I/RI in comparison to adult hearts. Whilst western blot analysis of cardiac samples 
obtained from these samples did not identify statistically significant changes in the 
expression of key AMPK signalling and survival signalling proteins, it is likely that this results 
from previously discussed issues with the experimental protocol. Indeed, bands visually 
Figure 102. An overview of the RISK-SAFE survival signalling pathways, with proteins 
identified to be biphasically expressed during postnatal development in the proteomic 
output highlighted (Key: ‘Trend’ = proteins with overall biphasic profile of expression, but 
the difference did not reach statistical significance between 7-day and 14-day old. 
‘Significant’ = proteins with statistically significant differences between 14-day old 




showed clear differences between the experimental groups that appeared consistent with 
the expected roles of each protein tested in cell survival and AMPK signalling (Section 6.4). 
This work has therefore identified AMPK as a target for future work into its role in the 
biphasic cardiac vulnerability profile, as well as a potential therapeutic target in the 
treatment of myocardial infarction. 
In addition to these protein-based findings, important age-related differences in cardiac 
ultrastructure – both in control hearts and hearts that have undergone ischemia and 
reperfusion – were identified. Consistent with their importance to cellular survival, as well 
as being key end targets for survival signalling pathways, analysis of mitochondrial 
morphology demonstrated that those from 14-day old samples displayed characteristics 
both pre- and post-ischemia that indicated a lesser degree of injury and dysfunction, such as 
less rounded morphologies – an indicator of mitochondrial fission and fragmentation – and 
smaller intercristae spaces – indicating mitochondrial disruption – than adults. Additionally, 
significant differences in the distribution of mitochondrial subpopulations was identified 
between the two age groups, with 14-day old hearts displaying a greater number of 
perinuclear mitochondria, in comparison with the high number of interfibrillar mitochondria 
seen in adults. While the significance of this difference is currently uncertain, the fact that 
these two subtypes have distinct functional roles highlights this as an important avenue of 
future research. In addition to these mitochondrial findings, MVBs and exosomes were 
identified as an interesting target for future investigation, due to their apparent abundance 
in 14-day old hearts in comparison with adults, as well as their reported cardioprotective 




9.2.1 Proteomics and phosphoproteomics 
In our first run of proteomic analysis (Chapter 3), it was found that some phosphoproteins 
had a phosphosite present in both runs covering all three age groups, showing a concordant 
pattern of change with postnatal development as that seen in the total phosphoprotein, but 
that were labelled as being at sites two or so residues apart. This calls into question the 
accuracy of detection of the individual phosphosites when in close physical proximity to one 
another, as well as the comparability of these sites between the two runs of 
phosphoproteomic analysis in some cases.  
A predominant limitation identified when conducting analysis of the second run of 
proteomic output (Chapter 4) was the fact that only four 7-day old samples were included, 
resulting in a large scatter for some proteins, and making the identification of outliers 
difficult in some cases. This may also have contributed to false negatives for proteins with 
statistically significant biphasic patterns of expression.  
9.2.2 Cardiomyocyte isolation 
Initial cardiomyocyte isolation experiments encountered issues in assessing the effect of 
simulated I/RI on viability (Section 5.3.1) as cell counts were initially performed manually 
using a cell counter and microscope. Due to the fact that this was undertaken during the 
experiment itself, and that a large number of cells from multiple fields were required in order 
to improve the reliability of these counts, the level of accuracy of these initial counts is 
uncertain. Furthermore, the time taken to perform these counts meant that there was a 20 
minute delay between the measurements taken from the experimental cell group to the 
control cell group, during which time the number of viable cells is likely to have decreased 
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with uncertain significance, making direct comparison between the two groups difficult. The 
implementation of a protocol adjustment, instead taking photographs of the cells through 
the microscope and performing these counts using the ImageJ count tool after the 
experiment itself, improved the accuracy of these cell viability measurements, but may 
affect direct comparability with the initial manually counted data.  
As mentioned in Section 5.3.2, analysis of protein expression in cells that had undergone 
simulated I/RI – with or without drug treatment – was difficult particularly for 14-day olds, 
as the number of cardiomyocytes that can be isolated from hearts of this age group are 
relatively low, therefore often producing samples with insufficient protein content to 
successfully run western blot analysis. Furthermore, protein was extracted from the cell 
pellets themselves, discarding the supernatant. However, other studies have shown that it 
may in fact be this supernatant that holds the relevant proteins released upon cell death, 
due to the necrosis-inducing action of H2O2 at the concentration used in this work (Marshall, 
Edwards et al. 2014). As a result, the lack of significant change in protein expression between 
the control and experimental groups in our isolated cardiomyocytes may not be 
representative of the true changes in protein expression following I/RI and the use of 
inhibitors. 
Another issue encountered during this work was the lack of inhibitors or activators for some 
proteins found to have strong, statistically significant biphasic trends in expression, such as 
Caveolin-1, -2 and -3. As a result, testing the differential effects of inhibition or activation of 
these proteins between 14-day old and adult hearts would require overexpression or 
knockout models. For those proteins that we were able to inhibit in cardiomyocyte viability 
studies, one issue was that, in the case of PKCε, no inhibitor specific for this isoform of the 
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protein was available, and thus experiments used a pan PKC inhibitor - chelerythrine. As a 
result, it cannot be concluded definitively that any resulting effects of inhibition on 
cardiomyocyte viability were solely due to PKCε alone. Future work may therefore benefit 
from utilising methods such as PKCε-specific knockdown in order to establish that any effects 
do relate to its activity, and not any other PKC isoforms.  Another issue was that addition of 
these drugs resulted in chronic inhibition, as they were left to incubate within the cell 
suspension for the full 2 hour experimental period. However, replication of this experiment 
in the case of AMPK inhibition was performed in whole hearts using Langendorff perfusion 
in order to address this issue. In addition to this, in many cases the inhibitors used are not 
isoform specific, or have been demonstrated to also affect other kinases that would likely 
have an effect on cell survival in these experiments. For example, chelerythrine was used to 
investigate the effects of PKCε inhibition, due to the lack of a specific inhibitor. This may 
account for the lack of a statistically significant change in pPKCε/PKCε expression in these 
isolated cardiomyocyte experiments (Section 5.3.2.1.1.3). 
9.2.3 Western blotting 
One of the most prominent limitations encountered during this work was the apparent 
variance in GAPDH expression between the different age groups, with the lowest levels seen 
in 14-day old protein samples. Repetition of protein quantification and sample preparation 
for western blotting produced these same differences in GAPDH expression, and was 
similarly seen in samples extracted from isolated cardiomyocytes. Similar age or nutrition-
related differences in GAPDH have previously been reported in the literature, a difference 
that may result from the role of GAPDH in glycolysis and the metabolic differences that exist 
at different stages of postnatal development within the heart (Lowe, Degens et al. 2000, 
Mozdziak, Dibner et al. 2003, Uddin, Cinar et al. 2011). This variance in the expression of 
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supposed housekeeping proteins during western blotting means that differences in protein 
expression between the three age groups tested may have been exaggerated, with 14-3-3η, 
for example, showing statistically significant difference between 14-day old and 28-day old 
hearts in the western blotting data that was not seen in the proteomic output. However, 
switching to the use of Ponceau S staining appeared to solve this issue, as shown in the 
Appendix (Figure 108). 
Another limiting factor was the fact that the electrophoresis gels used has a maximum 
number of 15 wells for sample loading, meaning samples had to be split onto two separate 
gels in order to be able to compare all experimental and age groups. While a pooled sample 
run on all gels was used in order to try and account for differences between the gels, this did 
not appear to be sufficient and the resulting data produced had large scatters and standard 
errors. This scatter is likely to account for the lack of statistically significant differences in 
protein expression seen, despite the clear differences visible when assessing the blots 
themselves.  
9.2.4 Langendorff perfusion and analysis of cardiac injury 
Analysis of cardiac injury in later experiments was limited by the fact that the original type 
of creatine kinase reagent used in initial experiments (Section 6.3.1) was subsequently 
discontinued, resulting in a switch to a supposedly equivalent product of smaller size. This 
meant that fresh bottles of reagent had to be made up often within individual runs – i.e. 
samples taken at 1-60 minutes of reperfusion for a single heart – as well as between control 
and inhibitor-treated hearts. This methodology appeared to produce a much larger variation 
in values and standard error in experiments described in Section 6.3.2 in comparison with 
the initial experiments in Section 6.3.1, and may have played a part in the lack of statistical 
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significance seen in creatine kinase measurements between control and dorsomorphin 
dihydrochloride treated hearts, despite the significant differences seen in infarct size 
between the two groups.  
Finally, measurement of infarct sizes themselves between the two age groups was difficult 
due to the greater resistance of 14-day old hearts to I/RI, and the subsequent smaller infarct 
sizes seen with the same 30 minute period of ischemia. 14-day old hearts therefore tended 
to only have regions of ischemia that were stained a light pink as opposed to the white 
regions seen in adult hearts. As a result, infarct sizes were measured as any regions not 
stained brick red in order to allow for direct comparison between the two age groups, which 
may therefore overlook differences in severe regions of infarction in adult hearts. Indeed, 
adult hearts treated with dorsomorphin dihydrochloride often appeared to have larger areas 
of tissue stained white than control hearts run simultaneously, which fits with previous 
reports of dorsomorphin dihydrochloride treatment increasing infarct size in adult rat 
hearts. 
9.2.5 Analysis of electron micrographs 
One of the main limitations encountered during analysis of electron micrograph data was 
the quality of sections, and the abundance of intact, correctly orientated sections of tissue 
to be able to accurately distinguish mitochondrial subtypes by location. This was particularly 
difficult in 14-day old samples, likely owing to the smaller cardiomyocyte size in this age 
group. Further disarray of tissue following reperfusion meant that it was not possible to find 
such sections in these samples, and thus mitochondrial morphology and subpopulation 
density measurements could not be collected. This also applied to finding intact sections of 
the membrane for caveolae quantification, with identification of caveolae in post-ischemic 
275 
 
samples becoming more difficult as a result of these distorted membranes and the presence 
of many vesicles around the membranes that arise following insult. In addition to this, 
quantitative measurements were not taken for MVB and exosome abundance due to similar 
issues in the identification and distinguishing of these structures from other vesicles in the 
myocardium. Many studies investigating MVBs and exosomes utilise, for example, 
immunogold staining of electron micrographs in order to correctly identify exosome carrying 
MVBs, as opposed to relying solely on visual identification.  
9.3 Future Work 
Having identified a number of potential candidates for the greater resistance of 14-day old 
hearts to I/RI, future work would benefit from further investigation of these proteins and 
their signalling partners, as well as confirmation of our current findings with greater sample 
sizes. This will be of particular importance to proteins that exhibited an overall biphasic trend 
in expression, but lacked statistical significance between 7-day old and 14-day old samples 
as a result of the scatter of proteomic data. Due to difficulties in analysing protein expression 
between multiple experimental and age groups using western blotting, alternatives such as 
proteomic and phosphoproteomic analysis of samples from all four age groups post-I/RI 
could eliminate these issues and provide a better understanding of potential changes in 
survival signalling proteins following cardiac injury between these age groups. It would also 
be important to include experiments supporting these inhibitor experiments, through use of 
specific activators of our proteins of interest to establish that these age-related differences 
are consistent both with inhibition and activation of such proteins. Moreover, replication of 
the dorsomorphin dihydrochloride experiments, but with the continued inhibition of AMPK 
throughout reperfusion as well as ischemia, may be of interest in order to identify any 
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potential resulting differences in cardiac injury between age groups, and in comparison to 
experiments with inhibition during ischemia alone. As current data mainly focus on 14-day 
old and adult hearts and samples, the inclusion of 7-day olds will be important to establish 
that these changes – for example, in the effect of AMPK inhibition or in the abundance of 
MVBs – also follow the biphasic trend of cardiac vulnerability seen during postnatal 
development. Clear differences between the 14-day old and adult samples in terms of 
mitochondrial morphology and their response to I/R were identified, in addition to 
expression of proteins linked to mitochondrial fission and fusion. As monitoring of these 
dynamic processes is limited using electron micrographs alone, future work would benefit 
from the inclusion of experiments, for example, using Mito Tracker in order to establish any 
differences between the age groups, and the subsequent effect this has on cardiac 
vulnerability. Finally, as localisation of signalling proteins and structures such as MVBs 
following I/RI is critical to their function and the conference of cardioprotection, future work 
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11. Appendix: Effect of age on housekeeping proteins 
expression 
Figure 103. Comparison of western blot analysis for GAPDH expression by 
age in two different sample preparations. 
Samples of cardiac tissue prepared using the Lowry method of quantification (‘First 
Preparation’) found a statistically significant difference in GAPDH expression between 14-
day old, 28-day old and Adult samples. 14-day old samples showed significantly lower levels 
of GAPDH than both 28-day old (p < 0.05) and adult samples (p < 0.05). To ensure that these 
differences were not caused by an error in protein quantification, samples from the same 
source underwent repeat quantification, this time using the Bradford method (‘Second 
Preparation’) and western blot analysis of GAPDH expression was repeated. 14-day old 
samples again showed a statistically significantly lower expression of GAPDH than both 28-















































Figure 103. Graphs to show mean expression of GAPDH from western blot analysis across three age 
groups 14-day old (n = 20), 28-day old (n = 20) and Adult (Ad.) (n = 20) samples. Data presented as 





Figure 104. Comparison of changes in GAPDH expression in 14-day old and 
adult samples following ischemia, I/R and drug treatment 
Western blotting was performed on Langendorff perfused samples – discussed in Chapter 6 
– and showed differences in GAPDH expression between 14-day old hearts and adult hearts 




Figure 104. Graph to show the expression of GAPDH in cardiac samples taken from 14-day 
old and adult rats either pre-ischemia (control), post-ischemia (ischemia), post-
ischemia/reperfusion (I/R) or post-ischemia/reperfusion + dorsomorphin dihydrochloride 
(dorsomorphin). Data presented as mean ± SE. * = Statistically significant difference in 
comparison with 14-day old samples. (n = 6/group) 
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Figure 105. Comparison of GAPDH expression between age groups in the 
proteomic output 
GAPDH expression was found to change in the proteomic output, with significantly greater 
expression in 28-day old and adult samples in comparison to both 7-day old and 14-day old 
samples (p < 0.05). 
 
 
* * # 
Figure 105. The trend in expression of GAPDH as detected by proteomic analysis across the 
4 age groups (7-day (n = 4), 14-day (n = 8), 28-day (n = 8) and adult (n = 7)). Data presented as 
Mean ± SE. * = Statistically significant difference in comparison with 7-day old samples. # = 
Statistically significant difference in comparison with 14-day old samples. 
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Figure 106. Comparison of changes in β-actin expression in 14-day old and 
adult samples following ischemia, I/R and drug treatment 
Whilst statistically, no significant differences were detected in β-actin expression between 
14-day old and adult samples, blots showed clearly that strong bands could be detected in 
14-day olds, whereas no bands were detected in adult samples. 
 
 
Figure 106. Graph to show the expression of B-actin in cardiac samples taken from 14-day 
old and adult rats either pre-ischemia (control), post-ischemia (ischemia), post-
ischemia/reperfusion (I/R) or post-ischemia/reperfusion + perfusion with dorsomorphin 
dihydrochloride (dorsomorphin). Data presented as mean ± SE. (n = 3/group) 
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Figure 107. Comparison of β-actin expression between age groups in the 
proteomic output 
Proteomic analysis showed statistically higher expression of β-actin in both 7-day old and 
14-day old samples in comparison with adult samples (p < 0.01). 
 
 
Figure 108. Comparison of whole lane protein staining using Ponceau S  
Other studies have demonstrated that the use of Ponceau S staining is an effective 
alternative to traditionally used housekeeping proteins to normalise protein bands (Romero-
Calvo, Ocon et al. 2010). In order to confirm Ponceau S staining as a viable alternative to 
traditional housekeeping proteins as a loading control, membranes were reversibly stained, 
* # 
Figure 107. The trend in expression of B-actin as detected by proteomic analysis across the 4 
age groups (7-day (n = 4), 14-day (n = 8), 28-day (n = 8) and adult (n = 7)). Data presented as Mean 
± SE. * = Statistically significant difference in comparison with 7-day old samples. # = Statistically 
significant difference in comparison with 14-day old samples. 
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and whole lane band intensities were measured using ImageJ. No statistically significant 




Figure 108. Graph to 
show mean Ponceau S 
lane intensity across three 
age groups 14-day old (n 
= 20), 28-day old (n = 20) 
and Adult (n = 20) 
samples. Data presented 
as Mean ± SE. 
 
